filgotinib vs upadacitinib

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Rheumatoid Arthritis

Shared mechanisms: JAK1 · JAK · full Rheumatoid Arthritis pipeline

filgotinib · Jyseleca

Marketed by Gilead Sciences and partners

Phase 3 in Rheumatoid ArthritisSmall molecule (JAK1-selective inhibitor)
Reliable signal

NCT02873936 · Phase 3 · completed

This was a randomized, double-blind, placebo-controlled trial in 449 patients; the primary endpoint, ACR20 response at week 12 (a validated rheumatoid-arthritis disease-activity measure), was significantly higher with both filgotinib doses than placebo (66.0% and 57.5% vs 31.1%, both p<0.001).

Next expected readout: April 2029 · NCT06687551 (registry estimate)

Reported efficacy

Percentage of Participants Who Achieved an American College of Rheumatology (ACR) 20% Improvement (ACR20) Response at Week 12: ACR20 at week 12 (primary endpoint): FIL200 76.6% vs placebo 49.9% (difference 26.7%, 95% CI 20.6-32.8, p<0.001); FIL100 69.8% vs placebo 49.9% (difference 19.9%, 95% CI 13.6-26.2, p<0.001) (met)

Result source: NCT02889796

upadacitinib · Rinvoq

Marketed by AbbVie

Approved in Rheumatoid ArthritisSmall molecule (JAK1-selective inhibitor)
Reliable signal

NCT02675426 · Phase 3 · completed

This was a randomized, quadruple-blind, placebo-controlled trial in 661 patients using two validated rheumatoid arthritis disease-activity measures as co-primary endpoints, and both upadacitinib doses produced significantly higher response rates than placebo on both measures (all comparisons p<0.001).

Next expected readout: March 2027 · NCT07636057 (registry estimate)

Reported efficacy

Change From Baseline in Disease Activity Score (DAS) 28 C-Reactive Protein (CRP) at Week 12 (Non-inferiority) (Baseline and Week 12): Change from baseline DAS28-CRP at week 12: -2.52 (95% CI -2.66 to -2.37) upadacitinib vs -2.00 (95% CI -2.14 to -1.85) abatacept; upadacitinib met primary non-inferiority and key secondary superiority endpoints. (met)

Result source: NCT03086343

Results for Rheumatoid Arthritis

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointfilgotinibupadacitinib
ACR2076.6% vs 49.9%+26.7 vs placebo200 mg · wk 12 · n 475NCT02889796
51 other results
  • 69.8% vs 49.9% 100 mg · wk 12 · n 480 · Phase 3 · primary NCT02889796
  • 66% vs 31.1% 200 mg · wk 12 · n 147 · Phase 3 · primary NCT02873936
  • 57.5% vs 31.1% 100 mg · wk 12 · n 153 · Phase 3 · primary NCT02873936
  • 78.1% vs 71.4% 200 mg · wk 24 · n 210 · Phase 3 · primary NCT02886728
  • 81% vs 71.4% 200 mg · wk 24 · n 416 · Phase 3 · primary NCT02886728
  • 80.2% vs 71.4% 100 mg · wk 24 · n 207 · Phase 3 · primary NCT02886728
  • 78.1% vs 59.2% 200 mg · wk 24 · n 475 · Phase 3 · secondary NCT02889796
  • 82.9% vs 86.9% 200 mg · wk 36 · n 475 · Phase 3 · secondary NCT02889796
  • 51.6% vs 31.8% 200 mg · wk 4 · n 475 · Phase 3 · secondary NCT02889796
  • 37.3% vs 14.9% 200 mg · wk 2 · n 475 · Phase 3 · secondary NCT02889796
  • 82.9% vs 85.9% 200 mg · wk 52 · n 475 · Phase 3 · secondary NCT02889796
  • 77.7% vs 59.2% 100 mg · wk 24 · n 480 · Phase 3 · secondary NCT02889796
  • 79.2% vs 86.9% 100 mg · wk 36 · n 480 · Phase 3 · secondary NCT02889796
  • 45.6% vs 31.8% 100 mg · wk 4 · n 480 · Phase 3 · secondary NCT02889796
  • 27.5% vs 14.9% 100 mg · wk 2 · n 480 · Phase 3 · secondary NCT02889796
  • 79.6% vs 85.9% 100 mg · wk 52 · n 480 · Phase 3 · secondary NCT02889796
  • 69.4% vs 34.5% 200 mg · wk 24 · n 147 · Phase 3 · secondary NCT02873936
  • 51.7% vs 25.7% 200 mg · wk 4 · n 147 · Phase 3 · secondary NCT02873936
  • 54.9% vs 34.5% 100 mg · wk 24 · n 153 · Phase 3 · secondary NCT02873936
  • 44.4% vs 25.7% 100 mg · wk 4 · n 153 · Phase 3 · secondary NCT02873936
  • 71.4% vs 59.4% 200 mg · wk 12 · n 210 · Phase 3 · secondary NCT02886728
  • 76.2% vs 68.3% 200 mg · wk 36 · n 210 · Phase 3 · secondary NCT02886728
  • 52.4% vs 33.4% 200 mg · wk 4 · n 210 · Phase 3 · secondary NCT02886728
  • 39.5% vs 16.6% 200 mg · wk 2 · n 210 · Phase 3 · secondary NCT02886728
  • 74.8% vs 61.8% 200 mg · wk 52 · n 210 · Phase 3 · secondary NCT02886728
  • 76.7% vs 59.4% 200 mg · wk 12 · n 416 · Phase 3 · secondary NCT02886728
  • 75.5% vs 68.3% 200 mg · wk 36 · n 416 · Phase 3 · secondary NCT02886728
  • 62.3% vs 33.4% 200 mg · wk 4 · n 416 · Phase 3 · secondary NCT02886728
  • 42.1% vs 16.6% 200 mg · wk 2 · n 416 · Phase 3 · secondary NCT02886728
  • 75% vs 61.8% 200 mg · wk 52 · n 416 · Phase 3 · secondary NCT02886728
  • 72% vs 59.4% 100 mg · wk 12 · n 207 · Phase 3 · secondary NCT02886728
  • 73.4% vs 68.3% 100 mg · wk 36 · n 207 · Phase 3 · secondary NCT02886728
  • 55.6% vs 33.4% 100 mg · wk 4 · n 207 · Phase 3 · secondary NCT02886728
  • 37.2% vs 16.6% 100 mg · wk 2 · n 207 · Phase 3 · secondary NCT02886728
  • 73.4% vs 61.8% 100 mg · wk 52 · n 207 · Phase 3 · secondary NCT02886728
  • 72.5% vs 29.2% 200 mg QD · wk 12 · n 69 · Phase 2 · primary NCT01894516
  • 68.6% vs 44.2% 200 mg QD · wk 12 · n 86 · Phase 2 · primary NCT01888874
  • 65.7% vs 29.2% 100 mg QD · wk 12 · n 70 · Phase 2 · primary NCT01894516
  • 63.5% vs 44.2% 100 mg QD · wk 12 · n 85 · Phase 2 · primary NCT01888874
  • 78.6% vs 44.2% 100 mg BID · wk 12 · n 84 · Phase 2 · primary NCT01888874
  • 66.7% vs 29.2% 50 mg QD · wk 12 · n 72 · Phase 2 · primary NCT01894516
  • 56.1% vs 44.2% 50 mg QD · wk 12 · n 82 · Phase 2 · primary NCT01888874
  • 60% vs 44.2% 50 mg BID · wk 12 · n 85 · Phase 2 · primary NCT01888874
  • 57% vs 44.2% 25 mg BID · wk 12 · n 86 · Phase 2 · primary NCT01888874
  • 73.3% vs 41.9% 200 mg QD · wk 24 · n 86 · Phase 2 · secondary NCT01888874
  • 61.2% vs 41.9% 100 mg QD · wk 24 · n 85 · Phase 2 · secondary NCT01888874
  • 79.8% vs 41.9% 100 mg BID · wk 24 · n 84 · Phase 2 · secondary NCT01888874
  • 54.9% vs 41.9% 50 mg QD · wk 24 · n 82 · Phase 2 · secondary NCT01888874
  • 60% vs 41.9% 50 mg BID · wk 24 · n 85 · Phase 2 · secondary NCT01888874
  • 55.8% vs 41.9% 25 mg BID · wk 24 · n 86 · Phase 2 · secondary NCT01888874
  • 81% vs 40.9% wk 12 · n 21 · Phase 2 · secondary NCT02885181
63.8% vs 35.7%+28.1 vs placebo15 mg · wk 12 · n 221NCT02675426
49 other results
  • 64.6% vs 28.4% 15 mg · wk 12 · n 164 · Phase 3 · primary NCT02706847
  • 71.6% vs 31.4% 15 mg · wk 12 · n 169 · Phase 3 · primary NCT02955212
  • 66.2% vs 35.7% 30 mg · wk 12 · n 219 · Phase 3 · primary NCT02675426
  • 56.4% vs 28.4% 30 mg · wk 12 · n 165 · Phase 3 · primary NCT02706847
  • 83.7% vs 42.9% 15 mg · wk 12 · n 49 · Phase 2/3 · primary NCT02720523
  • 80% vs 42.9% 30 mg · wk 12 · n 50 · Phase 2/3 · primary NCT02720523
  • 75.5% vs 42.9% 7.5 mg · wk 12 · n 49 · Phase 2/3 · primary NCT02720523
  • 67.7% vs 41.2% 15 mg · wk 14 · n 217 · Phase 3 · primary NCT02706951
  • 75.7% vs 54.1% 15 mg · wk 12 · n 317 · Phase 3 · primary NCT02706873
  • 71.2% vs 41.2% 30 mg · wk 14 · n 215 · Phase 3 · primary NCT02706951
  • 77.1% vs 54.1% 30 mg · wk 12 · n 314 · Phase 3 · primary NCT02706873
  • 22.2% vs 8.6% 15 mg · wk 1 · n 221 · Phase 3 · secondary NCT02675426
  • 27.4% vs 10.7% 15 mg · wk 1 · n 164 · Phase 3 · secondary NCT02706847
  • 25.4% vs 5.9% 15 mg · wk 1 · n 169 · Phase 3 · secondary NCT02955212
  • 28.3% vs 8.6% 30 mg · wk 1 · n 219 · Phase 3 · secondary NCT02675426
  • 24.8% vs 10.7% 30 mg · wk 1 · n 165 · Phase 3 · secondary NCT02706847
  • 24.5% vs 8.2% 15 mg · wk 1 · n 49 · Phase 2/3 · secondary NCT02720523
  • 34% vs 8.2% 30 mg · wk 1 · n 50 · Phase 2/3 · secondary NCT02720523
  • 30.6% vs 8.2% 7.5 mg · wk 1 · n 49 · Phase 2/3 · secondary NCT02720523
  • 78.9% vs 58.6% 15 mg · wk 24 · n 317 · Phase 3 · secondary NCT02706873
  • 78% vs 58.6% 30 mg · wk 24 · n 314 · Phase 3 · secondary NCT02706873
  • 85.2% vs 57.1% 15 mg · wk 12 · n 27 · Phase 3 · secondary NCT02706873
  • 78.6% vs 57.1% 30 mg · wk 12 · n 28 · Phase 3 · secondary NCT02706873
  • 85.5% vs 57.1% 7.5 mg · wk 12 · n 55 · Phase 3 · secondary NCT02706873
  • 81.6% vs 50% 24 mg QD · wk 12 · n 49 · Phase 2 · primary NCT02066389
  • 76.6% vs 50% 18 mg BID · wk 12 · n 47 · Phase 2 · primary NCT02066389
  • 70.9% vs 35.2% 18 mg BID · wk 12 · n 55 · Phase 2 · primary NCT01960855
  • 81.6% vs 50% 12 mg BID · wk 12 · n 49 · Phase 2 · primary NCT02066389
  • 72.7% vs 35.2% 12 mg BID · wk 12 · n 55 · Phase 2 · primary NCT01960855
  • 73.5% vs 50% 6 mg BID · wk 12 · n 49 · Phase 2 · primary NCT02066389
  • 63.5% vs 35.2% 6 mg BID · wk 12 · n 52 · Phase 2 · primary NCT01960855
  • 64.6% vs 50% 3 mg BID · wk 12 · n 48 · Phase 2 · primary NCT02066389
  • 55.6% vs 35.2% 3 mg BID · wk 12 · n 54 · Phase 2 · primary NCT01960855
  • 41.5% vs 47.4% 60 mg · wk 12 · n 41 · Phase 2 · secondary NCT03682705
  • 39% vs 36.8% 60 mg · wk 8 · n 41 · Phase 2 · secondary NCT03682705
  • 29.3% vs 42.1% 60 mg · wk 4 · n 41 · Phase 2 · secondary NCT03682705
  • 24.4% vs 21.1% 60 mg · wk 2 · n 41 · Phase 2 · secondary NCT03682705
  • 30.8% vs 47.4% 20 mg · wk 12 · n 39 · Phase 2 · secondary NCT03682705
  • 30.8% vs 36.8% 20 mg · wk 8 · n 39 · Phase 2 · secondary NCT03682705
  • 23.1% vs 42.1% 20 mg · wk 4 · n 39 · Phase 2 · secondary NCT03682705
  • 12.8% vs 21.1% 20 mg · wk 2 · n 39 · Phase 2 · secondary NCT03682705
  • 64.5% vs 47.4% 15 mg/60 mg · wk 12 · n 62 · Phase 2 · secondary NCT03682705
  • 64.5% vs 36.8% 15 mg/60 mg · wk 8 · n 62 · Phase 2 · secondary NCT03682705
  • 51.6% vs 42.1% 15 mg/60 mg · wk 4 · n 62 · Phase 2 · secondary NCT03682705
  • 45.2% vs 21.1% 15 mg/60 mg · wk 2 · n 62 · Phase 2 · secondary NCT03682705
  • 34.1% vs 47.4% 5 mg · wk 12 · n 41 · Phase 2 · secondary NCT03682705
  • 39% vs 36.8% 5 mg · wk 8 · n 41 · Phase 2 · secondary NCT03682705
  • 22% vs 42.1% 5 mg · wk 4 · n 41 · Phase 2 · secondary NCT03682705
  • 14.6% vs 21.1% 5 mg · wk 2 · n 41 · Phase 2 · secondary NCT03682705
ACR5057.9% vs 33.3%+24.6 vs placebo200 mg · wk 24 · n 475NCT02889796
87 other results
  • 47.2% vs 19.8% 200 mg · wk 12 · n 475 · Phase 3 · secondary NCT02889796
  • 63.2% vs 63.4% 200 mg · wk 36 · n 475 · Phase 3 · secondary NCT02889796
  • 22.3% vs 5.9% 200 mg · wk 4 · n 475 · Phase 3 · secondary NCT02889796
  • 9.1% vs 1.1% 200 mg · wk 2 · n 475 · Phase 3 · secondary NCT02889796
  • 64.2% vs 66% 200 mg · wk 52 · n 475 · Phase 3 · secondary NCT02889796
  • 52.7% vs 33.3% 100 mg · wk 24 · n 480 · Phase 3 · secondary NCT02889796
  • 36.5% vs 19.8% 100 mg · wk 12 · n 480 · Phase 3 · secondary NCT02889796
  • 57.7% vs 63.4% 100 mg · wk 36 · n 480 · Phase 3 · secondary NCT02889796
  • 12.9% vs 5.9% 100 mg · wk 4 · n 480 · Phase 3 · secondary NCT02889796
  • 5.8% vs 1.1% 100 mg · wk 2 · n 480 · Phase 3 · secondary NCT02889796
  • 60.6% vs 66% 100 mg · wk 52 · n 480 · Phase 3 · secondary NCT02889796
  • 45.6% vs 18.9% 200 mg · wk 24 · n 147 · Phase 3 · secondary NCT02873936
  • 42.9% vs 14.9% 200 mg · wk 12 · n 147 · Phase 3 · secondary NCT02873936
  • 22.4% vs 7.4% 200 mg · wk 4 · n 147 · Phase 3 · secondary NCT02873936
  • 35.3% vs 18.9% 100 mg · wk 24 · n 153 · Phase 3 · secondary NCT02873936
  • 32% vs 14.9% 100 mg · wk 12 · n 153 · Phase 3 · secondary NCT02873936
  • 21.6% vs 7.4% 100 mg · wk 4 · n 153 · Phase 3 · secondary NCT02873936
  • 58.1% vs 45.7% 200 mg · wk 24 · n 210 · Phase 3 · secondary NCT02886728
  • 45.7% vs 28.4% 200 mg · wk 12 · n 210 · Phase 3 · secondary NCT02886728
  • 58.6% vs 48.6% 200 mg · wk 36 · n 210 · Phase 3 · secondary NCT02886728
  • 25.7% vs 9.4% 200 mg · wk 4 · n 210 · Phase 3 · secondary NCT02886728
  • 16.2% vs 2.9% 200 mg · wk 2 · n 210 · Phase 3 · secondary NCT02886728
  • 61.4% vs 48.3% 200 mg · wk 52 · n 210 · Phase 3 · secondary NCT02886728
  • 61.5% vs 45.7% 200 mg · wk 24 · n 416 · Phase 3 · secondary NCT02886728
  • 53.1% vs 28.4% 200 mg · wk 12 · n 416 · Phase 3 · secondary NCT02886728
  • 60.6% vs 48.6% 200 mg · wk 36 · n 416 · Phase 3 · secondary NCT02886728
  • 29.3% vs 9.4% 200 mg · wk 4 · n 416 · Phase 3 · secondary NCT02886728
  • 13% vs 2.9% 200 mg · wk 2 · n 416 · Phase 3 · secondary NCT02886728
  • 62.3% vs 48.3% 200 mg · wk 52 · n 416 · Phase 3 · secondary NCT02886728
  • 57% vs 45.7% 100 mg · wk 24 · n 207 · Phase 3 · secondary NCT02886728
  • 44.4% vs 28.4% 100 mg · wk 12 · n 207 · Phase 3 · secondary NCT02886728
  • 55.6% vs 48.6% 100 mg · wk 36 · n 207 · Phase 3 · secondary NCT02886728
  • 20.8% vs 9.4% 100 mg · wk 4 · n 207 · Phase 3 · secondary NCT02886728
  • 9.2% vs 2.9% 100 mg · wk 2 · n 207 · Phase 3 · secondary NCT02886728
  • 59.4% vs 48.3% 100 mg · wk 52 · n 207 · Phase 3 · secondary NCT02886728
  • 50% vs 16.3% 200 mg QD · wk 24 · n 86 · Phase 2 · secondary NCT01888874
  • 43.5% vs 11.1% 200 mg QD · wk 12 · n 69 · Phase 2 · secondary NCT01894516
  • 43% vs 15.1% 200 mg QD · wk 12 · n 86 · Phase 2 · secondary NCT01888874
  • 31.9% vs 5.6% 200 mg QD · wk 8 · n 69 · Phase 2 · secondary NCT01894516
  • 33.7% vs 12.8% 200 mg QD · wk 8 · n 86 · Phase 2 · secondary NCT01888874
  • 23.2% vs 4.2% 200 mg QD · wk 4 · n 69 · Phase 2 · secondary NCT01894516
  • 17.4% vs 7% 200 mg QD · wk 4 · n 86 · Phase 2 · secondary NCT01888874
  • 21.7% vs 4.2% 200 mg QD · wk 2 · n 69 · Phase 2 · secondary NCT01894516
  • 10.5% vs 5.8% 200 mg QD · wk 2 · n 86 · Phase 2 · secondary NCT01888874
  • 7.2% vs 1.4% 200 mg QD · wk 1 · n 69 · Phase 2 · secondary NCT01894516
  • 4.7% vs 1.2% 200 mg QD · wk 1 · n 86 · Phase 2 · secondary NCT01888874
  • 47.1% vs 16.3% 100 mg QD · wk 24 · n 85 · Phase 2 · secondary NCT01888874
  • 54.8% vs 16.3% 100 mg BID · wk 24 · n 84 · Phase 2 · secondary NCT01888874
  • 37.1% vs 11.1% 100 mg QD · wk 12 · n 70 · Phase 2 · secondary NCT01894516
  • 37.6% vs 15.1% 100 mg QD · wk 12 · n 85 · Phase 2 · secondary NCT01888874
  • 54.8% vs 15.1% 100 mg BID · wk 12 · n 84 · Phase 2 · secondary NCT01888874
  • 25.7% vs 5.6% 100 mg QD · wk 8 · n 70 · Phase 2 · secondary NCT01894516
  • 35.3% vs 12.8% 100 mg QD · wk 8 · n 85 · Phase 2 · secondary NCT01888874
  • 45.2% vs 12.8% 100 mg BID · wk 8 · n 84 · Phase 2 · secondary NCT01888874
  • 18.6% vs 4.2% 100 mg QD · wk 4 · n 70 · Phase 2 · secondary NCT01894516
  • 32.9% vs 7% 100 mg QD · wk 4 · n 85 · Phase 2 · secondary NCT01888874
  • 34.5% vs 7% 100 mg BID · wk 4 · n 84 · Phase 2 · secondary NCT01888874
  • 7.1% vs 4.2% 100 mg QD · wk 2 · n 70 · Phase 2 · secondary NCT01894516
  • 20% vs 5.8% 100 mg QD · wk 2 · n 85 · Phase 2 · secondary NCT01888874
  • 21.4% vs 5.8% 100 mg BID · wk 2 · n 84 · Phase 2 · secondary NCT01888874
  • 10% vs 1.4% 100 mg QD · wk 1 · n 70 · Phase 2 · secondary NCT01894516
  • 4.7% vs 1.2% 100 mg QD · wk 1 · n 85 · Phase 2 · secondary NCT01888874
  • 7.1% vs 1.2% 100 mg BID · wk 1 · n 84 · Phase 2 · secondary NCT01888874
  • 35.4% vs 16.3% 50 mg QD · wk 24 · n 82 · Phase 2 · secondary NCT01888874
  • 35.3% vs 16.3% 50 mg BID · wk 24 · n 85 · Phase 2 · secondary NCT01888874
  • 34.7% vs 11.1% 50 mg QD · wk 12 · n 72 · Phase 2 · secondary NCT01894516
  • 32.9% vs 15.1% 50 mg QD · wk 12 · n 82 · Phase 2 · secondary NCT01888874
  • 34.1% vs 15.1% 50 mg BID · wk 12 · n 85 · Phase 2 · secondary NCT01888874
  • 16.7% vs 5.6% 50 mg QD · wk 8 · n 72 · Phase 2 · secondary NCT01894516
  • 26.8% vs 12.8% 50 mg QD · wk 8 · n 82 · Phase 2 · secondary NCT01888874
  • 34.1% vs 12.8% 50 mg BID · wk 8 · n 85 · Phase 2 · secondary NCT01888874
  • 15.3% vs 4.2% 50 mg QD · wk 4 · n 72 · Phase 2 · secondary NCT01894516
  • 13.4% vs 7% 50 mg QD · wk 4 · n 82 · Phase 2 · secondary NCT01888874
  • 18.8% vs 7% 50 mg BID · wk 4 · n 85 · Phase 2 · secondary NCT01888874
  • 5.6% vs 4.2% 50 mg QD · wk 2 · n 72 · Phase 2 · secondary NCT01894516
  • 7.3% vs 5.8% 50 mg QD · wk 2 · n 82 · Phase 2 · secondary NCT01888874
  • 11.8% vs 5.8% 50 mg BID · wk 2 · n 85 · Phase 2 · secondary NCT01888874
  • 1.4% vs 1.4% 50 mg QD · wk 1 · n 72 · Phase 2 · secondary NCT01894516
  • 2.4% vs 1.2% 50 mg QD · wk 1 · n 82 · Phase 2 · secondary NCT01888874
  • 7.1% vs 1.2% 50 mg BID · wk 1 · n 85 · Phase 2 · secondary NCT01888874
  • 34.9% vs 16.3% 25 mg BID · wk 24 · n 86 · Phase 2 · secondary NCT01888874
  • 27.9% vs 15.1% 25 mg BID · wk 12 · n 86 · Phase 2 · secondary NCT01888874
  • 25.6% vs 12.8% 25 mg BID · wk 8 · n 86 · Phase 2 · secondary NCT01888874
  • 15.1% vs 7% 25 mg BID · wk 4 · n 86 · Phase 2 · secondary NCT01888874
  • 7% vs 5.8% 25 mg BID · wk 2 · n 86 · Phase 2 · secondary NCT01888874
  • 3.5% vs 1.2% 25 mg BID · wk 1 · n 86 · Phase 2 · secondary NCT01888874
  • 47.6% vs 22.7% wk 12 · n 21 · Phase 2 · secondary NCT02885181
52.1% vs 28.3%vs Methotrexate15 mg · wk 12 · n 317NCT02706873
41 other results
  • 56.4% vs 28.3% 30 mg · wk 12 · n 314 · Phase 3 · primary NCT02706873
  • 38% vs 14.9% 15 mg · wk 12 · n 221 · Phase 3 · secondary NCT02675426
  • 34.1% vs 11.8% 15 mg · wk 12 · n 164 · Phase 3 · secondary NCT02706847
  • 40.8% vs 8.3% 15 mg · wk 12 · n 169 · Phase 3 · secondary NCT02955212
  • 43.4% vs 14.9% 30 mg · wk 12 · n 219 · Phase 3 · secondary NCT02675426
  • 35.8% vs 11.8% 30 mg · wk 12 · n 165 · Phase 3 · secondary NCT02706847
  • 65.3% vs 16.3% 15 mg · wk 12 · n 49 · Phase 2/3 · secondary NCT02720523
  • 58% vs 16.3% 30 mg · wk 12 · n 50 · Phase 2/3 · secondary NCT02720523
  • 40.8% vs 16.3% 7.5 mg · wk 12 · n 49 · Phase 2/3 · secondary NCT02720523
  • 60.3% vs 33.4% 15 mg · wk 24 · n 317 · Phase 3 · secondary NCT02706873
  • 41.9% vs 15.3% 15 mg · wk 14 · n 217 · Phase 3 · secondary NCT02706951
  • 65.6% vs 33.4% 30 mg · wk 24 · n 314 · Phase 3 · secondary NCT02706873
  • 52.1% vs 15.3% 30 mg · wk 14 · n 215 · Phase 3 · secondary NCT02706951
  • 66.7% vs 21.4% 15 mg · wk 12 · n 27 · Phase 3 · secondary NCT02706873
  • 71.4% vs 21.4% 30 mg · wk 12 · n 28 · Phase 3 · secondary NCT02706873
  • 60% vs 21.4% 7.5 mg · wk 12 · n 55 · Phase 3 · secondary NCT02706873
  • 29.3% vs 21.1% 60 mg · wk 12 · n 41 · Phase 2 · secondary NCT03682705
  • 19.5% vs 5.3% 60 mg · wk 8 · n 41 · Phase 2 · secondary NCT03682705
  • 17.1% vs 10.5% 60 mg · wk 4 · n 41 · Phase 2 · secondary NCT03682705
  • 4.9% vs 0% 60 mg · wk 2 · n 41 · Phase 2 · secondary NCT03682705
  • 43.8% vs 19.6% 24 mg QD · wk 12 · n 48 · Phase 2 · secondary NCT02066389
  • 12.8% vs 21.1% 20 mg · wk 12 · n 39 · Phase 2 · secondary NCT03682705
  • 12.8% vs 5.3% 20 mg · wk 8 · n 39 · Phase 2 · secondary NCT03682705
  • 2.6% vs 10.5% 20 mg · wk 4 · n 39 · Phase 2 · secondary NCT03682705
  • 0% vs 0% 20 mg · wk 2 · n 39 · Phase 2 · secondary NCT03682705
  • 44.7% vs 19.6% 18 mg BID · wk 12 · n 47 · Phase 2 · secondary NCT02066389
  • 40% vs 17% 18 mg BID · wk 12 · n 55 · Phase 2 · secondary NCT01960855
  • 45.2% vs 21.1% 15 mg/60 mg · wk 12 · n 62 · Phase 2 · secondary NCT03682705
  • 41.9% vs 5.3% 15 mg/60 mg · wk 8 · n 62 · Phase 2 · secondary NCT03682705
  • 19.4% vs 10.5% 15 mg/60 mg · wk 4 · n 62 · Phase 2 · secondary NCT03682705
  • 16.1% vs 0% 15 mg/60 mg · wk 2 · n 62 · Phase 2 · secondary NCT03682705
  • 50% vs 19.6% 12 mg BID · wk 12 · n 50 · Phase 2 · secondary NCT02066389
  • 43.6% vs 17% 12 mg BID · wk 12 · n 55 · Phase 2 · secondary NCT01960855
  • 49% vs 19.6% 6 mg BID · wk 12 · n 49 · Phase 2 · secondary NCT02066389
  • 38.5% vs 17% 6 mg BID · wk 12 · n 52 · Phase 2 · secondary NCT01960855
  • 17.1% vs 21.1% 5 mg · wk 12 · n 41 · Phase 2 · secondary NCT03682705
  • 7.3% vs 5.3% 5 mg · wk 8 · n 41 · Phase 2 · secondary NCT03682705
  • 4.9% vs 10.5% 5 mg · wk 4 · n 41 · Phase 2 · secondary NCT03682705
  • 0% vs 0% 5 mg · wk 2 · n 41 · Phase 2 · secondary NCT03682705
  • 39.6% vs 19.6% 3 mg BID · wk 12 · n 48 · Phase 2 · secondary NCT02066389
  • 24.1% vs 17% 3 mg BID · wk 12 · n 54 · Phase 2 · secondary NCT01960855
ACR7036.2% vs 14.9%+21.3 vs placebo200 mg · wk 24 · n 475NCT02889796
87 other results
  • 26.1% vs 6.7% 200 mg · wk 12 · n 475 · Phase 3 · secondary NCT02889796
  • 40.2% vs 34.6% 200 mg · wk 36 · n 475 · Phase 3 · secondary NCT02889796
  • 9.1% vs 1.5% 200 mg · wk 4 · n 475 · Phase 3 · secondary NCT02889796
  • 2.7% vs 0.4% 200 mg · wk 2 · n 475 · Phase 3 · secondary NCT02889796
  • 44.4% vs 37.7% 200 mg · wk 52 · n 475 · Phase 3 · secondary NCT02889796
  • 29.6% vs 14.9% 100 mg · wk 24 · n 480 · Phase 3 · secondary NCT02889796
  • 18.5% vs 6.7% 100 mg · wk 12 · n 480 · Phase 3 · secondary NCT02889796
  • 35.4% vs 34.6% 100 mg · wk 36 · n 480 · Phase 3 · secondary NCT02889796
  • 3.3% vs 1.5% 100 mg · wk 4 · n 480 · Phase 3 · secondary NCT02889796
  • 1.3% vs 0.4% 100 mg · wk 2 · n 480 · Phase 3 · secondary NCT02889796
  • 39% vs 37.7% 100 mg · wk 52 · n 480 · Phase 3 · secondary NCT02889796
  • 32% vs 8.1% 200 mg · wk 24 · n 147 · Phase 3 · secondary NCT02873936
  • 21.8% vs 6.8% 200 mg · wk 12 · n 147 · Phase 3 · secondary NCT02873936
  • 6.1% vs 2.7% 200 mg · wk 4 · n 147 · Phase 3 · secondary NCT02873936
  • 20.3% vs 8.1% 100 mg · wk 24 · n 153 · Phase 3 · secondary NCT02873936
  • 14.4% vs 6.8% 100 mg · wk 12 · n 153 · Phase 3 · secondary NCT02873936
  • 8.5% vs 2.7% 100 mg · wk 4 · n 153 · Phase 3 · secondary NCT02873936
  • 40% vs 26% 200 mg · wk 24 · n 210 · Phase 3 · secondary NCT02886728
  • 29% vs 13.2% 200 mg · wk 12 · n 210 · Phase 3 · secondary NCT02886728
  • 39.5% vs 32.2% 200 mg · wk 36 · n 210 · Phase 3 · secondary NCT02886728
  • 11.4% vs 3.8% 200 mg · wk 4 · n 210 · Phase 3 · secondary NCT02886728
  • 4.3% vs 0.7% 200 mg · wk 2 · n 210 · Phase 3 · secondary NCT02886728
  • 45.2% vs 29.8% 200 mg · wk 52 · n 210 · Phase 3 · secondary NCT02886728
  • 43.8% vs 26% 200 mg · wk 24 · n 416 · Phase 3 · secondary NCT02886728
  • 32.9% vs 13.2% 200 mg · wk 12 · n 416 · Phase 3 · secondary NCT02886728
  • 45.9% vs 32.2% 200 mg · wk 36 · n 416 · Phase 3 · secondary NCT02886728
  • 13% vs 3.8% 200 mg · wk 4 · n 416 · Phase 3 · secondary NCT02886728
  • 3.1% vs 0.7% 200 mg · wk 2 · n 416 · Phase 3 · secondary NCT02886728
  • 47.8% vs 29.8% 200 mg · wk 52 · n 416 · Phase 3 · secondary NCT02886728
  • 40.1% vs 26% 100 mg · wk 24 · n 207 · Phase 3 · secondary NCT02886728
  • 27.1% vs 13.2% 100 mg · wk 12 · n 207 · Phase 3 · secondary NCT02886728
  • 37.2% vs 32.2% 100 mg · wk 36 · n 207 · Phase 3 · secondary NCT02886728
  • 6.3% vs 3.8% 100 mg · wk 4 · n 207 · Phase 3 · secondary NCT02886728
  • 1.9% vs 0.7% 100 mg · wk 2 · n 207 · Phase 3 · secondary NCT02886728
  • 40.1% vs 29.8% 100 mg · wk 52 · n 207 · Phase 3 · secondary NCT02886728
  • 29.1% vs 9.3% 200 mg QD · wk 24 · n 86 · Phase 2 · secondary NCT01888874
  • 13% vs 2.8% 200 mg QD · wk 12 · n 69 · Phase 2 · secondary NCT01894516
  • 24.4% vs 8.1% 200 mg QD · wk 12 · n 86 · Phase 2 · secondary NCT01888874
  • 17.4% vs 2.8% 200 mg QD · wk 8 · n 69 · Phase 2 · secondary NCT01894516
  • 18.6% vs 7% 200 mg QD · wk 8 · n 86 · Phase 2 · secondary NCT01888874
  • 11.6% vs 1.4% 200 mg QD · wk 4 · n 69 · Phase 2 · secondary NCT01894516
  • 4.7% vs 3.5% 200 mg QD · wk 4 · n 86 · Phase 2 · secondary NCT01888874
  • 4.3% vs 2.8% 200 mg QD · wk 2 · n 69 · Phase 2 · secondary NCT01894516
  • 5.8% vs 1.2% 200 mg QD · wk 2 · n 86 · Phase 2 · secondary NCT01888874
  • 1.4% vs 0% 200 mg QD · wk 1 · n 69 · Phase 2 · secondary NCT01894516
  • 1.2% vs 1.2% 200 mg QD · wk 1 · n 86 · Phase 2 · secondary NCT01888874
  • 32.9% vs 9.3% 100 mg QD · wk 24 · n 85 · Phase 2 · secondary NCT01888874
  • 39.3% vs 9.3% 100 mg BID · wk 24 · n 84 · Phase 2 · secondary NCT01888874
  • 18.6% vs 2.8% 100 mg QD · wk 12 · n 70 · Phase 2 · secondary NCT01894516
  • 21.2% vs 8.1% 100 mg QD · wk 12 · n 85 · Phase 2 · secondary NCT01888874
  • 31% vs 8.1% 100 mg BID · wk 12 · n 84 · Phase 2 · secondary NCT01888874
  • 11.4% vs 2.8% 100 mg QD · wk 8 · n 70 · Phase 2 · secondary NCT01894516
  • 23.5% vs 7% 100 mg QD · wk 8 · n 85 · Phase 2 · secondary NCT01888874
  • 27.4% vs 7% 100 mg BID · wk 8 · n 84 · Phase 2 · secondary NCT01888874
  • 5.7% vs 1.4% 100 mg QD · wk 4 · n 70 · Phase 2 · secondary NCT01894516
  • 14.1% vs 3.5% 100 mg QD · wk 4 · n 85 · Phase 2 · secondary NCT01888874
  • 10.7% vs 3.5% 100 mg BID · wk 4 · n 84 · Phase 2 · secondary NCT01888874
  • 1.4% vs 2.8% 100 mg QD · wk 2 · n 70 · Phase 2 · secondary NCT01894516
  • 7.1% vs 1.2% 100 mg QD · wk 2 · n 85 · Phase 2 · secondary NCT01888874
  • 3.6% vs 1.2% 100 mg BID · wk 2 · n 84 · Phase 2 · secondary NCT01888874
  • 1.4% vs 0% 100 mg QD · wk 1 · n 70 · Phase 2 · secondary NCT01894516
  • 0% vs 1.2% 100 mg QD · wk 1 · n 85 · Phase 2 · secondary NCT01888874
  • 4.8% vs 1.2% 100 mg BID · wk 1 · n 84 · Phase 2 · secondary NCT01888874
  • 22% vs 9.3% 50 mg QD · wk 24 · n 82 · Phase 2 · secondary NCT01888874
  • 23.5% vs 9.3% 50 mg BID · wk 24 · n 85 · Phase 2 · secondary NCT01888874
  • 8.3% vs 2.8% 50 mg QD · wk 12 · n 72 · Phase 2 · secondary NCT01894516
  • 15.9% vs 8.1% 50 mg QD · wk 12 · n 82 · Phase 2 · secondary NCT01888874
  • 18.8% vs 8.1% 50 mg BID · wk 12 · n 85 · Phase 2 · secondary NCT01888874
  • 6.9% vs 2.8% 50 mg QD · wk 8 · n 72 · Phase 2 · secondary NCT01894516
  • 11% vs 7% 50 mg QD · wk 8 · n 82 · Phase 2 · secondary NCT01888874
  • 14.1% vs 7% 50 mg BID · wk 8 · n 85 · Phase 2 · secondary NCT01888874
  • 8.3% vs 1.4% 50 mg QD · wk 4 · n 72 · Phase 2 · secondary NCT01894516
  • 7.3% vs 3.5% 50 mg QD · wk 4 · n 82 · Phase 2 · secondary NCT01888874
  • 9.4% vs 3.5% 50 mg BID · wk 4 · n 85 · Phase 2 · secondary NCT01888874
  • 1.4% vs 2.8% 50 mg QD · wk 2 · n 72 · Phase 2 · secondary NCT01894516
  • 2.4% vs 1.2% 50 mg QD · wk 2 · n 82 · Phase 2 · secondary NCT01888874
  • 5.9% vs 1.2% 50 mg BID · wk 2 · n 85 · Phase 2 · secondary NCT01888874
  • 0% vs 0% 50 mg QD · wk 1 · n 72 · Phase 2 · secondary NCT01894516
  • 0% vs 1.2% 50 mg QD · wk 1 · n 82 · Phase 2 · secondary NCT01888874
  • 2.4% vs 1.2% 50 mg BID · wk 1 · n 85 · Phase 2 · secondary NCT01888874
  • 20.9% vs 9.3% 25 mg BID · wk 24 · n 86 · Phase 2 · secondary NCT01888874
  • 14% vs 8.1% 25 mg BID · wk 12 · n 86 · Phase 2 · secondary NCT01888874
  • 9.3% vs 7% 25 mg BID · wk 8 · n 86 · Phase 2 · secondary NCT01888874
  • 5.8% vs 3.5% 25 mg BID · wk 4 · n 86 · Phase 2 · secondary NCT01888874
  • 2.3% vs 1.2% 25 mg BID · wk 2 · n 86 · Phase 2 · secondary NCT01888874
  • 1.2% vs 1.2% 25 mg BID · wk 1 · n 86 · Phase 2 · secondary NCT01888874
  • 38.1% vs 13.6% wk 12 · n 21 · Phase 2 · secondary NCT02885181
20.8% vs 5.9%+14.9 vs placebo15 mg · wk 12 · n 221NCT02675426
41 other results
  • 11.6% vs 6.5% 15 mg · wk 12 · n 164 · Phase 3 · secondary NCT02706847
  • 21.3% vs 3.6% 15 mg · wk 12 · n 169 · Phase 3 · secondary NCT02955212
  • 26.5% vs 5.9% 30 mg · wk 12 · n 219 · Phase 3 · secondary NCT02675426
  • 23% vs 6.5% 30 mg · wk 12 · n 165 · Phase 3 · secondary NCT02706847
  • 34.7% vs 2% 15 mg · wk 12 · n 49 · Phase 2/3 · secondary NCT02720523
  • 28% vs 2% 30 mg · wk 12 · n 50 · Phase 2/3 · secondary NCT02720523
  • 20.4% vs 2% 7.5 mg · wk 12 · n 49 · Phase 2/3 · secondary NCT02720523
  • 44.5% vs 18.5% 15 mg · wk 24 · n 317 · Phase 3 · secondary NCT02706873
  • 22.6% vs 2.8% 15 mg · wk 14 · n 217 · Phase 3 · secondary NCT02706951
  • 32.5% vs 14% 15 mg · wk 12 · n 317 · Phase 3 · secondary NCT02706873
  • 49.7% vs 18.5% 30 mg · wk 24 · n 314 · Phase 3 · secondary NCT02706873
  • 33% vs 2.8% 30 mg · wk 14 · n 215 · Phase 3 · secondary NCT02706951
  • 36.9% vs 14% 30 mg · wk 12 · n 314 · Phase 3 · secondary NCT02706873
  • 51.9% vs 0% 15 mg · wk 12 · n 27 · Phase 3 · secondary NCT02706873
  • 64.3% vs 0% 30 mg · wk 12 · n 28 · Phase 3 · secondary NCT02706873
  • 34.5% vs 0% 7.5 mg · wk 12 · n 55 · Phase 3 · secondary NCT02706873
  • 14.6% vs 15.8% 60 mg · wk 12 · n 41 · Phase 2 · secondary NCT03682705
  • 4.9% vs 0% 60 mg · wk 8 · n 41 · Phase 2 · secondary NCT03682705
  • 4.9% vs 0% 60 mg · wk 4 · n 41 · Phase 2 · secondary NCT03682705
  • 2.4% vs 0% 60 mg · wk 2 · n 41 · Phase 2 · secondary NCT03682705
  • 25% vs 6.5% 24 mg QD · wk 12 · n 48 · Phase 2 · secondary NCT02066389
  • 5.1% vs 15.8% 20 mg · wk 12 · n 39 · Phase 2 · secondary NCT03682705
  • 2.6% vs 0% 20 mg · wk 8 · n 39 · Phase 2 · secondary NCT03682705
  • 2.6% vs 0% 20 mg · wk 4 · n 39 · Phase 2 · secondary NCT03682705
  • 0% vs 0% 20 mg · wk 2 · n 39 · Phase 2 · secondary NCT03682705
  • 27.7% vs 6.5% 18 mg BID · wk 12 · n 47 · Phase 2 · secondary NCT02066389
  • 21.8% vs 3.6% 18 mg BID · wk 12 · n 55 · Phase 2 · secondary NCT01960855
  • 25.8% vs 15.8% 15 mg/60 mg · wk 12 · n 62 · Phase 2 · secondary NCT03682705
  • 17.7% vs 0% 15 mg/60 mg · wk 8 · n 62 · Phase 2 · secondary NCT03682705
  • 9.7% vs 0% 15 mg/60 mg · wk 4 · n 62 · Phase 2 · secondary NCT03682705
  • 8.1% vs 0% 15 mg/60 mg · wk 2 · n 62 · Phase 2 · secondary NCT03682705
  • 16% vs 6.5% 12 mg BID · wk 12 · n 50 · Phase 2 · secondary NCT02066389
  • 21.8% vs 3.6% 12 mg BID · wk 12 · n 55 · Phase 2 · secondary NCT01960855
  • 30.6% vs 6.5% 6 mg BID · wk 12 · n 49 · Phase 2 · secondary NCT02066389
  • 26.9% vs 3.6% 6 mg BID · wk 12 · n 52 · Phase 2 · secondary NCT01960855
  • 9.8% vs 15.8% 5 mg · wk 12 · n 41 · Phase 2 · secondary NCT03682705
  • 0% vs 0% 5 mg · wk 8 · n 41 · Phase 2 · secondary NCT03682705
  • 0% vs 0% 5 mg · wk 4 · n 41 · Phase 2 · secondary NCT03682705
  • 0% vs 0% 5 mg · wk 2 · n 41 · Phase 2 · secondary NCT03682705
  • 23.4% vs 6.5% 3 mg BID · wk 12 · n 47 · Phase 2 · secondary NCT02066389
  • 13% vs 3.6% 3 mg BID · wk 12 · n 54 · Phase 2 · secondary NCT01960855
DAS28-CRP remission48.4% vs 16.2%+32.2 vs placebo200 mg · wk 24 · n 475NCT02889796
35 other results
  • 34.1% vs 9.3% 200 mg · wk 12 · n 475 · Phase 3 · secondary NCT02889796
  • 50.3% vs 46.1% 200 mg · wk 36 · n 475 · Phase 3 · secondary NCT02889796
  • 13.7% vs 2.9% 200 mg · wk 4 · n 475 · Phase 3 · secondary NCT02889796
  • 5.1% vs 0.6% 200 mg · wk 2 · n 475 · Phase 3 · secondary NCT02889796
  • 54.5% vs 50.8% 200 mg · wk 52 · n 475 · Phase 3 · secondary NCT02889796
  • 35.2% vs 16.2% 100 mg · wk 24 · n 480 · Phase 3 · secondary NCT02889796
  • 23.8% vs 9.3% 100 mg · wk 12 · n 480 · Phase 3 · secondary NCT02889796
  • 42.9% vs 46.1% 100 mg · wk 36 · n 480 · Phase 3 · secondary NCT02889796
  • 8.8% vs 2.9% 100 mg · wk 4 · n 480 · Phase 3 · secondary NCT02889796
  • 1.7% vs 0.6% 100 mg · wk 2 · n 480 · Phase 3 · secondary NCT02889796
  • 44.8% vs 50.8% 100 mg · wk 52 · n 480 · Phase 3 · secondary NCT02889796
  • 30.6% vs 12.2% 200 mg · wk 24 · n 147 · Phase 3 · secondary NCT02873936
  • 22.4% vs 8.1% 200 mg · wk 12 · n 147 · Phase 3 · secondary NCT02873936
  • 10.2% vs 2.7% 200 mg · wk 4 · n 147 · Phase 3 · secondary NCT02873936
  • 26.1% vs 12.2% 100 mg · wk 24 · n 153 · Phase 3 · secondary NCT02873936
  • 25.5% vs 8.1% 100 mg · wk 12 · n 153 · Phase 3 · secondary NCT02873936
  • 11.8% vs 2.7% 100 mg · wk 4 · n 153 · Phase 3 · secondary NCT02873936
  • 42.4% vs 29.1% 200 mg · wk 24 · n 210 · Phase 3 · secondary NCT02886728
  • 29.5% vs 17.1% 200 mg · wk 12 · n 210 · Phase 3 · secondary NCT02886728
  • 43.3% vs 34.4% 200 mg · wk 36 · n 210 · Phase 3 · secondary NCT02886728
  • 19.5% vs 4.8% 200 mg · wk 4 · n 210 · Phase 3 · secondary NCT02886728
  • 10% vs 1% 200 mg · wk 2 · n 210 · Phase 3 · secondary NCT02886728
  • 46.2% vs 31.5% 200 mg · wk 52 · n 210 · Phase 3 · secondary NCT02886728
  • 54.1% vs 29.1% 200 mg · wk 24 · n 416 · Phase 3 · secondary NCT02886728
  • 39.7% vs 17.1% 200 mg · wk 12 · n 416 · Phase 3 · secondary NCT02886728
  • 52.6% vs 34.4% 200 mg · wk 36 · n 416 · Phase 3 · secondary NCT02886728
  • 16.6% vs 4.8% 200 mg · wk 4 · n 416 · Phase 3 · secondary NCT02886728
  • 7.2% vs 1% 200 mg · wk 2 · n 416 · Phase 3 · secondary NCT02886728
  • 53.4% vs 31.5% 200 mg · wk 52 · n 416 · Phase 3 · secondary NCT02886728
  • 42.5% vs 29.1% 100 mg · wk 24 · n 207 · Phase 3 · secondary NCT02886728
  • 31.9% vs 17.1% 100 mg · wk 12 · n 207 · Phase 3 · secondary NCT02886728
  • 42% vs 34.4% 100 mg · wk 36 · n 207 · Phase 3 · secondary NCT02886728
  • 15% vs 4.8% 100 mg · wk 4 · n 207 · Phase 3 · secondary NCT02886728
  • 4.3% vs 1% 100 mg · wk 2 · n 207 · Phase 3 · secondary NCT02886728
  • 43% vs 31.5% 100 mg · wk 52 · n 207 · Phase 3 · secondary NCT02886728
48.3% vs 18.5%vs Methotrexate15 mg · wk 24 · n 317NCT02706873
22 other results
  • 50% vs 18.5% 30 mg · wk 24 · n 314 · Phase 3 · primary NCT02706873
  • 30.8% vs 10% 15 mg · wk 12 · n 221 · Phase 3 · secondary NCT02675426
  • 29.6% vs 5.3% 15 mg · wk 12 · n 169 · Phase 3 · secondary NCT02955212
  • 28.3% vs 10% 30 mg · wk 12 · n 219 · Phase 3 · secondary NCT02675426
  • 57.1% vs 6.1% 15 mg · wk 12 · n 49 · Phase 2/3 · secondary NCT02720523
  • 50% vs 6.1% 30 mg · wk 12 · n 50 · Phase 2/3 · secondary NCT02720523
  • 36.7% vs 6.1% 7.5 mg · wk 12 · n 49 · Phase 2/3 · secondary NCT02720523
  • 28.1% vs 8.3% 15 mg · wk 14 · n 217 · Phase 3 · secondary NCT02706951
  • 30% vs 13.3% 15 mg QD · wk 12 · n 303 · Phase 3 · secondary NCT03086343
  • 40.5% vs 8.3% 30 mg · wk 14 · n 215 · Phase 3 · secondary NCT02706951
  • 70.4% vs 17.9% 15 mg · wk 24 · n 27 · Phase 3 · secondary NCT02706873
  • 82.1% vs 17.9% 30 mg · wk 24 · n 28 · Phase 3 · secondary NCT02706873
  • 67.3% vs 17.9% 7.5 mg · wk 24 · n 55 · Phase 3 · secondary NCT02706873
  • 19.5% vs 10.5% 60 mg · wk 12 · n 41 · Phase 2 · secondary NCT03682705
  • 22.4% vs 14.9% 24 mg QD · wk 12 · n 49 · Phase 2 · secondary NCT02066389
  • 7.7% vs 10.5% 20 mg · wk 12 · n 39 · Phase 2 · secondary NCT03682705
  • 42.9% vs 14.9% 18 mg BID · wk 12 · n 49 · Phase 2 · secondary NCT02066389
  • 32.3% vs 10.5% 15 mg/60 mg · wk 12 · n 62 · Phase 2 · secondary NCT03682705
  • 34% vs 14.9% 12 mg BID · wk 12 · n 50 · Phase 2 · secondary NCT02066389
  • 38.8% vs 14.9% 6 mg BID · wk 12 · n 49 · Phase 2 · secondary NCT02066389
  • 9.8% vs 10.5% 5 mg · wk 12 · n 41 · Phase 2 · secondary NCT03682705
  • 36.7% vs 14.9% 3 mg BID · wk 12 · n 49 · Phase 2 · secondary NCT02066389
HAQ-DI, change-0.8 vs -0.6−0.2 vs placebo200 mg · wk 24 · n 475NCT02889796
36 other results
  • -0.7 vs -0.4 200 mg · wk 12 · n 475 · Phase 3 · secondary NCT02889796
  • -0.9 vs -0.7 200 mg · wk 36 · n 475 · Phase 3 · secondary NCT02889796
  • -0.4 vs -0.3 200 mg · wk 4 · n 475 · Phase 3 · secondary NCT02889796
  • -0.3 vs -0.1 200 mg · wk 2 · n 475 · Phase 3 · secondary NCT02889796
  • -0.9 vs -0.7 200 mg · wk 52 · n 475 · Phase 3 · secondary NCT02889796
  • -0.8 vs -0.6 100 mg · wk 24 · n 480 · Phase 3 · secondary NCT02889796
  • -0.6 vs -0.4 100 mg · wk 12 · n 480 · Phase 3 · secondary NCT02889796
  • -0.8 vs -0.7 100 mg · wk 36 · n 480 · Phase 3 · secondary NCT02889796
  • -0.3 vs -0.3 100 mg · wk 4 · n 480 · Phase 3 · secondary NCT02889796
  • -0.2 vs -0.1 100 mg · wk 2 · n 480 · Phase 3 · secondary NCT02889796
  • -0.8 vs -0.7 100 mg · wk 52 · n 480 · Phase 3 · secondary NCT02889796
  • -0.8 vs -0.4 200 mg · wk 24 · n 147 · Phase 3 · secondary NCT02873936
  • -0.6 vs -0.2 200 mg · wk 12 · n 147 · Phase 3 · secondary NCT02873936
  • -0.4 vs -0.2 200 mg · wk 4 · n 147 · Phase 3 · secondary NCT02873936
  • -0.6 vs -0.4 100 mg · wk 24 · n 153 · Phase 3 · secondary NCT02873936
  • -0.5 vs -0.2 100 mg · wk 12 · n 153 · Phase 3 · secondary NCT02873936
  • -0.3 vs -0.2 100 mg · wk 4 · n 153 · Phase 3 · secondary NCT02873936
  • -0.9 vs -0.8 200 mg · wk 24 · n 210 · Phase 3 · secondary NCT02886728
  • -0.8 vs -0.6 200 mg · wk 12 · n 210 · Phase 3 · secondary NCT02886728
  • -0.9 vs -0.9 200 mg · wk 36 · n 210 · Phase 3 · secondary NCT02886728
  • -0.5 vs -0.3 200 mg · wk 4 · n 210 · Phase 3 · secondary NCT02886728
  • -0.3 vs -0.2 200 mg · wk 2 · n 210 · Phase 3 · secondary NCT02886728
  • -0.9 vs -0.9 200 mg · wk 52 · n 210 · Phase 3 · secondary NCT02886728
  • -0.9 vs -0.8 200 mg · wk 24 · n 416 · Phase 3 · secondary NCT02886728
  • -0.8 vs -0.6 200 mg · wk 12 · n 416 · Phase 3 · secondary NCT02886728
  • -1.0 vs -0.9 200 mg · wk 36 · n 416 · Phase 3 · secondary NCT02886728
  • -0.6 vs -0.3 200 mg · wk 4 · n 416 · Phase 3 · secondary NCT02886728
  • -0.4 vs -0.2 200 mg · wk 2 · n 416 · Phase 3 · secondary NCT02886728
  • -1 vs -0.9 200 mg · wk 52 · n 416 · Phase 3 · secondary NCT02886728
  • -0.9 vs -0.8 100 mg · wk 24 · n 207 · Phase 3 · secondary NCT02886728
  • -0.8 vs -0.6 100 mg · wk 12 · n 207 · Phase 3 · secondary NCT02886728
  • -0.9 vs -0.9 100 mg · wk 36 · n 207 · Phase 3 · secondary NCT02886728
  • -0.5 vs -0.3 100 mg · wk 4 · n 207 · Phase 3 · secondary NCT02886728
  • -0.4 vs -0.2 100 mg · wk 2 · n 207 · Phase 3 · secondary NCT02886728
  • -1.0 vs -0.9 100 mg · wk 52 · n 207 · Phase 3 · secondary NCT02886728
  • -0.7 vs -0.4 wk 12 · n 21 · Phase 2 · secondary NCT02885181
-0.6 vs -0.3−0.3 vs placebo15 mg · wk 12 · n 216NCT02675426
32 other results
  • -0.4 vs -0.2 15 mg · wk 12 · n 163 · Phase 3 · secondary NCT02706847
  • -0.6 vs -0.2 15 mg · wk 12 · n 169 · Phase 3 · secondary NCT02955212
  • -0.5 vs -0.3 30 mg · wk 12 · n 219 · Phase 3 · secondary NCT02675426
  • -0.4 vs -0.2 30 mg · wk 12 · n 160 · Phase 3 · secondary NCT02706847
  • -0.5 vs -0.1 15 mg · wk 12 · n 49 · Phase 2/3 · secondary NCT02720523
  • -0.5 vs -0.1 30 mg · wk 12 · n 50 · Phase 2/3 · secondary NCT02720523
  • -0.4 vs -0.1 7.5 mg · wk 12 · n 49 · Phase 2/3 · secondary NCT02720523
  • -0.9 vs -0.6 15 mg · wk 24 · n 317 · Phase 3 · secondary NCT02706873
  • -0.7 vs -0.3 15 mg · wk 14 · n 216 · Phase 3 · secondary NCT02706951
  • -0.8 vs -0.5 15 mg · wk 12 · n 317 · Phase 3 · secondary NCT02706873
  • -0.9 vs -0.6 30 mg · wk 24 · n 310 · Phase 3 · secondary NCT02706873
  • -0.7 vs -0.3 30 mg · wk 14 · n 215 · Phase 3 · secondary NCT02706951
  • -0.9 vs -0.5 30 mg · wk 12 · n 310 · Phase 3 · secondary NCT02706873
  • -0.9 vs -0.2 15 mg · wk 12 · n 27 · Phase 3 · secondary NCT02706873
  • -0.9 vs -0.2 30 mg · wk 12 · n 28 · Phase 3 · secondary NCT02706873
  • -0.8 vs -0.2 7.5 mg · wk 12 · n 55 · Phase 3 · secondary NCT02706873
  • -0.3 vs -0.3 60 mg · wk 12 · n 39 · Phase 2 · secondary NCT03682705
  • -0.3 vs -0.2 60 mg · wk 8 · n 39 · Phase 2 · secondary NCT03682705
  • -0.1 vs -0.4 60 mg · wk 4 · n 39 · Phase 2 · secondary NCT03682705
  • -0.1 vs -0.2 60 mg · wk 2 · n 39 · Phase 2 · secondary NCT03682705
  • -0.1 vs -0.3 20 mg · wk 12 · n 35 · Phase 2 · secondary NCT03682705
  • -0.1 vs -0.2 20 mg · wk 8 · n 35 · Phase 2 · secondary NCT03682705
  • -0.1 vs -0.4 20 mg · wk 4 · n 35 · Phase 2 · secondary NCT03682705
  • -0.1 vs -0.2 20 mg · wk 2 · n 35 · Phase 2 · secondary NCT03682705
  • -0.5 vs -0.3 15 mg/60 mg · wk 12 · n 59 · Phase 2 · secondary NCT03682705
  • -0.5 vs -0.2 15 mg/60 mg · wk 8 · n 59 · Phase 2 · secondary NCT03682705
  • -0.4 vs -0.4 15 mg/60 mg · wk 4 · n 59 · Phase 2 · secondary NCT03682705
  • -0.3 vs -0.2 15 mg/60 mg · wk 2 · n 59 · Phase 2 · secondary NCT03682705
  • -0.2 vs -0.3 5 mg · wk 12 · n 40 · Phase 2 · secondary NCT03682705
  • -0.1 vs -0.2 5 mg · wk 8 · n 40 · Phase 2 · secondary NCT03682705
  • -0.2 vs -0.4 5 mg · wk 4 · n 40 · Phase 2 · secondary NCT03682705
  • -0.2 vs -0.2 5 mg · wk 2 · n 40 · Phase 2 · secondary NCT03682705
Modified Sharp score, change0.1 vs 0.4−0.2 vs placebo200 mg · wk 24 · n 467NCT02889796
9 other results
  • 0.2 vs 0.9 200 mg · wk 52 · n 468 · Phase 3 · secondary NCT02889796
  • 0.2 vs 0.4 100 mg · wk 24 · n 471 · Phase 3 · secondary NCT02889796
  • 0.5 vs 0.9 100 mg · wk 52 · n 472 · Phase 3 · secondary NCT02889796
  • -0.0 vs 0.5 200 mg · wk 24 · n 210 · Phase 3 · secondary NCT02886728
  • 0.3 vs 0.8 200 mg · wk 52 · n 210 · Phase 3 · secondary NCT02886728
  • 0.2 vs 0.5 200 mg · wk 24 · n 416 · Phase 3 · secondary NCT02886728
  • 0.3 vs 0.8 200 mg · wk 52 · n 416 · Phase 3 · secondary NCT02886728
  • 0.2 vs 0.5 100 mg · wk 24 · n 207 · Phase 3 · secondary NCT02886728
  • 0.2 vs 0.8 100 mg · wk 52 · n 207 · Phase 3 · secondary NCT02886728
0.1 vs 0.7vs Methotrexate15 mg · wk 24 · n 279NCT02706873
4 other results
  • 0.1 vs 0.7 30 mg · wk 24 · n 270 · Phase 3 · primary NCT02706873
  • 0.2 vs 2.6 15 mg · wk 24 · n 26 · Phase 3 · secondary NCT02706873
  • 0.2 vs 2.6 30 mg · wk 24 · n 24 · Phase 3 · secondary NCT02706873
  • 0.9 vs 2.6 7.5 mg · wk 24 · n 51 · Phase 3 · secondary NCT02706873

ACR20

filgotinib
76.6% vs 49.9%+26.7 vs placebo200 mg · wk 12 · n 475NCT02889796
51 other results
  • 69.8% vs 49.9% 100 mg · wk 12 · n 480 · Phase 3 · primary NCT02889796
  • 66% vs 31.1% 200 mg · wk 12 · n 147 · Phase 3 · primary NCT02873936
  • 57.5% vs 31.1% 100 mg · wk 12 · n 153 · Phase 3 · primary NCT02873936
  • 78.1% vs 71.4% 200 mg · wk 24 · n 210 · Phase 3 · primary NCT02886728
  • 81% vs 71.4% 200 mg · wk 24 · n 416 · Phase 3 · primary NCT02886728
  • 80.2% vs 71.4% 100 mg · wk 24 · n 207 · Phase 3 · primary NCT02886728
  • 78.1% vs 59.2% 200 mg · wk 24 · n 475 · Phase 3 · secondary NCT02889796
  • 82.9% vs 86.9% 200 mg · wk 36 · n 475 · Phase 3 · secondary NCT02889796
  • 51.6% vs 31.8% 200 mg · wk 4 · n 475 · Phase 3 · secondary NCT02889796
  • 37.3% vs 14.9% 200 mg · wk 2 · n 475 · Phase 3 · secondary NCT02889796
  • 82.9% vs 85.9% 200 mg · wk 52 · n 475 · Phase 3 · secondary NCT02889796
  • 77.7% vs 59.2% 100 mg · wk 24 · n 480 · Phase 3 · secondary NCT02889796
  • 79.2% vs 86.9% 100 mg · wk 36 · n 480 · Phase 3 · secondary NCT02889796
  • 45.6% vs 31.8% 100 mg · wk 4 · n 480 · Phase 3 · secondary NCT02889796
  • 27.5% vs 14.9% 100 mg · wk 2 · n 480 · Phase 3 · secondary NCT02889796
  • 79.6% vs 85.9% 100 mg · wk 52 · n 480 · Phase 3 · secondary NCT02889796
  • 69.4% vs 34.5% 200 mg · wk 24 · n 147 · Phase 3 · secondary NCT02873936
  • 51.7% vs 25.7% 200 mg · wk 4 · n 147 · Phase 3 · secondary NCT02873936
  • 54.9% vs 34.5% 100 mg · wk 24 · n 153 · Phase 3 · secondary NCT02873936
  • 44.4% vs 25.7% 100 mg · wk 4 · n 153 · Phase 3 · secondary NCT02873936
  • 71.4% vs 59.4% 200 mg · wk 12 · n 210 · Phase 3 · secondary NCT02886728
  • 76.2% vs 68.3% 200 mg · wk 36 · n 210 · Phase 3 · secondary NCT02886728
  • 52.4% vs 33.4% 200 mg · wk 4 · n 210 · Phase 3 · secondary NCT02886728
  • 39.5% vs 16.6% 200 mg · wk 2 · n 210 · Phase 3 · secondary NCT02886728
  • 74.8% vs 61.8% 200 mg · wk 52 · n 210 · Phase 3 · secondary NCT02886728
  • 76.7% vs 59.4% 200 mg · wk 12 · n 416 · Phase 3 · secondary NCT02886728
  • 75.5% vs 68.3% 200 mg · wk 36 · n 416 · Phase 3 · secondary NCT02886728
  • 62.3% vs 33.4% 200 mg · wk 4 · n 416 · Phase 3 · secondary NCT02886728
  • 42.1% vs 16.6% 200 mg · wk 2 · n 416 · Phase 3 · secondary NCT02886728
  • 75% vs 61.8% 200 mg · wk 52 · n 416 · Phase 3 · secondary NCT02886728
  • 72% vs 59.4% 100 mg · wk 12 · n 207 · Phase 3 · secondary NCT02886728
  • 73.4% vs 68.3% 100 mg · wk 36 · n 207 · Phase 3 · secondary NCT02886728
  • 55.6% vs 33.4% 100 mg · wk 4 · n 207 · Phase 3 · secondary NCT02886728
  • 37.2% vs 16.6% 100 mg · wk 2 · n 207 · Phase 3 · secondary NCT02886728
  • 73.4% vs 61.8% 100 mg · wk 52 · n 207 · Phase 3 · secondary NCT02886728
  • 72.5% vs 29.2% 200 mg QD · wk 12 · n 69 · Phase 2 · primary NCT01894516
  • 68.6% vs 44.2% 200 mg QD · wk 12 · n 86 · Phase 2 · primary NCT01888874
  • 65.7% vs 29.2% 100 mg QD · wk 12 · n 70 · Phase 2 · primary NCT01894516
  • 63.5% vs 44.2% 100 mg QD · wk 12 · n 85 · Phase 2 · primary NCT01888874
  • 78.6% vs 44.2% 100 mg BID · wk 12 · n 84 · Phase 2 · primary NCT01888874
  • 66.7% vs 29.2% 50 mg QD · wk 12 · n 72 · Phase 2 · primary NCT01894516
  • 56.1% vs 44.2% 50 mg QD · wk 12 · n 82 · Phase 2 · primary NCT01888874
  • 60% vs 44.2% 50 mg BID · wk 12 · n 85 · Phase 2 · primary NCT01888874
  • 57% vs 44.2% 25 mg BID · wk 12 · n 86 · Phase 2 · primary NCT01888874
  • 73.3% vs 41.9% 200 mg QD · wk 24 · n 86 · Phase 2 · secondary NCT01888874
  • 61.2% vs 41.9% 100 mg QD · wk 24 · n 85 · Phase 2 · secondary NCT01888874
  • 79.8% vs 41.9% 100 mg BID · wk 24 · n 84 · Phase 2 · secondary NCT01888874
  • 54.9% vs 41.9% 50 mg QD · wk 24 · n 82 · Phase 2 · secondary NCT01888874
  • 60% vs 41.9% 50 mg BID · wk 24 · n 85 · Phase 2 · secondary NCT01888874
  • 55.8% vs 41.9% 25 mg BID · wk 24 · n 86 · Phase 2 · secondary NCT01888874
  • 81% vs 40.9% wk 12 · n 21 · Phase 2 · secondary NCT02885181
upadacitinib
63.8% vs 35.7%+28.1 vs placebo15 mg · wk 12 · n 221NCT02675426
49 other results
  • 64.6% vs 28.4% 15 mg · wk 12 · n 164 · Phase 3 · primary NCT02706847
  • 71.6% vs 31.4% 15 mg · wk 12 · n 169 · Phase 3 · primary NCT02955212
  • 66.2% vs 35.7% 30 mg · wk 12 · n 219 · Phase 3 · primary NCT02675426
  • 56.4% vs 28.4% 30 mg · wk 12 · n 165 · Phase 3 · primary NCT02706847
  • 83.7% vs 42.9% 15 mg · wk 12 · n 49 · Phase 2/3 · primary NCT02720523
  • 80% vs 42.9% 30 mg · wk 12 · n 50 · Phase 2/3 · primary NCT02720523
  • 75.5% vs 42.9% 7.5 mg · wk 12 · n 49 · Phase 2/3 · primary NCT02720523
  • 67.7% vs 41.2% 15 mg · wk 14 · n 217 · Phase 3 · primary NCT02706951
  • 75.7% vs 54.1% 15 mg · wk 12 · n 317 · Phase 3 · primary NCT02706873
  • 71.2% vs 41.2% 30 mg · wk 14 · n 215 · Phase 3 · primary NCT02706951
  • 77.1% vs 54.1% 30 mg · wk 12 · n 314 · Phase 3 · primary NCT02706873
  • 22.2% vs 8.6% 15 mg · wk 1 · n 221 · Phase 3 · secondary NCT02675426
  • 27.4% vs 10.7% 15 mg · wk 1 · n 164 · Phase 3 · secondary NCT02706847
  • 25.4% vs 5.9% 15 mg · wk 1 · n 169 · Phase 3 · secondary NCT02955212
  • 28.3% vs 8.6% 30 mg · wk 1 · n 219 · Phase 3 · secondary NCT02675426
  • 24.8% vs 10.7% 30 mg · wk 1 · n 165 · Phase 3 · secondary NCT02706847
  • 24.5% vs 8.2% 15 mg · wk 1 · n 49 · Phase 2/3 · secondary NCT02720523
  • 34% vs 8.2% 30 mg · wk 1 · n 50 · Phase 2/3 · secondary NCT02720523
  • 30.6% vs 8.2% 7.5 mg · wk 1 · n 49 · Phase 2/3 · secondary NCT02720523
  • 78.9% vs 58.6% 15 mg · wk 24 · n 317 · Phase 3 · secondary NCT02706873
  • 78% vs 58.6% 30 mg · wk 24 · n 314 · Phase 3 · secondary NCT02706873
  • 85.2% vs 57.1% 15 mg · wk 12 · n 27 · Phase 3 · secondary NCT02706873
  • 78.6% vs 57.1% 30 mg · wk 12 · n 28 · Phase 3 · secondary NCT02706873
  • 85.5% vs 57.1% 7.5 mg · wk 12 · n 55 · Phase 3 · secondary NCT02706873
  • 81.6% vs 50% 24 mg QD · wk 12 · n 49 · Phase 2 · primary NCT02066389
  • 76.6% vs 50% 18 mg BID · wk 12 · n 47 · Phase 2 · primary NCT02066389
  • 70.9% vs 35.2% 18 mg BID · wk 12 · n 55 · Phase 2 · primary NCT01960855
  • 81.6% vs 50% 12 mg BID · wk 12 · n 49 · Phase 2 · primary NCT02066389
  • 72.7% vs 35.2% 12 mg BID · wk 12 · n 55 · Phase 2 · primary NCT01960855
  • 73.5% vs 50% 6 mg BID · wk 12 · n 49 · Phase 2 · primary NCT02066389
  • 63.5% vs 35.2% 6 mg BID · wk 12 · n 52 · Phase 2 · primary NCT01960855
  • 64.6% vs 50% 3 mg BID · wk 12 · n 48 · Phase 2 · primary NCT02066389
  • 55.6% vs 35.2% 3 mg BID · wk 12 · n 54 · Phase 2 · primary NCT01960855
  • 41.5% vs 47.4% 60 mg · wk 12 · n 41 · Phase 2 · secondary NCT03682705
  • 39% vs 36.8% 60 mg · wk 8 · n 41 · Phase 2 · secondary NCT03682705
  • 29.3% vs 42.1% 60 mg · wk 4 · n 41 · Phase 2 · secondary NCT03682705
  • 24.4% vs 21.1% 60 mg · wk 2 · n 41 · Phase 2 · secondary NCT03682705
  • 30.8% vs 47.4% 20 mg · wk 12 · n 39 · Phase 2 · secondary NCT03682705
  • 30.8% vs 36.8% 20 mg · wk 8 · n 39 · Phase 2 · secondary NCT03682705
  • 23.1% vs 42.1% 20 mg · wk 4 · n 39 · Phase 2 · secondary NCT03682705
  • 12.8% vs 21.1% 20 mg · wk 2 · n 39 · Phase 2 · secondary NCT03682705
  • 64.5% vs 47.4% 15 mg/60 mg · wk 12 · n 62 · Phase 2 · secondary NCT03682705
  • 64.5% vs 36.8% 15 mg/60 mg · wk 8 · n 62 · Phase 2 · secondary NCT03682705
  • 51.6% vs 42.1% 15 mg/60 mg · wk 4 · n 62 · Phase 2 · secondary NCT03682705
  • 45.2% vs 21.1% 15 mg/60 mg · wk 2 · n 62 · Phase 2 · secondary NCT03682705
  • 34.1% vs 47.4% 5 mg · wk 12 · n 41 · Phase 2 · secondary NCT03682705
  • 39% vs 36.8% 5 mg · wk 8 · n 41 · Phase 2 · secondary NCT03682705
  • 22% vs 42.1% 5 mg · wk 4 · n 41 · Phase 2 · secondary NCT03682705
  • 14.6% vs 21.1% 5 mg · wk 2 · n 41 · Phase 2 · secondary NCT03682705

ACR50

filgotinib
57.9% vs 33.3%+24.6 vs placebo200 mg · wk 24 · n 475NCT02889796
87 other results
  • 47.2% vs 19.8% 200 mg · wk 12 · n 475 · Phase 3 · secondary NCT02889796
  • 63.2% vs 63.4% 200 mg · wk 36 · n 475 · Phase 3 · secondary NCT02889796
  • 22.3% vs 5.9% 200 mg · wk 4 · n 475 · Phase 3 · secondary NCT02889796
  • 9.1% vs 1.1% 200 mg · wk 2 · n 475 · Phase 3 · secondary NCT02889796
  • 64.2% vs 66% 200 mg · wk 52 · n 475 · Phase 3 · secondary NCT02889796
  • 52.7% vs 33.3% 100 mg · wk 24 · n 480 · Phase 3 · secondary NCT02889796
  • 36.5% vs 19.8% 100 mg · wk 12 · n 480 · Phase 3 · secondary NCT02889796
  • 57.7% vs 63.4% 100 mg · wk 36 · n 480 · Phase 3 · secondary NCT02889796
  • 12.9% vs 5.9% 100 mg · wk 4 · n 480 · Phase 3 · secondary NCT02889796
  • 5.8% vs 1.1% 100 mg · wk 2 · n 480 · Phase 3 · secondary NCT02889796
  • 60.6% vs 66% 100 mg · wk 52 · n 480 · Phase 3 · secondary NCT02889796
  • 45.6% vs 18.9% 200 mg · wk 24 · n 147 · Phase 3 · secondary NCT02873936
  • 42.9% vs 14.9% 200 mg · wk 12 · n 147 · Phase 3 · secondary NCT02873936
  • 22.4% vs 7.4% 200 mg · wk 4 · n 147 · Phase 3 · secondary NCT02873936
  • 35.3% vs 18.9% 100 mg · wk 24 · n 153 · Phase 3 · secondary NCT02873936
  • 32% vs 14.9% 100 mg · wk 12 · n 153 · Phase 3 · secondary NCT02873936
  • 21.6% vs 7.4% 100 mg · wk 4 · n 153 · Phase 3 · secondary NCT02873936
  • 58.1% vs 45.7% 200 mg · wk 24 · n 210 · Phase 3 · secondary NCT02886728
  • 45.7% vs 28.4% 200 mg · wk 12 · n 210 · Phase 3 · secondary NCT02886728
  • 58.6% vs 48.6% 200 mg · wk 36 · n 210 · Phase 3 · secondary NCT02886728
  • 25.7% vs 9.4% 200 mg · wk 4 · n 210 · Phase 3 · secondary NCT02886728
  • 16.2% vs 2.9% 200 mg · wk 2 · n 210 · Phase 3 · secondary NCT02886728
  • 61.4% vs 48.3% 200 mg · wk 52 · n 210 · Phase 3 · secondary NCT02886728
  • 61.5% vs 45.7% 200 mg · wk 24 · n 416 · Phase 3 · secondary NCT02886728
  • 53.1% vs 28.4% 200 mg · wk 12 · n 416 · Phase 3 · secondary NCT02886728
  • 60.6% vs 48.6% 200 mg · wk 36 · n 416 · Phase 3 · secondary NCT02886728
  • 29.3% vs 9.4% 200 mg · wk 4 · n 416 · Phase 3 · secondary NCT02886728
  • 13% vs 2.9% 200 mg · wk 2 · n 416 · Phase 3 · secondary NCT02886728
  • 62.3% vs 48.3% 200 mg · wk 52 · n 416 · Phase 3 · secondary NCT02886728
  • 57% vs 45.7% 100 mg · wk 24 · n 207 · Phase 3 · secondary NCT02886728
  • 44.4% vs 28.4% 100 mg · wk 12 · n 207 · Phase 3 · secondary NCT02886728
  • 55.6% vs 48.6% 100 mg · wk 36 · n 207 · Phase 3 · secondary NCT02886728
  • 20.8% vs 9.4% 100 mg · wk 4 · n 207 · Phase 3 · secondary NCT02886728
  • 9.2% vs 2.9% 100 mg · wk 2 · n 207 · Phase 3 · secondary NCT02886728
  • 59.4% vs 48.3% 100 mg · wk 52 · n 207 · Phase 3 · secondary NCT02886728
  • 50% vs 16.3% 200 mg QD · wk 24 · n 86 · Phase 2 · secondary NCT01888874
  • 43.5% vs 11.1% 200 mg QD · wk 12 · n 69 · Phase 2 · secondary NCT01894516
  • 43% vs 15.1% 200 mg QD · wk 12 · n 86 · Phase 2 · secondary NCT01888874
  • 31.9% vs 5.6% 200 mg QD · wk 8 · n 69 · Phase 2 · secondary NCT01894516
  • 33.7% vs 12.8% 200 mg QD · wk 8 · n 86 · Phase 2 · secondary NCT01888874
  • 23.2% vs 4.2% 200 mg QD · wk 4 · n 69 · Phase 2 · secondary NCT01894516
  • 17.4% vs 7% 200 mg QD · wk 4 · n 86 · Phase 2 · secondary NCT01888874
  • 21.7% vs 4.2% 200 mg QD · wk 2 · n 69 · Phase 2 · secondary NCT01894516
  • 10.5% vs 5.8% 200 mg QD · wk 2 · n 86 · Phase 2 · secondary NCT01888874
  • 7.2% vs 1.4% 200 mg QD · wk 1 · n 69 · Phase 2 · secondary NCT01894516
  • 4.7% vs 1.2% 200 mg QD · wk 1 · n 86 · Phase 2 · secondary NCT01888874
  • 47.1% vs 16.3% 100 mg QD · wk 24 · n 85 · Phase 2 · secondary NCT01888874
  • 54.8% vs 16.3% 100 mg BID · wk 24 · n 84 · Phase 2 · secondary NCT01888874
  • 37.1% vs 11.1% 100 mg QD · wk 12 · n 70 · Phase 2 · secondary NCT01894516
  • 37.6% vs 15.1% 100 mg QD · wk 12 · n 85 · Phase 2 · secondary NCT01888874
  • 54.8% vs 15.1% 100 mg BID · wk 12 · n 84 · Phase 2 · secondary NCT01888874
  • 25.7% vs 5.6% 100 mg QD · wk 8 · n 70 · Phase 2 · secondary NCT01894516
  • 35.3% vs 12.8% 100 mg QD · wk 8 · n 85 · Phase 2 · secondary NCT01888874
  • 45.2% vs 12.8% 100 mg BID · wk 8 · n 84 · Phase 2 · secondary NCT01888874
  • 18.6% vs 4.2% 100 mg QD · wk 4 · n 70 · Phase 2 · secondary NCT01894516
  • 32.9% vs 7% 100 mg QD · wk 4 · n 85 · Phase 2 · secondary NCT01888874
  • 34.5% vs 7% 100 mg BID · wk 4 · n 84 · Phase 2 · secondary NCT01888874
  • 7.1% vs 4.2% 100 mg QD · wk 2 · n 70 · Phase 2 · secondary NCT01894516
  • 20% vs 5.8% 100 mg QD · wk 2 · n 85 · Phase 2 · secondary NCT01888874
  • 21.4% vs 5.8% 100 mg BID · wk 2 · n 84 · Phase 2 · secondary NCT01888874
  • 10% vs 1.4% 100 mg QD · wk 1 · n 70 · Phase 2 · secondary NCT01894516
  • 4.7% vs 1.2% 100 mg QD · wk 1 · n 85 · Phase 2 · secondary NCT01888874
  • 7.1% vs 1.2% 100 mg BID · wk 1 · n 84 · Phase 2 · secondary NCT01888874
  • 35.4% vs 16.3% 50 mg QD · wk 24 · n 82 · Phase 2 · secondary NCT01888874
  • 35.3% vs 16.3% 50 mg BID · wk 24 · n 85 · Phase 2 · secondary NCT01888874
  • 34.7% vs 11.1% 50 mg QD · wk 12 · n 72 · Phase 2 · secondary NCT01894516
  • 32.9% vs 15.1% 50 mg QD · wk 12 · n 82 · Phase 2 · secondary NCT01888874
  • 34.1% vs 15.1% 50 mg BID · wk 12 · n 85 · Phase 2 · secondary NCT01888874
  • 16.7% vs 5.6% 50 mg QD · wk 8 · n 72 · Phase 2 · secondary NCT01894516
  • 26.8% vs 12.8% 50 mg QD · wk 8 · n 82 · Phase 2 · secondary NCT01888874
  • 34.1% vs 12.8% 50 mg BID · wk 8 · n 85 · Phase 2 · secondary NCT01888874
  • 15.3% vs 4.2% 50 mg QD · wk 4 · n 72 · Phase 2 · secondary NCT01894516
  • 13.4% vs 7% 50 mg QD · wk 4 · n 82 · Phase 2 · secondary NCT01888874
  • 18.8% vs 7% 50 mg BID · wk 4 · n 85 · Phase 2 · secondary NCT01888874
  • 5.6% vs 4.2% 50 mg QD · wk 2 · n 72 · Phase 2 · secondary NCT01894516
  • 7.3% vs 5.8% 50 mg QD · wk 2 · n 82 · Phase 2 · secondary NCT01888874
  • 11.8% vs 5.8% 50 mg BID · wk 2 · n 85 · Phase 2 · secondary NCT01888874
  • 1.4% vs 1.4% 50 mg QD · wk 1 · n 72 · Phase 2 · secondary NCT01894516
  • 2.4% vs 1.2% 50 mg QD · wk 1 · n 82 · Phase 2 · secondary NCT01888874
  • 7.1% vs 1.2% 50 mg BID · wk 1 · n 85 · Phase 2 · secondary NCT01888874
  • 34.9% vs 16.3% 25 mg BID · wk 24 · n 86 · Phase 2 · secondary NCT01888874
  • 27.9% vs 15.1% 25 mg BID · wk 12 · n 86 · Phase 2 · secondary NCT01888874
  • 25.6% vs 12.8% 25 mg BID · wk 8 · n 86 · Phase 2 · secondary NCT01888874
  • 15.1% vs 7% 25 mg BID · wk 4 · n 86 · Phase 2 · secondary NCT01888874
  • 7% vs 5.8% 25 mg BID · wk 2 · n 86 · Phase 2 · secondary NCT01888874
  • 3.5% vs 1.2% 25 mg BID · wk 1 · n 86 · Phase 2 · secondary NCT01888874
  • 47.6% vs 22.7% wk 12 · n 21 · Phase 2 · secondary NCT02885181
upadacitinib
52.1% vs 28.3%vs Methotrexate15 mg · wk 12 · n 317NCT02706873
41 other results
  • 56.4% vs 28.3% 30 mg · wk 12 · n 314 · Phase 3 · primary NCT02706873
  • 38% vs 14.9% 15 mg · wk 12 · n 221 · Phase 3 · secondary NCT02675426
  • 34.1% vs 11.8% 15 mg · wk 12 · n 164 · Phase 3 · secondary NCT02706847
  • 40.8% vs 8.3% 15 mg · wk 12 · n 169 · Phase 3 · secondary NCT02955212
  • 43.4% vs 14.9% 30 mg · wk 12 · n 219 · Phase 3 · secondary NCT02675426
  • 35.8% vs 11.8% 30 mg · wk 12 · n 165 · Phase 3 · secondary NCT02706847
  • 65.3% vs 16.3% 15 mg · wk 12 · n 49 · Phase 2/3 · secondary NCT02720523
  • 58% vs 16.3% 30 mg · wk 12 · n 50 · Phase 2/3 · secondary NCT02720523
  • 40.8% vs 16.3% 7.5 mg · wk 12 · n 49 · Phase 2/3 · secondary NCT02720523
  • 60.3% vs 33.4% 15 mg · wk 24 · n 317 · Phase 3 · secondary NCT02706873
  • 41.9% vs 15.3% 15 mg · wk 14 · n 217 · Phase 3 · secondary NCT02706951
  • 65.6% vs 33.4% 30 mg · wk 24 · n 314 · Phase 3 · secondary NCT02706873
  • 52.1% vs 15.3% 30 mg · wk 14 · n 215 · Phase 3 · secondary NCT02706951
  • 66.7% vs 21.4% 15 mg · wk 12 · n 27 · Phase 3 · secondary NCT02706873
  • 71.4% vs 21.4% 30 mg · wk 12 · n 28 · Phase 3 · secondary NCT02706873
  • 60% vs 21.4% 7.5 mg · wk 12 · n 55 · Phase 3 · secondary NCT02706873
  • 29.3% vs 21.1% 60 mg · wk 12 · n 41 · Phase 2 · secondary NCT03682705
  • 19.5% vs 5.3% 60 mg · wk 8 · n 41 · Phase 2 · secondary NCT03682705
  • 17.1% vs 10.5% 60 mg · wk 4 · n 41 · Phase 2 · secondary NCT03682705
  • 4.9% vs 0% 60 mg · wk 2 · n 41 · Phase 2 · secondary NCT03682705
  • 43.8% vs 19.6% 24 mg QD · wk 12 · n 48 · Phase 2 · secondary NCT02066389
  • 12.8% vs 21.1% 20 mg · wk 12 · n 39 · Phase 2 · secondary NCT03682705
  • 12.8% vs 5.3% 20 mg · wk 8 · n 39 · Phase 2 · secondary NCT03682705
  • 2.6% vs 10.5% 20 mg · wk 4 · n 39 · Phase 2 · secondary NCT03682705
  • 0% vs 0% 20 mg · wk 2 · n 39 · Phase 2 · secondary NCT03682705
  • 44.7% vs 19.6% 18 mg BID · wk 12 · n 47 · Phase 2 · secondary NCT02066389
  • 40% vs 17% 18 mg BID · wk 12 · n 55 · Phase 2 · secondary NCT01960855
  • 45.2% vs 21.1% 15 mg/60 mg · wk 12 · n 62 · Phase 2 · secondary NCT03682705
  • 41.9% vs 5.3% 15 mg/60 mg · wk 8 · n 62 · Phase 2 · secondary NCT03682705
  • 19.4% vs 10.5% 15 mg/60 mg · wk 4 · n 62 · Phase 2 · secondary NCT03682705
  • 16.1% vs 0% 15 mg/60 mg · wk 2 · n 62 · Phase 2 · secondary NCT03682705
  • 50% vs 19.6% 12 mg BID · wk 12 · n 50 · Phase 2 · secondary NCT02066389
  • 43.6% vs 17% 12 mg BID · wk 12 · n 55 · Phase 2 · secondary NCT01960855
  • 49% vs 19.6% 6 mg BID · wk 12 · n 49 · Phase 2 · secondary NCT02066389
  • 38.5% vs 17% 6 mg BID · wk 12 · n 52 · Phase 2 · secondary NCT01960855
  • 17.1% vs 21.1% 5 mg · wk 12 · n 41 · Phase 2 · secondary NCT03682705
  • 7.3% vs 5.3% 5 mg · wk 8 · n 41 · Phase 2 · secondary NCT03682705
  • 4.9% vs 10.5% 5 mg · wk 4 · n 41 · Phase 2 · secondary NCT03682705
  • 0% vs 0% 5 mg · wk 2 · n 41 · Phase 2 · secondary NCT03682705
  • 39.6% vs 19.6% 3 mg BID · wk 12 · n 48 · Phase 2 · secondary NCT02066389
  • 24.1% vs 17% 3 mg BID · wk 12 · n 54 · Phase 2 · secondary NCT01960855

ACR70

filgotinib
36.2% vs 14.9%+21.3 vs placebo200 mg · wk 24 · n 475NCT02889796
87 other results
  • 26.1% vs 6.7% 200 mg · wk 12 · n 475 · Phase 3 · secondary NCT02889796
  • 40.2% vs 34.6% 200 mg · wk 36 · n 475 · Phase 3 · secondary NCT02889796
  • 9.1% vs 1.5% 200 mg · wk 4 · n 475 · Phase 3 · secondary NCT02889796
  • 2.7% vs 0.4% 200 mg · wk 2 · n 475 · Phase 3 · secondary NCT02889796
  • 44.4% vs 37.7% 200 mg · wk 52 · n 475 · Phase 3 · secondary NCT02889796
  • 29.6% vs 14.9% 100 mg · wk 24 · n 480 · Phase 3 · secondary NCT02889796
  • 18.5% vs 6.7% 100 mg · wk 12 · n 480 · Phase 3 · secondary NCT02889796
  • 35.4% vs 34.6% 100 mg · wk 36 · n 480 · Phase 3 · secondary NCT02889796
  • 3.3% vs 1.5% 100 mg · wk 4 · n 480 · Phase 3 · secondary NCT02889796
  • 1.3% vs 0.4% 100 mg · wk 2 · n 480 · Phase 3 · secondary NCT02889796
  • 39% vs 37.7% 100 mg · wk 52 · n 480 · Phase 3 · secondary NCT02889796
  • 32% vs 8.1% 200 mg · wk 24 · n 147 · Phase 3 · secondary NCT02873936
  • 21.8% vs 6.8% 200 mg · wk 12 · n 147 · Phase 3 · secondary NCT02873936
  • 6.1% vs 2.7% 200 mg · wk 4 · n 147 · Phase 3 · secondary NCT02873936
  • 20.3% vs 8.1% 100 mg · wk 24 · n 153 · Phase 3 · secondary NCT02873936
  • 14.4% vs 6.8% 100 mg · wk 12 · n 153 · Phase 3 · secondary NCT02873936
  • 8.5% vs 2.7% 100 mg · wk 4 · n 153 · Phase 3 · secondary NCT02873936
  • 40% vs 26% 200 mg · wk 24 · n 210 · Phase 3 · secondary NCT02886728
  • 29% vs 13.2% 200 mg · wk 12 · n 210 · Phase 3 · secondary NCT02886728
  • 39.5% vs 32.2% 200 mg · wk 36 · n 210 · Phase 3 · secondary NCT02886728
  • 11.4% vs 3.8% 200 mg · wk 4 · n 210 · Phase 3 · secondary NCT02886728
  • 4.3% vs 0.7% 200 mg · wk 2 · n 210 · Phase 3 · secondary NCT02886728
  • 45.2% vs 29.8% 200 mg · wk 52 · n 210 · Phase 3 · secondary NCT02886728
  • 43.8% vs 26% 200 mg · wk 24 · n 416 · Phase 3 · secondary NCT02886728
  • 32.9% vs 13.2% 200 mg · wk 12 · n 416 · Phase 3 · secondary NCT02886728
  • 45.9% vs 32.2% 200 mg · wk 36 · n 416 · Phase 3 · secondary NCT02886728
  • 13% vs 3.8% 200 mg · wk 4 · n 416 · Phase 3 · secondary NCT02886728
  • 3.1% vs 0.7% 200 mg · wk 2 · n 416 · Phase 3 · secondary NCT02886728
  • 47.8% vs 29.8% 200 mg · wk 52 · n 416 · Phase 3 · secondary NCT02886728
  • 40.1% vs 26% 100 mg · wk 24 · n 207 · Phase 3 · secondary NCT02886728
  • 27.1% vs 13.2% 100 mg · wk 12 · n 207 · Phase 3 · secondary NCT02886728
  • 37.2% vs 32.2% 100 mg · wk 36 · n 207 · Phase 3 · secondary NCT02886728
  • 6.3% vs 3.8% 100 mg · wk 4 · n 207 · Phase 3 · secondary NCT02886728
  • 1.9% vs 0.7% 100 mg · wk 2 · n 207 · Phase 3 · secondary NCT02886728
  • 40.1% vs 29.8% 100 mg · wk 52 · n 207 · Phase 3 · secondary NCT02886728
  • 29.1% vs 9.3% 200 mg QD · wk 24 · n 86 · Phase 2 · secondary NCT01888874
  • 13% vs 2.8% 200 mg QD · wk 12 · n 69 · Phase 2 · secondary NCT01894516
  • 24.4% vs 8.1% 200 mg QD · wk 12 · n 86 · Phase 2 · secondary NCT01888874
  • 17.4% vs 2.8% 200 mg QD · wk 8 · n 69 · Phase 2 · secondary NCT01894516
  • 18.6% vs 7% 200 mg QD · wk 8 · n 86 · Phase 2 · secondary NCT01888874
  • 11.6% vs 1.4% 200 mg QD · wk 4 · n 69 · Phase 2 · secondary NCT01894516
  • 4.7% vs 3.5% 200 mg QD · wk 4 · n 86 · Phase 2 · secondary NCT01888874
  • 4.3% vs 2.8% 200 mg QD · wk 2 · n 69 · Phase 2 · secondary NCT01894516
  • 5.8% vs 1.2% 200 mg QD · wk 2 · n 86 · Phase 2 · secondary NCT01888874
  • 1.4% vs 0% 200 mg QD · wk 1 · n 69 · Phase 2 · secondary NCT01894516
  • 1.2% vs 1.2% 200 mg QD · wk 1 · n 86 · Phase 2 · secondary NCT01888874
  • 32.9% vs 9.3% 100 mg QD · wk 24 · n 85 · Phase 2 · secondary NCT01888874
  • 39.3% vs 9.3% 100 mg BID · wk 24 · n 84 · Phase 2 · secondary NCT01888874
  • 18.6% vs 2.8% 100 mg QD · wk 12 · n 70 · Phase 2 · secondary NCT01894516
  • 21.2% vs 8.1% 100 mg QD · wk 12 · n 85 · Phase 2 · secondary NCT01888874
  • 31% vs 8.1% 100 mg BID · wk 12 · n 84 · Phase 2 · secondary NCT01888874
  • 11.4% vs 2.8% 100 mg QD · wk 8 · n 70 · Phase 2 · secondary NCT01894516
  • 23.5% vs 7% 100 mg QD · wk 8 · n 85 · Phase 2 · secondary NCT01888874
  • 27.4% vs 7% 100 mg BID · wk 8 · n 84 · Phase 2 · secondary NCT01888874
  • 5.7% vs 1.4% 100 mg QD · wk 4 · n 70 · Phase 2 · secondary NCT01894516
  • 14.1% vs 3.5% 100 mg QD · wk 4 · n 85 · Phase 2 · secondary NCT01888874
  • 10.7% vs 3.5% 100 mg BID · wk 4 · n 84 · Phase 2 · secondary NCT01888874
  • 1.4% vs 2.8% 100 mg QD · wk 2 · n 70 · Phase 2 · secondary NCT01894516
  • 7.1% vs 1.2% 100 mg QD · wk 2 · n 85 · Phase 2 · secondary NCT01888874
  • 3.6% vs 1.2% 100 mg BID · wk 2 · n 84 · Phase 2 · secondary NCT01888874
  • 1.4% vs 0% 100 mg QD · wk 1 · n 70 · Phase 2 · secondary NCT01894516
  • 0% vs 1.2% 100 mg QD · wk 1 · n 85 · Phase 2 · secondary NCT01888874
  • 4.8% vs 1.2% 100 mg BID · wk 1 · n 84 · Phase 2 · secondary NCT01888874
  • 22% vs 9.3% 50 mg QD · wk 24 · n 82 · Phase 2 · secondary NCT01888874
  • 23.5% vs 9.3% 50 mg BID · wk 24 · n 85 · Phase 2 · secondary NCT01888874
  • 8.3% vs 2.8% 50 mg QD · wk 12 · n 72 · Phase 2 · secondary NCT01894516
  • 15.9% vs 8.1% 50 mg QD · wk 12 · n 82 · Phase 2 · secondary NCT01888874
  • 18.8% vs 8.1% 50 mg BID · wk 12 · n 85 · Phase 2 · secondary NCT01888874
  • 6.9% vs 2.8% 50 mg QD · wk 8 · n 72 · Phase 2 · secondary NCT01894516
  • 11% vs 7% 50 mg QD · wk 8 · n 82 · Phase 2 · secondary NCT01888874
  • 14.1% vs 7% 50 mg BID · wk 8 · n 85 · Phase 2 · secondary NCT01888874
  • 8.3% vs 1.4% 50 mg QD · wk 4 · n 72 · Phase 2 · secondary NCT01894516
  • 7.3% vs 3.5% 50 mg QD · wk 4 · n 82 · Phase 2 · secondary NCT01888874
  • 9.4% vs 3.5% 50 mg BID · wk 4 · n 85 · Phase 2 · secondary NCT01888874
  • 1.4% vs 2.8% 50 mg QD · wk 2 · n 72 · Phase 2 · secondary NCT01894516
  • 2.4% vs 1.2% 50 mg QD · wk 2 · n 82 · Phase 2 · secondary NCT01888874
  • 5.9% vs 1.2% 50 mg BID · wk 2 · n 85 · Phase 2 · secondary NCT01888874
  • 0% vs 0% 50 mg QD · wk 1 · n 72 · Phase 2 · secondary NCT01894516
  • 0% vs 1.2% 50 mg QD · wk 1 · n 82 · Phase 2 · secondary NCT01888874
  • 2.4% vs 1.2% 50 mg BID · wk 1 · n 85 · Phase 2 · secondary NCT01888874
  • 20.9% vs 9.3% 25 mg BID · wk 24 · n 86 · Phase 2 · secondary NCT01888874
  • 14% vs 8.1% 25 mg BID · wk 12 · n 86 · Phase 2 · secondary NCT01888874
  • 9.3% vs 7% 25 mg BID · wk 8 · n 86 · Phase 2 · secondary NCT01888874
  • 5.8% vs 3.5% 25 mg BID · wk 4 · n 86 · Phase 2 · secondary NCT01888874
  • 2.3% vs 1.2% 25 mg BID · wk 2 · n 86 · Phase 2 · secondary NCT01888874
  • 1.2% vs 1.2% 25 mg BID · wk 1 · n 86 · Phase 2 · secondary NCT01888874
  • 38.1% vs 13.6% wk 12 · n 21 · Phase 2 · secondary NCT02885181
upadacitinib
20.8% vs 5.9%+14.9 vs placebo15 mg · wk 12 · n 221NCT02675426
41 other results
  • 11.6% vs 6.5% 15 mg · wk 12 · n 164 · Phase 3 · secondary NCT02706847
  • 21.3% vs 3.6% 15 mg · wk 12 · n 169 · Phase 3 · secondary NCT02955212
  • 26.5% vs 5.9% 30 mg · wk 12 · n 219 · Phase 3 · secondary NCT02675426
  • 23% vs 6.5% 30 mg · wk 12 · n 165 · Phase 3 · secondary NCT02706847
  • 34.7% vs 2% 15 mg · wk 12 · n 49 · Phase 2/3 · secondary NCT02720523
  • 28% vs 2% 30 mg · wk 12 · n 50 · Phase 2/3 · secondary NCT02720523
  • 20.4% vs 2% 7.5 mg · wk 12 · n 49 · Phase 2/3 · secondary NCT02720523
  • 44.5% vs 18.5% 15 mg · wk 24 · n 317 · Phase 3 · secondary NCT02706873
  • 22.6% vs 2.8% 15 mg · wk 14 · n 217 · Phase 3 · secondary NCT02706951
  • 32.5% vs 14% 15 mg · wk 12 · n 317 · Phase 3 · secondary NCT02706873
  • 49.7% vs 18.5% 30 mg · wk 24 · n 314 · Phase 3 · secondary NCT02706873
  • 33% vs 2.8% 30 mg · wk 14 · n 215 · Phase 3 · secondary NCT02706951
  • 36.9% vs 14% 30 mg · wk 12 · n 314 · Phase 3 · secondary NCT02706873
  • 51.9% vs 0% 15 mg · wk 12 · n 27 · Phase 3 · secondary NCT02706873
  • 64.3% vs 0% 30 mg · wk 12 · n 28 · Phase 3 · secondary NCT02706873
  • 34.5% vs 0% 7.5 mg · wk 12 · n 55 · Phase 3 · secondary NCT02706873
  • 14.6% vs 15.8% 60 mg · wk 12 · n 41 · Phase 2 · secondary NCT03682705
  • 4.9% vs 0% 60 mg · wk 8 · n 41 · Phase 2 · secondary NCT03682705
  • 4.9% vs 0% 60 mg · wk 4 · n 41 · Phase 2 · secondary NCT03682705
  • 2.4% vs 0% 60 mg · wk 2 · n 41 · Phase 2 · secondary NCT03682705
  • 25% vs 6.5% 24 mg QD · wk 12 · n 48 · Phase 2 · secondary NCT02066389
  • 5.1% vs 15.8% 20 mg · wk 12 · n 39 · Phase 2 · secondary NCT03682705
  • 2.6% vs 0% 20 mg · wk 8 · n 39 · Phase 2 · secondary NCT03682705
  • 2.6% vs 0% 20 mg · wk 4 · n 39 · Phase 2 · secondary NCT03682705
  • 0% vs 0% 20 mg · wk 2 · n 39 · Phase 2 · secondary NCT03682705
  • 27.7% vs 6.5% 18 mg BID · wk 12 · n 47 · Phase 2 · secondary NCT02066389
  • 21.8% vs 3.6% 18 mg BID · wk 12 · n 55 · Phase 2 · secondary NCT01960855
  • 25.8% vs 15.8% 15 mg/60 mg · wk 12 · n 62 · Phase 2 · secondary NCT03682705
  • 17.7% vs 0% 15 mg/60 mg · wk 8 · n 62 · Phase 2 · secondary NCT03682705
  • 9.7% vs 0% 15 mg/60 mg · wk 4 · n 62 · Phase 2 · secondary NCT03682705
  • 8.1% vs 0% 15 mg/60 mg · wk 2 · n 62 · Phase 2 · secondary NCT03682705
  • 16% vs 6.5% 12 mg BID · wk 12 · n 50 · Phase 2 · secondary NCT02066389
  • 21.8% vs 3.6% 12 mg BID · wk 12 · n 55 · Phase 2 · secondary NCT01960855
  • 30.6% vs 6.5% 6 mg BID · wk 12 · n 49 · Phase 2 · secondary NCT02066389
  • 26.9% vs 3.6% 6 mg BID · wk 12 · n 52 · Phase 2 · secondary NCT01960855
  • 9.8% vs 15.8% 5 mg · wk 12 · n 41 · Phase 2 · secondary NCT03682705
  • 0% vs 0% 5 mg · wk 8 · n 41 · Phase 2 · secondary NCT03682705
  • 0% vs 0% 5 mg · wk 4 · n 41 · Phase 2 · secondary NCT03682705
  • 0% vs 0% 5 mg · wk 2 · n 41 · Phase 2 · secondary NCT03682705
  • 23.4% vs 6.5% 3 mg BID · wk 12 · n 47 · Phase 2 · secondary NCT02066389
  • 13% vs 3.6% 3 mg BID · wk 12 · n 54 · Phase 2 · secondary NCT01960855

DAS28-CRP remission

filgotinib
48.4% vs 16.2%+32.2 vs placebo200 mg · wk 24 · n 475NCT02889796
35 other results
  • 34.1% vs 9.3% 200 mg · wk 12 · n 475 · Phase 3 · secondary NCT02889796
  • 50.3% vs 46.1% 200 mg · wk 36 · n 475 · Phase 3 · secondary NCT02889796
  • 13.7% vs 2.9% 200 mg · wk 4 · n 475 · Phase 3 · secondary NCT02889796
  • 5.1% vs 0.6% 200 mg · wk 2 · n 475 · Phase 3 · secondary NCT02889796
  • 54.5% vs 50.8% 200 mg · wk 52 · n 475 · Phase 3 · secondary NCT02889796
  • 35.2% vs 16.2% 100 mg · wk 24 · n 480 · Phase 3 · secondary NCT02889796
  • 23.8% vs 9.3% 100 mg · wk 12 · n 480 · Phase 3 · secondary NCT02889796
  • 42.9% vs 46.1% 100 mg · wk 36 · n 480 · Phase 3 · secondary NCT02889796
  • 8.8% vs 2.9% 100 mg · wk 4 · n 480 · Phase 3 · secondary NCT02889796
  • 1.7% vs 0.6% 100 mg · wk 2 · n 480 · Phase 3 · secondary NCT02889796
  • 44.8% vs 50.8% 100 mg · wk 52 · n 480 · Phase 3 · secondary NCT02889796
  • 30.6% vs 12.2% 200 mg · wk 24 · n 147 · Phase 3 · secondary NCT02873936
  • 22.4% vs 8.1% 200 mg · wk 12 · n 147 · Phase 3 · secondary NCT02873936
  • 10.2% vs 2.7% 200 mg · wk 4 · n 147 · Phase 3 · secondary NCT02873936
  • 26.1% vs 12.2% 100 mg · wk 24 · n 153 · Phase 3 · secondary NCT02873936
  • 25.5% vs 8.1% 100 mg · wk 12 · n 153 · Phase 3 · secondary NCT02873936
  • 11.8% vs 2.7% 100 mg · wk 4 · n 153 · Phase 3 · secondary NCT02873936
  • 42.4% vs 29.1% 200 mg · wk 24 · n 210 · Phase 3 · secondary NCT02886728
  • 29.5% vs 17.1% 200 mg · wk 12 · n 210 · Phase 3 · secondary NCT02886728
  • 43.3% vs 34.4% 200 mg · wk 36 · n 210 · Phase 3 · secondary NCT02886728
  • 19.5% vs 4.8% 200 mg · wk 4 · n 210 · Phase 3 · secondary NCT02886728
  • 10% vs 1% 200 mg · wk 2 · n 210 · Phase 3 · secondary NCT02886728
  • 46.2% vs 31.5% 200 mg · wk 52 · n 210 · Phase 3 · secondary NCT02886728
  • 54.1% vs 29.1% 200 mg · wk 24 · n 416 · Phase 3 · secondary NCT02886728
  • 39.7% vs 17.1% 200 mg · wk 12 · n 416 · Phase 3 · secondary NCT02886728
  • 52.6% vs 34.4% 200 mg · wk 36 · n 416 · Phase 3 · secondary NCT02886728
  • 16.6% vs 4.8% 200 mg · wk 4 · n 416 · Phase 3 · secondary NCT02886728
  • 7.2% vs 1% 200 mg · wk 2 · n 416 · Phase 3 · secondary NCT02886728
  • 53.4% vs 31.5% 200 mg · wk 52 · n 416 · Phase 3 · secondary NCT02886728
  • 42.5% vs 29.1% 100 mg · wk 24 · n 207 · Phase 3 · secondary NCT02886728
  • 31.9% vs 17.1% 100 mg · wk 12 · n 207 · Phase 3 · secondary NCT02886728
  • 42% vs 34.4% 100 mg · wk 36 · n 207 · Phase 3 · secondary NCT02886728
  • 15% vs 4.8% 100 mg · wk 4 · n 207 · Phase 3 · secondary NCT02886728
  • 4.3% vs 1% 100 mg · wk 2 · n 207 · Phase 3 · secondary NCT02886728
  • 43% vs 31.5% 100 mg · wk 52 · n 207 · Phase 3 · secondary NCT02886728
upadacitinib
48.3% vs 18.5%vs Methotrexate15 mg · wk 24 · n 317NCT02706873
22 other results
  • 50% vs 18.5% 30 mg · wk 24 · n 314 · Phase 3 · primary NCT02706873
  • 30.8% vs 10% 15 mg · wk 12 · n 221 · Phase 3 · secondary NCT02675426
  • 29.6% vs 5.3% 15 mg · wk 12 · n 169 · Phase 3 · secondary NCT02955212
  • 28.3% vs 10% 30 mg · wk 12 · n 219 · Phase 3 · secondary NCT02675426
  • 57.1% vs 6.1% 15 mg · wk 12 · n 49 · Phase 2/3 · secondary NCT02720523
  • 50% vs 6.1% 30 mg · wk 12 · n 50 · Phase 2/3 · secondary NCT02720523
  • 36.7% vs 6.1% 7.5 mg · wk 12 · n 49 · Phase 2/3 · secondary NCT02720523
  • 28.1% vs 8.3% 15 mg · wk 14 · n 217 · Phase 3 · secondary NCT02706951
  • 30% vs 13.3% 15 mg QD · wk 12 · n 303 · Phase 3 · secondary NCT03086343
  • 40.5% vs 8.3% 30 mg · wk 14 · n 215 · Phase 3 · secondary NCT02706951
  • 70.4% vs 17.9% 15 mg · wk 24 · n 27 · Phase 3 · secondary NCT02706873
  • 82.1% vs 17.9% 30 mg · wk 24 · n 28 · Phase 3 · secondary NCT02706873
  • 67.3% vs 17.9% 7.5 mg · wk 24 · n 55 · Phase 3 · secondary NCT02706873
  • 19.5% vs 10.5% 60 mg · wk 12 · n 41 · Phase 2 · secondary NCT03682705
  • 22.4% vs 14.9% 24 mg QD · wk 12 · n 49 · Phase 2 · secondary NCT02066389
  • 7.7% vs 10.5% 20 mg · wk 12 · n 39 · Phase 2 · secondary NCT03682705
  • 42.9% vs 14.9% 18 mg BID · wk 12 · n 49 · Phase 2 · secondary NCT02066389
  • 32.3% vs 10.5% 15 mg/60 mg · wk 12 · n 62 · Phase 2 · secondary NCT03682705
  • 34% vs 14.9% 12 mg BID · wk 12 · n 50 · Phase 2 · secondary NCT02066389
  • 38.8% vs 14.9% 6 mg BID · wk 12 · n 49 · Phase 2 · secondary NCT02066389
  • 9.8% vs 10.5% 5 mg · wk 12 · n 41 · Phase 2 · secondary NCT03682705
  • 36.7% vs 14.9% 3 mg BID · wk 12 · n 49 · Phase 2 · secondary NCT02066389

HAQ-DI, change

filgotinib
-0.8 vs -0.6−0.2 vs placebo200 mg · wk 24 · n 475NCT02889796
36 other results
  • -0.7 vs -0.4 200 mg · wk 12 · n 475 · Phase 3 · secondary NCT02889796
  • -0.9 vs -0.7 200 mg · wk 36 · n 475 · Phase 3 · secondary NCT02889796
  • -0.4 vs -0.3 200 mg · wk 4 · n 475 · Phase 3 · secondary NCT02889796
  • -0.3 vs -0.1 200 mg · wk 2 · n 475 · Phase 3 · secondary NCT02889796
  • -0.9 vs -0.7 200 mg · wk 52 · n 475 · Phase 3 · secondary NCT02889796
  • -0.8 vs -0.6 100 mg · wk 24 · n 480 · Phase 3 · secondary NCT02889796
  • -0.6 vs -0.4 100 mg · wk 12 · n 480 · Phase 3 · secondary NCT02889796
  • -0.8 vs -0.7 100 mg · wk 36 · n 480 · Phase 3 · secondary NCT02889796
  • -0.3 vs -0.3 100 mg · wk 4 · n 480 · Phase 3 · secondary NCT02889796
  • -0.2 vs -0.1 100 mg · wk 2 · n 480 · Phase 3 · secondary NCT02889796
  • -0.8 vs -0.7 100 mg · wk 52 · n 480 · Phase 3 · secondary NCT02889796
  • -0.8 vs -0.4 200 mg · wk 24 · n 147 · Phase 3 · secondary NCT02873936
  • -0.6 vs -0.2 200 mg · wk 12 · n 147 · Phase 3 · secondary NCT02873936
  • -0.4 vs -0.2 200 mg · wk 4 · n 147 · Phase 3 · secondary NCT02873936
  • -0.6 vs -0.4 100 mg · wk 24 · n 153 · Phase 3 · secondary NCT02873936
  • -0.5 vs -0.2 100 mg · wk 12 · n 153 · Phase 3 · secondary NCT02873936
  • -0.3 vs -0.2 100 mg · wk 4 · n 153 · Phase 3 · secondary NCT02873936
  • -0.9 vs -0.8 200 mg · wk 24 · n 210 · Phase 3 · secondary NCT02886728
  • -0.8 vs -0.6 200 mg · wk 12 · n 210 · Phase 3 · secondary NCT02886728
  • -0.9 vs -0.9 200 mg · wk 36 · n 210 · Phase 3 · secondary NCT02886728
  • -0.5 vs -0.3 200 mg · wk 4 · n 210 · Phase 3 · secondary NCT02886728
  • -0.3 vs -0.2 200 mg · wk 2 · n 210 · Phase 3 · secondary NCT02886728
  • -0.9 vs -0.9 200 mg · wk 52 · n 210 · Phase 3 · secondary NCT02886728
  • -0.9 vs -0.8 200 mg · wk 24 · n 416 · Phase 3 · secondary NCT02886728
  • -0.8 vs -0.6 200 mg · wk 12 · n 416 · Phase 3 · secondary NCT02886728
  • -1.0 vs -0.9 200 mg · wk 36 · n 416 · Phase 3 · secondary NCT02886728
  • -0.6 vs -0.3 200 mg · wk 4 · n 416 · Phase 3 · secondary NCT02886728
  • -0.4 vs -0.2 200 mg · wk 2 · n 416 · Phase 3 · secondary NCT02886728
  • -1 vs -0.9 200 mg · wk 52 · n 416 · Phase 3 · secondary NCT02886728
  • -0.9 vs -0.8 100 mg · wk 24 · n 207 · Phase 3 · secondary NCT02886728
  • -0.8 vs -0.6 100 mg · wk 12 · n 207 · Phase 3 · secondary NCT02886728
  • -0.9 vs -0.9 100 mg · wk 36 · n 207 · Phase 3 · secondary NCT02886728
  • -0.5 vs -0.3 100 mg · wk 4 · n 207 · Phase 3 · secondary NCT02886728
  • -0.4 vs -0.2 100 mg · wk 2 · n 207 · Phase 3 · secondary NCT02886728
  • -1.0 vs -0.9 100 mg · wk 52 · n 207 · Phase 3 · secondary NCT02886728
  • -0.7 vs -0.4 wk 12 · n 21 · Phase 2 · secondary NCT02885181
upadacitinib
-0.6 vs -0.3−0.3 vs placebo15 mg · wk 12 · n 216NCT02675426
32 other results
  • -0.4 vs -0.2 15 mg · wk 12 · n 163 · Phase 3 · secondary NCT02706847
  • -0.6 vs -0.2 15 mg · wk 12 · n 169 · Phase 3 · secondary NCT02955212
  • -0.5 vs -0.3 30 mg · wk 12 · n 219 · Phase 3 · secondary NCT02675426
  • -0.4 vs -0.2 30 mg · wk 12 · n 160 · Phase 3 · secondary NCT02706847
  • -0.5 vs -0.1 15 mg · wk 12 · n 49 · Phase 2/3 · secondary NCT02720523
  • -0.5 vs -0.1 30 mg · wk 12 · n 50 · Phase 2/3 · secondary NCT02720523
  • -0.4 vs -0.1 7.5 mg · wk 12 · n 49 · Phase 2/3 · secondary NCT02720523
  • -0.9 vs -0.6 15 mg · wk 24 · n 317 · Phase 3 · secondary NCT02706873
  • -0.7 vs -0.3 15 mg · wk 14 · n 216 · Phase 3 · secondary NCT02706951
  • -0.8 vs -0.5 15 mg · wk 12 · n 317 · Phase 3 · secondary NCT02706873
  • -0.9 vs -0.6 30 mg · wk 24 · n 310 · Phase 3 · secondary NCT02706873
  • -0.7 vs -0.3 30 mg · wk 14 · n 215 · Phase 3 · secondary NCT02706951
  • -0.9 vs -0.5 30 mg · wk 12 · n 310 · Phase 3 · secondary NCT02706873
  • -0.9 vs -0.2 15 mg · wk 12 · n 27 · Phase 3 · secondary NCT02706873
  • -0.9 vs -0.2 30 mg · wk 12 · n 28 · Phase 3 · secondary NCT02706873
  • -0.8 vs -0.2 7.5 mg · wk 12 · n 55 · Phase 3 · secondary NCT02706873
  • -0.3 vs -0.3 60 mg · wk 12 · n 39 · Phase 2 · secondary NCT03682705
  • -0.3 vs -0.2 60 mg · wk 8 · n 39 · Phase 2 · secondary NCT03682705
  • -0.1 vs -0.4 60 mg · wk 4 · n 39 · Phase 2 · secondary NCT03682705
  • -0.1 vs -0.2 60 mg · wk 2 · n 39 · Phase 2 · secondary NCT03682705
  • -0.1 vs -0.3 20 mg · wk 12 · n 35 · Phase 2 · secondary NCT03682705
  • -0.1 vs -0.2 20 mg · wk 8 · n 35 · Phase 2 · secondary NCT03682705
  • -0.1 vs -0.4 20 mg · wk 4 · n 35 · Phase 2 · secondary NCT03682705
  • -0.1 vs -0.2 20 mg · wk 2 · n 35 · Phase 2 · secondary NCT03682705
  • -0.5 vs -0.3 15 mg/60 mg · wk 12 · n 59 · Phase 2 · secondary NCT03682705
  • -0.5 vs -0.2 15 mg/60 mg · wk 8 · n 59 · Phase 2 · secondary NCT03682705
  • -0.4 vs -0.4 15 mg/60 mg · wk 4 · n 59 · Phase 2 · secondary NCT03682705
  • -0.3 vs -0.2 15 mg/60 mg · wk 2 · n 59 · Phase 2 · secondary NCT03682705
  • -0.2 vs -0.3 5 mg · wk 12 · n 40 · Phase 2 · secondary NCT03682705
  • -0.1 vs -0.2 5 mg · wk 8 · n 40 · Phase 2 · secondary NCT03682705
  • -0.2 vs -0.4 5 mg · wk 4 · n 40 · Phase 2 · secondary NCT03682705
  • -0.2 vs -0.2 5 mg · wk 2 · n 40 · Phase 2 · secondary NCT03682705

Modified Sharp score, change

filgotinib
0.1 vs 0.4−0.2 vs placebo200 mg · wk 24 · n 467NCT02889796
9 other results
  • 0.2 vs 0.9 200 mg · wk 52 · n 468 · Phase 3 · secondary NCT02889796
  • 0.2 vs 0.4 100 mg · wk 24 · n 471 · Phase 3 · secondary NCT02889796
  • 0.5 vs 0.9 100 mg · wk 52 · n 472 · Phase 3 · secondary NCT02889796
  • -0.0 vs 0.5 200 mg · wk 24 · n 210 · Phase 3 · secondary NCT02886728
  • 0.3 vs 0.8 200 mg · wk 52 · n 210 · Phase 3 · secondary NCT02886728
  • 0.2 vs 0.5 200 mg · wk 24 · n 416 · Phase 3 · secondary NCT02886728
  • 0.3 vs 0.8 200 mg · wk 52 · n 416 · Phase 3 · secondary NCT02886728
  • 0.2 vs 0.5 100 mg · wk 24 · n 207 · Phase 3 · secondary NCT02886728
  • 0.2 vs 0.8 100 mg · wk 52 · n 207 · Phase 3 · secondary NCT02886728
upadacitinib
0.1 vs 0.7vs Methotrexate15 mg · wk 24 · n 279NCT02706873
4 other results
  • 0.1 vs 0.7 30 mg · wk 24 · n 270 · Phase 3 · primary NCT02706873
  • 0.2 vs 2.6 15 mg · wk 24 · n 26 · Phase 3 · secondary NCT02706873
  • 0.2 vs 2.6 30 mg · wk 24 · n 24 · Phase 3 · secondary NCT02706873
  • 0.9 vs 2.6 7.5 mg · wk 24 · n 51 · Phase 3 · secondary NCT02706873
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
14 other shared endpoints and safety

Coverage. filgotinib: 18 of 18 rows · upadacitinib: 18 of 18 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricfilgotinib
Rows use multiple source trials
upadacitinib
Rows use multiple source trials
Boolean Remission
responder rate · % of participants
4.3% (n=69) vs 1.4% (n=72) placebo @ 12wk200 mg QDa,b
NCT01894516 · Phase 2 · registry result, not featured evidence
show 2 more doses
4.3% (n=70) vs 1.4% (n=72) placebo @ 12wk100 mg QD
NCT01894516 · Phase 2 · registry result, not featured evidence
1.4% (n=72) vs 1.4% (n=72) placebo @ 12wk50 mg QD
NCT01894516 · Phase 2 · registry result, not featured evidence
9.8% (n=41) vs 0% (n=19) placebo @ 12wk60 mga,b
NCT03682705 · Phase 2 · registry result, not featured evidence
show 3 more doses
2.6% (n=39) vs 0% (n=19) placebo @ 12wk20 mg
NCT03682705 · Phase 2 · registry result, not featured evidence
11.3% (n=62) vs 0% (n=19) placebo @ 12wk15 mg/60 mg
NCT03682705 · Phase 2 · registry result, not featured evidence · combination
2.4% (n=41) vs 0% (n=19) placebo @ 12wk5 mg
NCT03682705 · Phase 2 · registry result, not featured evidence
CDAI
absolute change · score
-26.2 vs -17.3 placebo score @ 12wk200 mga,c,b
NCT02873936 · Phase 3
show 1 more dose
-23.8 vs -17.3 placebo score @ 12wk100 mg
NCT02873936 · Phase 3
-17.5 vs -14.57 placebo score @ 12wk60 mga,c,b
NCT03682705 · Phase 2 · registry result, not featured evidence
show 3 more doses
-16.7 vs -14.57 placebo score @ 12wk20 mg
NCT03682705 · Phase 2 · registry result, not featured evidence
-27 vs -14.57 placebo score @ 12wk15 mg/60 mg
NCT03682705 · Phase 2 · registry result, not featured evidence · combination
-16.51 vs -14.57 placebo score @ 12wk5 mg
NCT03682705 · Phase 2 · registry result, not featured evidence
CRP Change
absolute change · mg
-11.86 vs 0.57 placebo mg @ 12wk200 mga,c,b
NCT02873936 · Phase 3
show 1 more dose
-12.02 vs 0.57 placebo mg @ 12wk100 mg
NCT02873936 · Phase 3
-4.58 vs 1.45 placebo mg @ 12wk60 mga,c,b
NCT03682705 · Phase 2 · registry result, not featured evidence
show 3 more doses
-5.78 vs 1.45 placebo mg @ 12wk20 mg
NCT03682705 · Phase 2 · registry result, not featured evidence
-10.95 vs 1.45 placebo mg @ 12wk15 mg/60 mg
NCT03682705 · Phase 2 · registry result, not featured evidence · combination
-0.81 vs 1.45 placebo mg @ 12wk5 mg
NCT03682705 · Phase 2 · registry result, not featured evidence
DAS Low Disease Activity
responder rate · % of participants
48.3% (n=147) vs 20.9% (n=148) placebo @ 24wk200 mga,b,d
NCT02873936 · Phase 3
show 1 more dose
37.9% (n=153) vs 20.9% (n=148) placebo @ 24wk100 mg
NCT02873936 · Phase 3
59.9% (n=317) vs 32.2% (n=314) Methotrexate @ 24wk15 mga,b,d
NCT02706873 · Phase 3
show 1 more dose
65% (n=314) vs 32.2% (n=314) Methotrexate @ 24wk30 mg
NCT02706873 · Phase 3
DAS28-CRP
absolute change · score
-2.9 vs -2.1 placebo score @ 24wk200 mga,b,d
NCT02873936 · Phase 3
show 1 more dose
-2.6 vs -2.1 placebo score @ 24wk100 mg
NCT02873936 · Phase 3
-3.07 vs -2.15 Methotrexate score @ 24wk15 mga,b,d
NCT02706873 · Phase 3
show 1 more dose
-3.34 vs -2.15 Methotrexate score @ 24wk30 mg
NCT02706873 · Phase 3
FACIT-Fatigue
absolute change · score
9.6 vs 4.5 placebo score @ 12wk200 mga,b,d
NCT02873936 · Phase 3
show 1 more dose
8.3 vs 4.5 placebo score @ 12wk100 mg
NCT02873936 · Phase 3
7.91 vs 2.96 placebo score @ 12wk15 mga,b,d
NCT02675426 · Phase 3
show 1 more dose
7.74 vs 2.96 placebo score @ 12wk30 mg
NCT02675426 · Phase 3
HAQ-DI
responder rate · % of participants
78.9% (n=475) vs 57.9% (n=475) placebo @ 12wk200 mga,c,b
NCT02889796 · Phase 3
show 1 more dose
71.5% (n=480) vs 57.9% (n=475) placebo @ 12wk100 mg
NCT02889796 · Phase 3
53.7% (n=41) vs 47.4% (n=19) placebo @ 12wk60 mga,c,b
NCT03682705 · Phase 2 · registry result, not featured evidence
show 3 more doses
43.6% (n=39) vs 47.4% (n=19) placebo @ 12wk20 mg
NCT03682705 · Phase 2 · registry result, not featured evidence
58.1% (n=62) vs 47.4% (n=19) placebo @ 12wk15 mg/60 mg
NCT03682705 · Phase 2 · registry result, not featured evidence · combination
43.9% (n=41) vs 47.4% (n=19) placebo @ 12wk5 mg
NCT03682705 · Phase 2 · registry result, not featured evidence
Patient Assessment of Arthritis Pain
absolute change · score
-30 vs -14 placebo score @ 12wk200 mga,c,b
NCT02873936 · Phase 3
show 1 more dose
-27 vs -14 placebo score @ 12wk100 mg
NCT02873936 · Phase 3
-19.52 vs -23.37 placebo score @ 12wk60 mga,c,b
NCT03682705 · Phase 2 · registry result, not featured evidence
show 3 more doses
-10.46 vs -23.37 placebo score @ 12wk20 mg
NCT03682705 · Phase 2 · registry result, not featured evidence
-32.27 vs -23.37 placebo score @ 12wk15 mg/60 mg
NCT03682705 · Phase 2 · registry result, not featured evidence · combination
-17.84 vs -23.37 placebo score @ 12wk5 mg
NCT03682705 · Phase 2 · registry result, not featured evidence
Patient Global Assessment
absolute change · score
-31 vs -14 placebo score @ 12wk200 mga,c,b
NCT02873936 · Phase 3
show 1 more dose
-27 vs -14 placebo score @ 12wk100 mg
NCT02873936 · Phase 3
-19.47 vs -19.55 placebo score @ 12wk60 mga,c,b
NCT03682705 · Phase 2 · registry result, not featured evidence
show 3 more doses
-8.45 vs -19.55 placebo score @ 12wk20 mg
NCT03682705 · Phase 2 · registry result, not featured evidence
-30.52 vs -19.55 placebo score @ 12wk15 mg/60 mg
NCT03682705 · Phase 2 · registry result, not featured evidence · combination
-16.4 vs -19.55 placebo score @ 12wk5 mg
NCT03682705 · Phase 2 · registry result, not featured evidence
Physician Global Assessment
absolute change · score
-45 vs -28 placebo score @ 12wk200 mga,c,b
NCT02873936 · Phase 3
show 1 more dose
-41 vs -28 placebo score @ 12wk100 mg
NCT02873936 · Phase 3
-30.15 vs -23.19 placebo score @ 12wk60 mga,c,b
NCT03682705 · Phase 2 · registry result, not featured evidence
show 3 more doses
-31.68 vs -23.19 placebo score @ 12wk20 mg
NCT03682705 · Phase 2 · registry result, not featured evidence
-46.98 vs -23.19 placebo score @ 12wk15 mg/60 mg
NCT03682705 · Phase 2 · registry result, not featured evidence · combination
-24.55 vs -23.19 placebo score @ 12wk5 mg
NCT03682705 · Phase 2 · registry result, not featured evidence
SDAI
absolute change · score
-27.6 vs -17.2 placebo score @ 12wk200 mga,c,b
NCT02873936 · Phase 3
show 1 more dose
-24.9 vs -17.2 placebo score @ 12wk100 mg
NCT02873936 · Phase 3
-18.01 vs -14.44 placebo score @ 12wk60 mga,c,b
NCT03682705 · Phase 2 · registry result, not featured evidence
show 3 more doses
-17.12 vs -14.44 placebo score @ 12wk20 mg
NCT03682705 · Phase 2 · registry result, not featured evidence
-28.06 vs -14.44 placebo score @ 12wk15 mg/60 mg
NCT03682705 · Phase 2 · registry result, not featured evidence · combination
-16.73 vs -14.44 placebo score @ 12wk5 mg
NCT03682705 · Phase 2 · registry result, not featured evidence
SF-36 PCS
absolute change · score
9.4 vs 6.6 placebo score @ 24wk200 mga,b,d
NCT02873936 · Phase 3
show 1 more dose
9 vs 6.6 placebo score @ 24wk100 mg
NCT02873936 · Phase 3
10.7 vs 6.97 Methotrexate score @ 24wk15 mga,b,d
NCT02706873 · Phase 3
show 1 more dose
11.39 vs 6.97 Methotrexate score @ 24wk30 mg
NCT02706873 · Phase 3
Swollen Joint Count
absolute change · count
-12 vs -8 placebo count @ 12wk200 mga,c,b
NCT02873936 · Phase 3
show 1 more dose
-10 vs -8 placebo count @ 12wk100 mg
NCT02873936 · Phase 3
-6.68 vs -5.58 placebo count @ 12wk60 mga,c,b
NCT03682705 · Phase 2 · registry result, not featured evidence
show 3 more doses
-7.85 vs -5.58 placebo count @ 12wk20 mg
NCT03682705 · Phase 2 · registry result, not featured evidence
-10.86 vs -5.58 placebo count @ 12wk15 mg/60 mg
NCT03682705 · Phase 2 · registry result, not featured evidence · combination
-8.59 vs -5.58 placebo count @ 12wk5 mg
NCT03682705 · Phase 2 · registry result, not featured evidence
Tender Joint Count
absolute change · count
-18 vs -12 placebo count @ 12wk200 mga,c,b
NCT02873936 · Phase 3
show 1 more dose
-16 vs -12 placebo count @ 12wk100 mg
NCT02873936 · Phase 3
-9.14 vs -8.47 placebo count @ 12wk60 mga,c,b
NCT03682705 · Phase 2 · registry result, not featured evidence
show 3 more doses
-9.33 vs -8.47 placebo count @ 12wk20 mg
NCT03682705 · Phase 2 · registry result, not featured evidence
-16.33 vs -8.47 placebo count @ 12wk15 mg/60 mg
NCT03682705 · Phase 2 · registry result, not featured evidence · combination
-12.58 vs -8.47 placebo count @ 12wk5 mg
NCT03682705 · Phase 2 · registry result, not featured evidence
Dropout rate
8.8%200 mge
NCT02873936 · Phase 3
show 26 more results
15%100 mg
NCT02873936 · Phase 3
17.1%200 mg
NCT02886728 · Phase 3 · monotherapy
17.3%200 mg
NCT02886728 · Phase 3 · combination
15.5%100 mg
NCT02886728 · Phase 3 · combination
11.1%200 mg
NCT02889796 · Phase 3
12.1%100 mg
NCT02889796 · Phase 3
52.1%200 mg
NCT03025308 · Phase 3 · registry result, not featured evidence
53%200 mg
NCT03025308 · Phase 3 · registry result, not featured evidence
53.7%100 mg
NCT03025308 · Phase 3 · registry result, not featured evidence
61.6%100 mg
NCT03025308 · Phase 3 · registry result, not featured evidence
—200 mg
NCT03926195 · Phase 2 · registry result, not featured evidence
—200 mg
NCT03926195 · Phase 2 · registry result, not featured evidence
—200 mg
NCT03926195 · Phase 2 · registry result, not featured evidence
0%Filgonitib
NCT03926195 · Phase 2 · registry result, not featured evidence
67.6%Filgotinib Darwin 1
NCT02065700 · Phase 2 · registry result, not featured evidence
66.5%Filgotinib Darwin 2
NCT02065700 · Phase 2 · registry result, not featured evidence
0%
NCT02885181 · Phase 2 · registry result, not featured evidence · background therapy
4.3%200 mg QD
NCT01894516 · Phase 2 · registry result, not featured evidence
4.3%100 mg QD
NCT01894516 · Phase 2 · registry result, not featured evidence
6.9%50 mg QD
NCT01894516 · Phase 2 · registry result, not featured evidence
7%200 mg QD
NCT01888874 · Phase 2 · registry result, not featured evidence
1.2%100 mg BID
NCT01888874 · Phase 2 · registry result, not featured evidence
8.2%100 mg QD
NCT01888874 · Phase 2 · registry result, not featured evidence
5.9%50 mg BID
NCT01888874 · Phase 2 · registry result, not featured evidence
7.3%50 mg QD
NCT01888874 · Phase 2 · registry result, not featured evidence
10.5%25 mg BID
NCT01888874 · Phase 2 · registry result, not featured evidence
—15 mge
NCT02675426 · Phase 3
show 55 more results
—15 mg
NCT02675426 · Phase 3
—15 mg
NCT02675426 · Phase 3
3.6%15 mg
NCT02675426 · Phase 3
—30 mg
NCT02675426 · Phase 3
—30 mg
NCT02675426 · Phase 3
8.2%30 mg
NCT02675426 · Phase 3
—15 mg
NCT02706873 · Phase 3 · monotherapy
12.6%15 mg
NCT02706873 · Phase 3
—15 mg
NCT02706873 · Phase 3 · monotherapy
—15 mg
NCT02706873 · Phase 3 · monotherapy
14%30 mg
NCT02706873 · Phase 3
—30 mg
NCT02706873 · Phase 3 · monotherapy
—30 mg
NCT02706873 · Phase 3 · monotherapy
7.3%7.5 mg
NCT02706873 · Phase 3
—7.5 mg
NCT02706873 · Phase 3 · monotherapy
—7.5 mg
NCT02706873 · Phase 3 · monotherapy
—15 mg QD
NCT03086343 · Phase 3
—15 mg QD
NCT03086343 · Phase 3
—30 mg QD
NCT03086343 · Phase 3
—30 mg QD
NCT03086343 · Phase 3
7.4%15 mg
NCT02706951 · Phase 3
—15 mg
NCT02706951 · Phase 3
—15 mg
NCT02706951 · Phase 3
4.7%30 mg
NCT02706951 · Phase 3
—30 mg
NCT02706951 · Phase 3
4.8%15 mg
NCT02706847 · Phase 3
—15 mg
NCT02706847 · Phase 3
—15 mg
NCT02706847 · Phase 3
—15 mg
NCT02706847 · Phase 3
9.7%30 mg
NCT02706847 · Phase 3
—30 mg
NCT02706847 · Phase 3
—30 mg
NCT02706847 · Phase 3
—15 mg
NCT02955212 · Phase 3 · registry result, not featured evidence
—15 mg
NCT02955212 · Phase 3 · registry result, not featured evidence
—15 mg
NCT02720523 · Phase 2/3 · registry result, not featured evidence
4.1%15 mg
NCT02720523 · Phase 2/3 · registry result, not featured evidence
—30 mg
NCT02720523 · Phase 2/3 · registry result, not featured evidence
12%30 mg
NCT02720523 · Phase 2/3 · registry result, not featured evidence
—7.5 mg
NCT02720523 · Phase 2/3 · registry result, not featured evidence
0%7.5 mg
NCT02720523 · Phase 2/3 · registry result, not featured evidence
—12 mg BID/30 mg QD
NCT02049138 · Phase 2 · registry result, not featured evidence
—6 mg BID/15 mg QD
NCT02049138 · Phase 2 · registry result, not featured evidence
7.3%60 mg
NCT03682705 · Phase 2 · registry result, not featured evidence
12.8%20 mg
NCT03682705 · Phase 2 · registry result, not featured evidence
6.5%15 mg/60 mg
NCT03682705 · Phase 2 · registry result, not featured evidence · combination
14.6%5 mg
NCT03682705 · Phase 2 · registry result, not featured evidence
10%24 mg QD
NCT02066389 · Phase 2 · registry result, not featured evidence
14%18 mg BID
NCT02066389 · Phase 2 · registry result, not featured evidence
6%12 mg BID
NCT02066389 · Phase 2 · registry result, not featured evidence
12%6 mg BID
NCT02066389 · Phase 2 · registry result, not featured evidence
2%3 mg BID
NCT02066389 · Phase 2 · registry result, not featured evidence
9.1%18 mg BID
NCT01960855 · Phase 2 · registry result, not featured evidence
7.3%12 mg BID
NCT01960855 · Phase 2 · registry result, not featured evidence
16.4%6 mg BID
NCT01960855 · Phase 2 · registry result, not featured evidence
7.3%3 mg BID
NCT01960855 · Phase 2 · registry result, not featured evidence
Discontinued due to AEs
2%200 mge
NCT02873936 · Phase 3
show 26 more results
3.3%100 mg
NCT02873936 · Phase 3
2.4%200 mg
NCT02886728 · Phase 3 · monotherapy
3.1%200 mg
NCT02886728 · Phase 3 · combination
2.4%100 mg
NCT02886728 · Phase 3 · combination
3.6%200 mg
NCT02889796 · Phase 3
1.7%100 mg
NCT02889796 · Phase 3
12.3%200 mg
NCT03025308 · Phase 3 · registry result, not featured evidence
13.4%200 mg
NCT03025308 · Phase 3 · registry result, not featured evidence
14%100 mg
NCT03025308 · Phase 3 · registry result, not featured evidence
12.2%100 mg
NCT03025308 · Phase 3 · registry result, not featured evidence
—200 mg
NCT03926195 · Phase 2 · registry result, not featured evidence
—200 mg
NCT03926195 · Phase 2 · registry result, not featured evidence
—200 mg
NCT03926195 · Phase 2 · registry result, not featured evidence
—Filgonitib
NCT03926195 · Phase 2 · registry result, not featured evidence
33.2%Filgotinib Darwin 1
NCT02065700 · Phase 2 · registry result, not featured evidence
42.6%Filgotinib Darwin 2
NCT02065700 · Phase 2 · registry result, not featured evidence
0%
NCT02885181 · Phase 2 · registry result, not featured evidence · background therapy
1.4%200 mg QD
NCT01894516 · Phase 2 · registry result, not featured evidence
0%100 mg QD
NCT01894516 · Phase 2 · registry result, not featured evidence
0%50 mg QD
NCT01894516 · Phase 2 · registry result, not featured evidence
1.2%200 mg QD
NCT01888874 · Phase 2 · registry result, not featured evidence
0%100 mg BID
NCT01888874 · Phase 2 · registry result, not featured evidence
3.5%100 mg QD
NCT01888874 · Phase 2 · registry result, not featured evidence
1.2%50 mg BID
NCT01888874 · Phase 2 · registry result, not featured evidence
2.4%50 mg QD
NCT01888874 · Phase 2 · registry result, not featured evidence
3.5%25 mg BID
NCT01888874 · Phase 2 · registry result, not featured evidence
—15 mge
NCT02675426 · Phase 3
show 55 more results
—15 mg
NCT02675426 · Phase 3
—15 mg
NCT02675426 · Phase 3
1.4%15 mg
NCT02675426 · Phase 3
—30 mg
NCT02675426 · Phase 3
—30 mg
NCT02675426 · Phase 3
4.1%30 mg
NCT02675426 · Phase 3
—15 mg
NCT02706873 · Phase 3 · monotherapy
5.7%15 mg
NCT02706873 · Phase 3
—15 mg
NCT02706873 · Phase 3 · monotherapy
—15 mg
NCT02706873 · Phase 3 · monotherapy
3.5%30 mg
NCT02706873 · Phase 3
—30 mg
NCT02706873 · Phase 3 · monotherapy
—30 mg
NCT02706873 · Phase 3 · monotherapy
5.5%7.5 mg
NCT02706873 · Phase 3
—7.5 mg
NCT02706873 · Phase 3 · monotherapy
—7.5 mg
NCT02706873 · Phase 3 · monotherapy
—15 mg QD
NCT03086343 · Phase 3
—15 mg QD
NCT03086343 · Phase 3
—30 mg QD
NCT03086343 · Phase 3
—30 mg QD
NCT03086343 · Phase 3
2.3%15 mg
NCT02706951 · Phase 3
—15 mg
NCT02706951 · Phase 3
—15 mg
NCT02706951 · Phase 3
1.4%30 mg
NCT02706951 · Phase 3
—30 mg
NCT02706951 · Phase 3
0.6%15 mg
NCT02706847 · Phase 3
—15 mg
NCT02706847 · Phase 3
—15 mg
NCT02706847 · Phase 3
—15 mg
NCT02706847 · Phase 3
7.3%30 mg
NCT02706847 · Phase 3
—30 mg
NCT02706847 · Phase 3
—30 mg
NCT02706847 · Phase 3
—15 mg
NCT02955212 · Phase 3 · registry result, not featured evidence
—15 mg
NCT02955212 · Phase 3 · registry result, not featured evidence
—15 mg
NCT02720523 · Phase 2/3 · registry result, not featured evidence
2%15 mg
NCT02720523 · Phase 2/3 · registry result, not featured evidence
—30 mg
NCT02720523 · Phase 2/3 · registry result, not featured evidence
10%30 mg
NCT02720523 · Phase 2/3 · registry result, not featured evidence
—7.5 mg
NCT02720523 · Phase 2/3 · registry result, not featured evidence
0%7.5 mg
NCT02720523 · Phase 2/3 · registry result, not featured evidence
—12 mg BID/30 mg QD
NCT02049138 · Phase 2 · registry result, not featured evidence
—6 mg BID/15 mg QD
NCT02049138 · Phase 2 · registry result, not featured evidence
2.4%60 mg
NCT03682705 · Phase 2 · registry result, not featured evidence
0%20 mg
NCT03682705 · Phase 2 · registry result, not featured evidence
1.6%15 mg/60 mg
NCT03682705 · Phase 2 · registry result, not featured evidence · combination
2.4%5 mg
NCT03682705 · Phase 2 · registry result, not featured evidence
2%24 mg QD
NCT02066389 · Phase 2 · registry result, not featured evidence
10%18 mg BID
NCT02066389 · Phase 2 · registry result, not featured evidence
2%12 mg BID
NCT02066389 · Phase 2 · registry result, not featured evidence
2%6 mg BID
NCT02066389 · Phase 2 · registry result, not featured evidence
2%3 mg BID
NCT02066389 · Phase 2 · registry result, not featured evidence
3.6%18 mg BID
NCT01960855 · Phase 2 · registry result, not featured evidence
3.6%12 mg BID
NCT01960855 · Phase 2 · registry result, not featured evidence
10.9%6 mg BID
NCT01960855 · Phase 2 · registry result, not featured evidence
0%3 mg BID
NCT01960855 · Phase 2 · registry result, not featured evidence
Serious AEs
4.1%200 mge
NCT02873936 · Phase 3
show 26 more results
5.2%100 mg
NCT02873936 · Phase 3
8.1%200 mg
NCT02886728 · Phase 3 · monotherapy
6.3%200 mg
NCT02886728 · Phase 3 · combination
6.3%100 mg
NCT02886728 · Phase 3 · combination
7.4%200 mg
NCT02889796 · Phase 3
8.3%100 mg
NCT02889796 · Phase 3
24.1%200 mg
NCT03025308 · Phase 3 · registry result, not featured evidence
22.1%200 mg
NCT03025308 · Phase 3 · registry result, not featured evidence
24.6%100 mg
NCT03025308 · Phase 3 · registry result, not featured evidence
25.9%100 mg
NCT03025308 · Phase 3 · registry result, not featured evidence
3.7%200 mg
NCT03926195 · Phase 2 · registry result, not featured evidence
12.8%200 mg
NCT03926195 · Phase 2 · registry result, not featured evidence
14.3%200 mg
NCT03926195 · Phase 2 · registry result, not featured evidence
—Filgonitib
NCT03926195 · Phase 2 · registry result, not featured evidence
16.9%Filgotinib Darwin 1
NCT02065700 · Phase 2 · registry result, not featured evidence
19.8%Filgotinib Darwin 2
NCT02065700 · Phase 2 · registry result, not featured evidence
0%
NCT02885181 · Phase 2 · registry result, not featured evidence · background therapy
4.3%200 mg QD
NCT01894516 · Phase 2 · registry result, not featured evidence
3.5%100 mg QD
NCT01894516 · Phase 2 · registry result, not featured evidence
2.8%50 mg QD
NCT01894516 · Phase 2 · registry result, not featured evidence
2.3%200 mg QD
NCT01888874 · Phase 2 · registry result, not featured evidence
3.6%100 mg BID
NCT01888874 · Phase 2 · registry result, not featured evidence
3.4%100 mg QD
NCT01888874 · Phase 2 · registry result, not featured evidence
0%50 mg BID
NCT01888874 · Phase 2 · registry result, not featured evidence
0%50 mg QD
NCT01888874 · Phase 2 · registry result, not featured evidence
2.3%25 mg BID
NCT01888874 · Phase 2 · registry result, not featured evidence
28.1%15 mge
NCT02675426 · Phase 3
show 55 more results
4.5%15 mg
NCT02675426 · Phase 3
10.6%15 mg
NCT02675426 · Phase 3
—15 mg
NCT02675426 · Phase 3
3.2%30 mg
NCT02675426 · Phase 3
31.8%30 mg
NCT02675426 · Phase 3
—30 mg
NCT02675426 · Phase 3
15.5%15 mg
NCT02706873 · Phase 3 · monotherapy
—15 mg
NCT02706873 · Phase 3
5%15 mg
NCT02706873 · Phase 3 · monotherapy
21.5%15 mg
NCT02706873 · Phase 3 · monotherapy
—30 mg
NCT02706873 · Phase 3
6.4%30 mg
NCT02706873 · Phase 3 · monotherapy
22.6%30 mg
NCT02706873 · Phase 3 · monotherapy
—7.5 mg
NCT02706873 · Phase 3
9.1%7.5 mg
NCT02706873 · Phase 3 · monotherapy
23.6%7.5 mg
NCT02706873 · Phase 3 · monotherapy
4%15 mg QD
NCT03086343 · Phase 3
23.6%15 mg QD
NCT03086343 · Phase 3
19%30 mg QD
NCT03086343 · Phase 3
35.3%30 mg QD
NCT03086343 · Phase 3
5.1%15 mg
NCT02706951 · Phase 3
10.7%15 mg
NCT02706951 · Phase 3
29.9%15 mg
NCT02706951 · Phase 3
2.8%30 mg
NCT02706951 · Phase 3
24.1%30 mg
NCT02706951 · Phase 3
—15 mg
NCT02706847 · Phase 3
15.2%15 mg
NCT02706847 · Phase 3
5.5%15 mg
NCT02706847 · Phase 3
36.9%15 mg
NCT02706847 · Phase 3
—30 mg
NCT02706847 · Phase 3
7.3%30 mg
NCT02706847 · Phase 3
29.6%30 mg
NCT02706847 · Phase 3
17.1%15 mg
NCT02955212 · Phase 3 · registry result, not featured evidence
7.1%15 mg
NCT02955212 · Phase 3 · registry result, not featured evidence
21.9%15 mg
NCT02720523 · Phase 2/3 · registry result, not featured evidence
2%15 mg
NCT02720523 · Phase 2/3 · registry result, not featured evidence
27.3%30 mg
NCT02720523 · Phase 2/3 · registry result, not featured evidence
10%30 mg
NCT02720523 · Phase 2/3 · registry result, not featured evidence
13.8%7.5 mg
NCT02720523 · Phase 2/3 · registry result, not featured evidence
2%7.5 mg
NCT02720523 · Phase 2/3 · registry result, not featured evidence
22.5%12 mg BID/30 mg QD
NCT02049138 · Phase 2 · registry result, not featured evidence
13.8%6 mg BID/15 mg QD
NCT02049138 · Phase 2 · registry result, not featured evidence
0%60 mg
NCT03682705 · Phase 2 · registry result, not featured evidence
5.1%20 mg
NCT03682705 · Phase 2 · registry result, not featured evidence
0%15 mg/60 mg
NCT03682705 · Phase 2 · registry result, not featured evidence · combination
7.3%5 mg
NCT03682705 · Phase 2 · registry result, not featured evidence
4.1%24 mg QD
NCT02066389 · Phase 2 · registry result, not featured evidence
6%18 mg BID
NCT02066389 · Phase 2 · registry result, not featured evidence
2%12 mg BID
NCT02066389 · Phase 2 · registry result, not featured evidence
4%6 mg BID
NCT02066389 · Phase 2 · registry result, not featured evidence
0%3 mg BID
NCT02066389 · Phase 2 · registry result, not featured evidence
1.8%18 mg BID
NCT01960855 · Phase 2 · registry result, not featured evidence
0%12 mg BID
NCT01960855 · Phase 2 · registry result, not featured evidence
3.6%6 mg BID
NCT01960855 · Phase 2 · registry result, not featured evidence
3.6%3 mg BID
NCT01960855 · Phase 2 · registry result, not featured evidence
Most frequent reported AEs
200 mge
nasopharyngitis 10.2% (placebo 4.7%)
bronchitis 5.4% (placebo 5.4%)
headache 5.4% (placebo 1.4%)
NCT02873936 · Phase 3
show 25 more results
100 mg
headache 5.9% (placebo 1.4%)
nasopharyngitis 5.9% (placebo 4.7%)
upper respiratory tract infection 5.9% (placebo 4.1%)
NCT02873936 · Phase 3
200 mg
nasopharyngitis 8.1%
hypertension 7.1%
nausea 7.1%
NCT02886728 · Phase 3 · monotherapy
200 mg
nausea 12.3%
upper respiratory tract infection 10.1%
alanine aminotransferase increased 5.5%
NCT02886728 · Phase 3 · combination
100 mg
nausea 16.9%
nasopharyngitis 8.2%
alopecia 7.2%
NCT02886728 · Phase 3 · combination
200 mg
nasopharyngitis 9.1% (placebo 5.3%)
upper respiratory tract infection 8.6% (placebo 2.9%)
nausea 5.5% (placebo 1.5%)
NCT02889796 · Phase 3
100 mg
upper respiratory tract infection 10.2% (placebo 2.9%)
nasopharyngitis 10% (placebo 5.3%)
alanine aminotransferase increased 5.2% (placebo 2.3%)
NCT02889796 · Phase 3
200 mg
covid-19 18.3%
nasopharyngitis 13.1%
upper respiratory tract infection 11%
NCT03025308 · Phase 3 · registry result, not featured evidence
200 mg
covid-19 17.3%
upper respiratory tract infection 13.1%
rheumatoid arthritis 11.9%
NCT03025308 · Phase 3 · registry result, not featured evidence
100 mg
covid-19 15.3%
nasopharyngitis 15.1%
rheumatoid arthritis 13.9%
NCT03025308 · Phase 3 · registry result, not featured evidence
100 mg
covid-19 18.5%
rheumatoid arthritis 12.2%
upper respiratory tract infection 11.9%
NCT03025308 · Phase 3 · registry result, not featured evidence
200 mg
nasopharyngitis 7.4% (placebo 7.3%)
dyslipidaemia 3.7% (placebo 0%)
headache 3.7% (placebo 1.8%)
NCT03926195 · Phase 2 · registry result, not featured evidence
200 mg
covid-19 15.4% (placebo 0%)
ankylosing spondylitis 7.7% (placebo 0%)
latent tuberculosis 7.7% (placebo 0%)
NCT03926195 · Phase 2 · registry result, not featured evidence
200 mg
nasopharyngitis 57.1% (placebo 7.3%)
covid-19 42.9% (placebo 0%)
alanine aminotransferase increased 14.3% (placebo 0%)
NCT03926195 · Phase 2 · registry result, not featured evidence
hypertension 15.1%
urinary tract infection 14.5%
nasopharyngitis 14.1%
NCT02065700 · Phase 2 · registry result, not featured evidence
mycobacterium tuberculosis complex test positive 16.5%
upper respiratory tract infection 15.3%
hypercholesterolaemia 12.4%
NCT02065700 · Phase 2 · registry result, not featured evidence
asthenia 9.5% (placebo 0%)
blood creatine phosphokinase increased 4.8% (placebo 0%)
dyspepsia 4.8% (placebo 0%)
NCT02885181 · Phase 2 · registry result, not featured evidence · background therapy
200 mg QD
anaemia 5.8% (placebo 0%)
upper respiratory tract infection 5.8% (placebo 2.8%)
urinary tract infection 5.8% (placebo 1.4%)
NCT01894516 · Phase 2 · registry result, not featured evidence
100 mg QD
urinary tract infection 8.2% (placebo 1.4%)
hypercholesterolaemia 5.9% (placebo 4.2%)
hypertriglyceridaemia 5.9% (placebo 1.4%)
NCT01894516 · Phase 2 · registry result, not featured evidence
50 mg QD
headache 5.6% (placebo 1.4%)
hypercholesterolaemia 5.6% (placebo 4.2%)
hypertension 4.2% (placebo 5.6%)
NCT01894516 · Phase 2 · registry result, not featured evidence
200 mg QD
headache 7% (placebo 4.7%)
hypercholesterolaemia 5.8% (placebo 0%)
hypertension 4.7% (placebo 2.3%)
NCT01888874 · Phase 2 · registry result, not featured evidence
100 mg BID
hypercholesterolaemia 4.8% (placebo 0%)
nasopharyngitis 4.8% (placebo 4.7%)
headache 2.4% (placebo 4.7%)
NCT01888874 · Phase 2 · registry result, not featured evidence
100 mg QD
hypertension 5% (placebo 2.3%)
nasopharyngitis 2.5% (placebo 4.7%)
upper respiratory tract infection 1.7% (placebo 1.2%)
NCT01888874 · Phase 2 · registry result, not featured evidence
50 mg BID
upper respiratory tract infection 5.1% (placebo 1.2%)
vomiting 5.1% (placebo 1.2%)
hypertension 3.4% (placebo 2.3%)
NCT01888874 · Phase 2 · registry result, not featured evidence
50 mg QD
nasopharyngitis 9.8% (placebo 4.7%)
nausea 8.5% (placebo 3.5%)
hypertension 3.7% (placebo 2.3%)
NCT01888874 · Phase 2 · registry result, not featured evidence
25 mg BID
headache 7% (placebo 4.7%)
gastroenteritis 5.8% (placebo 0%)
nasopharyngitis 4.7% (placebo 4.7%)
NCT01888874 · Phase 2 · registry result, not featured evidence
15 mge
upper respiratory tract infection 19.8% (placebo 4.1%)
nasopharyngitis 18.5% (placebo 4.1%)
urinary tract infection 17% (placebo 3.6%)
NCT02675426 · Phase 3
show 48 more results
15 mg
nausea 6.8% (placebo 3.2%)
nasopharyngitis 5.4% (placebo 4.1%)
upper respiratory tract infection 5.4% (placebo 4.1%)
NCT02675426 · Phase 3
15 mg
covid-19 8.9% (placebo 0%)
rheumatoid arthritis 4.5% (placebo 4.5%)
fall 2.8% (placebo 0.5%)
NCT02675426 · Phase 3
30 mg
nasopharyngitis 5.9% (placebo 4.1%)
upper respiratory tract infection 5.5% (placebo 4.1%)
headache 3.7% (placebo 5.4%)
NCT02675426 · Phase 3
30 mg
upper respiratory tract infection 17.8% (placebo 4.1%)
urinary tract infection 14.3% (placebo 3.6%)
nasopharyngitis 14% (placebo 4.1%)
NCT02675426 · Phase 3
15 mg
covid-19 10.5%
rheumatoid arthritis 9.4%
urinary tract infection 7.2%
NCT02706873 · Phase 3 · monotherapy
15 mg
upper respiratory tract infection 6.3%
nasopharyngitis 5.7%
nausea 5.7%
NCT02706873 · Phase 3 · monotherapy
15 mg
upper respiratory tract infection 15.5%
nasopharyngitis 15.1%
urinary tract infection 13.6%
NCT02706873 · Phase 3 · monotherapy
30 mg
blood creatine phosphokinase increased 10.8%
upper respiratory tract infection 7.3%
urinary tract infection 5.7%
NCT02706873 · Phase 3 · monotherapy
30 mg
blood creatine phosphokinase increased 16.2%
nasopharyngitis 16.2%
hypertension 14%
NCT02706873 · Phase 3 · monotherapy
7.5 mg
nasopharyngitis 9.1%
pharyngitis 9.1%
stomatitis 7.3%
NCT02706873 · Phase 3 · monotherapy
7.5 mg
nasopharyngitis 40%
herpes zoster 21.8%
pharyngitis 21.8%
NCT02706873 · Phase 3 · monotherapy
15 mg QD
upper respiratory tract infection 8.6%
nasopharyngitis 7.3%
urinary tract infection 6.6%
NCT03086343 · Phase 3
15 mg QD
covid-19 23.6%
urinary tract infection 14.8%
nasopharyngitis 13.7%
NCT03086343 · Phase 3
30 mg QD
rheumatoid arthritis 14.3%
arthralgia 9.5%
cough 9.5%
NCT03086343 · Phase 3
30 mg QD
hypertension 23.5%
upper respiratory tract infection 23.5%
bronchitis 17.6%
NCT03086343 · Phase 3
15 mg
urinary tract infection 4.6%
upper respiratory tract infection 4.1%
blood creatine phosphokinase increased 2.3%
NCT02706951 · Phase 3
15 mg
covid-19 9.8%
urinary tract infection 6.3%
rheumatoid arthritis 4.4%
NCT02706951 · Phase 3
15 mg
nasopharyngitis 17.6%
rheumatoid arthritis 14.2%
urinary tract infection 13.5%
NCT02706951 · Phase 3
30 mg
urinary tract infection 4.7%
blood creatine phosphokinase increased 4.2%
upper respiratory tract infection 2.8%
NCT02706951 · Phase 3
30 mg
blood creatine phosphokinase increased 18.6%
urinary tract infection 15.1%
upper respiratory tract infection 14.8%
NCT02706951 · Phase 3
15 mg
rheumatoid arthritis 9.4% (placebo 5.9%)
urinary tract infection 8% (placebo 5.9%)
back pain 5.8% (placebo 2.4%)
NCT02706847 · Phase 3
15 mg
urinary tract infection 9.8% (placebo 5.9%)
upper respiratory tract infection 7.9% (placebo 7.7%)
bronchitis 4.3% (placebo 2.4%)
NCT02706847 · Phase 3
15 mg
upper respiratory tract infection 31.4% (placebo 7.7%)
urinary tract infection 18.2% (placebo 5.9%)
nasopharyngitis 14.4% (placebo 6.5%)
NCT02706847 · Phase 3
30 mg
upper respiratory tract infection 6.7% (placebo 7.7%)
nasopharyngitis 5.5% (placebo 6.5%)
urinary tract infection 5.5% (placebo 5.9%)
NCT02706847 · Phase 3
30 mg
upper respiratory tract infection 27.9% (placebo 7.7%)
urinary tract infection 20.4% (placebo 5.9%)
nasopharyngitis 17.1% (placebo 6.5%)
NCT02706847 · Phase 3
15 mg
upper respiratory tract infection 20.2% (placebo 6.5%)
alanine aminotransferase increased 9.3% (placebo 1.2%)
blood creatine phosphokinase increased 9% (placebo 0%)
NCT02955212 · Phase 3 · registry result, not featured evidence
15 mg
upper respiratory tract infection 9.5% (placebo 6.5%)
alanine aminotransferase increased 5.3% (placebo 1.2%)
anaemia 0% (placebo 0%)
NCT02955212 · Phase 3 · registry result, not featured evidence
15 mg
nasopharyngitis 54.7% (placebo 10.2%)
herpes zoster 14.1% (placebo 2%)
influenza 14.1% (placebo 4.1%)
NCT02720523 · Phase 2/3 · registry result, not featured evidence
15 mg
nasopharyngitis 12.2% (placebo 10.2%)
liver function test increased 6.1% (placebo 0%)
constipation 4.1% (placebo 0%)
NCT02720523 · Phase 2/3 · registry result, not featured evidence
30 mg
nasopharyngitis 43.9% (placebo 10.2%)
constipation 15.2% (placebo 0%)
herpes zoster 15.2% (placebo 2%)
NCT02720523 · Phase 2/3 · registry result, not featured evidence
30 mg
nasopharyngitis 18% (placebo 10.2%)
blood creatine phosphokinase increased 6% (placebo 0%)
headache 6% (placebo 0%)
NCT02720523 · Phase 2/3 · registry result, not featured evidence
7.5 mg
nasopharyngitis 53.8% (placebo 10.2%)
stomatitis 20% (placebo 6.1%)
hypertension 12.3% (placebo 0%)
NCT02720523 · Phase 2/3 · registry result, not featured evidence
7.5 mg
nasopharyngitis 10.2% (placebo 10.2%)
hypertension 6.1% (placebo 0%)
stomatitis 6.1% (placebo 6.1%)
NCT02720523 · Phase 2/3 · registry result, not featured evidence
12 mg BID/30 mg QD
upper respiratory tract infection 20.3%
urinary tract infection 15%
herpes zoster 11.2%
NCT02049138 · Phase 2 · registry result, not featured evidence
6 mg BID/15 mg QD
upper respiratory tract infection 9.9%
nasopharyngitis 9.5%
urinary tract infection 9.5%
NCT02049138 · Phase 2 · registry result, not featured evidence
60 mg
urinary tract infection 9.8% (placebo 0%)
diarrhoea 7.3% (placebo 0%)
rheumatoid arthritis 7.3% (placebo 10.5%)
NCT03682705 · Phase 2 · registry result, not featured evidence
20 mg
rheumatoid arthritis 7.7% (placebo 10.5%)
upper respiratory tract infection 7.7% (placebo 5.3%)
alopecia 5.1% (placebo 0%)
NCT03682705 · Phase 2 · registry result, not featured evidence
15 mg/60 mg
upper respiratory tract infection 6.5% (placebo 5.3%)
arthralgia 1.6% (placebo 5.3%)
cough 1.6% (placebo 0%)
NCT03682705 · Phase 2 · registry result, not featured evidence · combination
5 mg
rheumatoid arthritis 7.3% (placebo 10.5%)
upper respiratory tract infection 4.9% (placebo 5.3%)
urinary tract infection 4.9% (placebo 0%)
NCT03682705 · Phase 2 · registry result, not featured evidence
24 mg QD
nasopharyngitis 6.1% (placebo 2%)
back pain 2% (placebo 0%)
blood creatine phosphokinase increased 2% (placebo 0%)
NCT02066389 · Phase 2 · registry result, not featured evidence
18 mg BID
blood creatine phosphokinase increased 4% (placebo 0%)
nasopharyngitis 4% (placebo 2%)
cough 2% (placebo 0%)
NCT02066389 · Phase 2 · registry result, not featured evidence
12 mg BID
influenza 8% (placebo 0%)
nasopharyngitis 8% (placebo 2%)
blood creatine phosphokinase increased 6% (placebo 0%)
NCT02066389 · Phase 2 · registry result, not featured evidence
6 mg BID
back pain 6% (placebo 0%)
nasopharyngitis 4% (placebo 2%)
cough 2% (placebo 0%)
NCT02066389 · Phase 2 · registry result, not featured evidence
3 mg BID
headache 4% (placebo 2%)
back pain 2% (placebo 0%)
cough 2% (placebo 0%)
NCT02066389 · Phase 2 · registry result, not featured evidence
18 mg BID
urinary tract infection 12.7% (placebo 3.6%)
blood creatine phosphokinase increased 9.1% (placebo 0%)
constipation 7.3% (placebo 0%)
NCT01960855 · Phase 2 · registry result, not featured evidence
12 mg BID
upper respiratory tract infection 7.3% (placebo 1.8%)
headache 5.5% (placebo 1.8%)
leukopenia 5.5% (placebo 0%)
NCT01960855 · Phase 2 · registry result, not featured evidence
6 mg BID
headache 5.5% (placebo 1.8%)
hyperlipidaemia 3.6% (placebo 1.8%)
constipation 1.8% (placebo 0%)
NCT01960855 · Phase 2 · registry result, not featured evidence
3 mg BID
nausea 7.3% (placebo 1.8%)
arthralgia 5.5% (placebo 0%)
headache 5.5% (placebo 1.8%)
NCT01960855 · Phase 2 · registry result, not featured evidence

Notes

  1. aThis study reports multiple eligible drug arms; no representative arm has been reviewed.
  2. bPopulation comparability has not been reviewed for both studies.
  3. cTrial phases differ: Phase 2 versus Phase 3.
  4. dTreatment context has not been resolved for both arms.
  5. ePopulation comparability has not been reviewed for these studies.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

filgotinib

HAQ Improvement 60.4% (n=147) vs 40.3% (n=148) placebo @ 4wk200 mg
responder rate · % of participants
NCT02873936 · Phase 3
show 23 more results
66.7% (n=147) vs 44.4% (n=148) placebo @ 12wk200 mg
NCT02873936 · Phase 3
68.8% (n=147) vs 35.4% (n=148) placebo @ 24wk200 mg
NCT02873936 · Phase 3
53.9% (n=210) vs 42.2% (n=416) MTX @ 2wk200 mg
NCT02886728 · Phase 3 · monotherapy
68.6% (n=210) vs 53.9% (n=416) MTX @ 4wk200 mg
NCT02886728 · Phase 3 · monotherapy
74% (n=210) vs 69.8% (n=416) MTX @ 12wk200 mg
NCT02886728 · Phase 3 · monotherapy
77% (n=210) vs 73.9% (n=416) MTX @ 24wk200 mg
NCT02886728 · Phase 3 · monotherapy
73.5% (n=210) vs 67.1% (n=416) MTX @ 36wk200 mg
NCT02886728 · Phase 3 · monotherapy
70.6% (n=210) vs 61% (n=416) MTX @ 52wk200 mg
NCT02886728 · Phase 3 · monotherapy
54.7% (n=153) vs 40.3% (n=148) placebo @ 4wk100 mg
NCT02873936 · Phase 3
66.2% (n=153) vs 44.4% (n=148) placebo @ 12wk100 mg
NCT02873936 · Phase 3
54.1% (n=153) vs 35.4% (n=148) placebo @ 24wk100 mg
NCT02873936 · Phase 3
61.9% (n=416) vs 42.2% (n=416) MTX @ 2wk200 mg
NCT02886728 · Phase 3 · combination
72.4% (n=416) vs 53.9% (n=416) MTX @ 4wk200 mg
NCT02886728 · Phase 3 · combination
80.3% (n=416) vs 69.8% (n=416) MTX @ 12wk200 mg
NCT02886728 · Phase 3 · combination
76.6% (n=416) vs 73.9% (n=416) MTX @ 24wk200 mg
NCT02886728 · Phase 3 · combination
73.4% (n=416) vs 67.1% (n=416) MTX @ 36wk200 mg
NCT02886728 · Phase 3 · combination
70.9% (n=416) vs 61% (n=416) MTX @ 52wk200 mg
NCT02886728 · Phase 3 · combination
58.5% (n=207) vs 42.2% (n=416) MTX @ 2wk100 mg
NCT02886728 · Phase 3 · combination
61% (n=207) vs 53.9% (n=416) MTX @ 4wk100 mg
NCT02886728 · Phase 3 · combination
74.5% (n=207) vs 69.8% (n=416) MTX @ 12wk100 mg
NCT02886728 · Phase 3 · combination
78.5% (n=207) vs 73.9% (n=416) MTX @ 24wk100 mg
NCT02886728 · Phase 3 · combination
76.5% (n=207) vs 67.1% (n=416) MTX @ 36wk100 mg
NCT02886728 · Phase 3 · combination
71.5% (n=207) vs 61% (n=416) MTX @ 52wk100 mg
NCT02886728 · Phase 3 · combination
ACR-N 26.9% (n=147) vs 13.7% (n=148) placebo @ 4wk200 mg
absolute value · percentage points
NCT02873936 · Phase 3
show 17 more results
43.4% (n=147) vs 19.7% (n=148) placebo @ 12wk200 mg
NCT02873936 · Phase 3
53.5% (n=147) vs 31.9% (n=148) placebo @ 24wk200 mg
NCT02873936 · Phase 3
18.3% (n=475) vs 8% (n=475) placebo @ 2wk200 mg
NCT02889796 · Phase 3
27.4% (n=475) vs 15.1% (n=475) placebo @ 4wk200 mg
NCT02889796 · Phase 3
46.8% (n=475) vs 28.1% (n=475) placebo @ 12wk200 mg
NCT02889796 · Phase 3
58.8% (n=475) vs 42.6% (n=475) placebo @ 24wk200 mg
NCT02889796 · Phase 3
62.5% (n=475) vs 63.2% (n=190) placebo @ 36wk200 mg
NCT02889796 · Phase 3
66% (n=475) vs 63.8% (n=190) placebo @ 52wk200 mg
NCT02889796 · Phase 3
25.8% (n=153) vs 13.7% (n=148) placebo @ 4wk100 mg
NCT02873936 · Phase 3
37.1% (n=153) vs 19.7% (n=148) placebo @ 12wk100 mg
NCT02873936 · Phase 3
45.5% (n=153) vs 31.9% (n=148) placebo @ 24wk100 mg
NCT02873936 · Phase 3
14% (n=480) vs 8% (n=475) placebo @ 2wk100 mg
NCT02889796 · Phase 3
23% (n=480) vs 15.1% (n=475) placebo @ 4wk100 mg
NCT02889796 · Phase 3
40.6% (n=480) vs 28.1% (n=475) placebo @ 12wk100 mg
NCT02889796 · Phase 3
55.4% (n=480) vs 42.6% (n=475) placebo @ 24wk100 mg
NCT02889796 · Phase 3
59.1% (n=480) vs 63.2% (n=190) placebo @ 36wk100 mg
NCT02889796 · Phase 3
63.1% (n=480) vs 63.8% (n=190) placebo @ 52wk100 mg
NCT02889796 · Phase 3
EULAR Good 21.8% (n=147) vs 8.8% (n=148) placebo @ 4wk200 mg
responder rate · % of participants
Week 4 · Good Response
NCT02873936 · Phase 3 · converted to % from 32 Participants as posted
show 6 more results
30% (n=210) vs 10.8% (n=416) MTX @ 4wk*200 mg
Week 4 · Good Response
NCT02886728 · Phase 3 · monotherapy · converted to % from 63 Participants as posted
24.6% (n=475) vs 7.8% (n=475) placebo @ 4wk*200 mg
Week 4 · Good Response
NCT02889796 · Phase 3 · converted to % from 117 Participants as posted
22.2% (n=153) vs 8.8% (n=148) placebo @ 4wk*100 mg
Week 4 · Good Response
NCT02873936 · Phase 3 · converted to % from 34 Participants as posted
17.9% (n=480) vs 7.8% (n=475) placebo @ 4wk*100 mg
Week 4 · Good Response
NCT02889796 · Phase 3 · converted to % from 86 Participants as posted
28.8% (n=416) vs 10.8% (n=416) MTX @ 4wk*200 mg
Week 4 · Good Response
NCT02886728 · Phase 3 · combination · converted to % from 120 Participants as posted
21.7% (n=207) vs 10.8% (n=416) MTX @ 4wk*100 mg
Week 4 · Good Response
NCT02886728 · Phase 3 · combination · converted to % from 45 Participants as posted
EULAR Moderate 50.3% (n=147) vs 35.8% (n=148) placebo @ 4wk200 mg
responder rate · % of participants
Week 4 · Moderate Response
NCT02873936 · Phase 3 · converted to % from 74 Participants as posted
show 6 more results
46.2% (n=210) vs 38.7% (n=416) MTX @ 4wk*200 mg
Week 4 · Moderate Response
NCT02886728 · Phase 3 · monotherapy · converted to % from 97 Participants as posted
48.6% (n=475) vs 39.8% (n=475) placebo @ 4wk*200 mg
Week 4 · Moderate Response
NCT02889796 · Phase 3 · converted to % from 231 Participants as posted
42.5% (n=153) vs 35.8% (n=148) placebo @ 4wk*100 mg
Week 4 · Moderate Response
NCT02873936 · Phase 3 · converted to % from 65 Participants as posted
50.4% (n=480) vs 39.8% (n=475) placebo @ 4wk*100 mg
Week 4 · Moderate Response
NCT02889796 · Phase 3 · converted to % from 242 Participants as posted
49.5% (n=416) vs 38.7% (n=416) MTX @ 4wk*200 mg
Week 4 · Moderate Response
NCT02886728 · Phase 3 · combination · converted to % from 206 Participants as posted
50.2% (n=207) vs 38.7% (n=416) MTX @ 4wk*100 mg
Week 4 · Moderate Response
NCT02886728 · Phase 3 · combination · converted to % from 104 Participants as posted
EULAR Good 39.5% (n=147) vs 15.5% (n=148) placebo @ 12wk200 mg
responder rate · % of participants
Week 12 · Good Response
NCT02873936 · Phase 3 · converted to % from 58 Participants as posted
show 6 more results
46.7% (n=210) vs 27.9% (n=416) MTX @ 12wk*200 mg
Week 12 · Good Response
NCT02886728 · Phase 3 · monotherapy · converted to % from 98 Participants as posted
49.3% (n=475) vs 22.3% (n=475) placebo @ 12wk*200 mg
Week 12 · Good Response
NCT02889796 · Phase 3 · converted to % from 234 Participants as posted
36.6% (n=153) vs 15.5% (n=148) placebo @ 12wk*100 mg
Week 12 · Good Response
NCT02873936 · Phase 3 · converted to % from 56 Participants as posted
36.9% (n=480) vs 22.3% (n=475) placebo @ 12wk*100 mg
Week 12 · Good Response
NCT02889796 · Phase 3 · converted to % from 177 Participants as posted
55.3% (n=416) vs 27.9% (n=416) MTX @ 12wk*200 mg
Week 12 · Good Response
NCT02886728 · Phase 3 · combination · converted to % from 230 Participants as posted
48.3% (n=207) vs 27.9% (n=416) MTX @ 12wk*100 mg
Week 12 · Good Response
NCT02886728 · Phase 3 · combination · converted to % from 100 Participants as posted
EULAR Moderate 44.2% (n=147) vs 34.5% (n=148) placebo @ 12wk200 mg
responder rate · % of participants
Week 12 · Moderate Response
NCT02873936 · Phase 3 · converted to % from 65 Participants as posted
show 6 more results
36.7% (n=210) vs 45.7% (n=416) MTX @ 12wk*200 mg
Week 12 · Moderate Response
NCT02886728 · Phase 3 · monotherapy · converted to % from 77 Participants as posted
39.6% (n=475) vs 47.2% (n=475) placebo @ 12wk*200 mg
Week 12 · Moderate Response
NCT02889796 · Phase 3 · converted to % from 188 Participants as posted
37.9% (n=153) vs 34.5% (n=148) placebo @ 12wk*100 mg
Week 12 · Moderate Response
NCT02873936 · Phase 3 · converted to % from 58 Participants as posted
46.9% (n=480) vs 47.2% (n=475) placebo @ 12wk*100 mg
Week 12 · Moderate Response
NCT02889796 · Phase 3 · converted to % from 225 Participants as posted
31.3% (n=416) vs 45.7% (n=416) MTX @ 12wk*200 mg
Week 12 · Moderate Response
NCT02886728 · Phase 3 · combination · converted to % from 130 Participants as posted
38.2% (n=207) vs 45.7% (n=416) MTX @ 12wk*100 mg
Week 12 · Moderate Response
NCT02886728 · Phase 3 · combination · converted to % from 79 Participants as posted
EULAR Good 47.6% (n=147) vs 20.9% (n=148) placebo @ 24wk200 mg
responder rate · % of participants
Week 24 · Good Response
NCT02873936 · Phase 3 · converted to % from 70 Participants as posted
show 6 more results
60% (n=210) vs 44.7% (n=416) MTX @ 24wk*200 mg
Week 24 · Good Response
NCT02886728 · Phase 3 · monotherapy · converted to % from 126 Participants as posted
59.8% (n=475) vs 32.4% (n=475) placebo @ 24wk*200 mg
Week 24 · Good Response
NCT02889796 · Phase 3 · converted to % from 284 Participants as posted
37.9% (n=153) vs 20.9% (n=148) placebo @ 24wk*100 mg
Week 24 · Good Response
NCT02873936 · Phase 3 · converted to % from 58 Participants as posted
52.1% (n=480) vs 32.4% (n=475) placebo @ 24wk*100 mg
Week 24 · Good Response
NCT02889796 · Phase 3 · converted to % from 250 Participants as posted
68% (n=416) vs 44.7% (n=416) MTX @ 24wk*200 mg
Week 24 · Good Response
NCT02886728 · Phase 3 · combination · converted to % from 283 Participants as posted
61.4% (n=207) vs 44.7% (n=416) MTX @ 24wk*100 mg
Week 24 · Good Response
NCT02886728 · Phase 3 · combination · converted to % from 127 Participants as posted
EULAR Moderate 29.3% (n=147) vs 30.4% (n=148) placebo @ 24wk200 mg
responder rate · % of participants
Week 24 · Moderate Response
NCT02873936 · Phase 3 · converted to % from 43 Participants as posted
show 6 more results
24.8% (n=210) vs 36.8% (n=416) MTX @ 24wk*200 mg
Week 24 · Moderate Response
NCT02886728 · Phase 3 · monotherapy · converted to % from 52 Participants as posted
26.1% (n=475) vs 35.8% (n=475) placebo @ 24wk*200 mg
Week 24 · Moderate Response
NCT02889796 · Phase 3 · converted to % from 124 Participants as posted
30.7% (n=153) vs 30.4% (n=148) placebo @ 24wk*100 mg
Week 24 · Moderate Response
NCT02873936 · Phase 3 · converted to % from 47 Participants as posted
32.5% (n=480) vs 35.8% (n=475) placebo @ 24wk*100 mg
Week 24 · Moderate Response
NCT02889796 · Phase 3 · converted to % from 156 Participants as posted
19.7% (n=416) vs 36.8% (n=416) MTX @ 24wk*200 mg
Week 24 · Moderate Response
NCT02886728 · Phase 3 · combination · converted to % from 82 Participants as posted
26.6% (n=207) vs 36.8% (n=416) MTX @ 24wk*100 mg
Week 24 · Moderate Response
NCT02886728 · Phase 3 · combination · converted to % from 55 Participants as posted
SF-36 MCS 3.5 vs 1.2 placebo score @ 4wk200 mg
absolute change · score
NCT02873936 · Phase 3
show 30 more results
5.3 vs 3.7 placebo score @ 12wk200 mg
NCT02873936 · Phase 3
6.5 vs 4.3 placebo score @ 24wk200 mg
NCT02873936 · Phase 3
4.5 vs 1.9 MTX score @ 4wk200 mg
NCT02886728 · Phase 3 · monotherapy
5.5 vs 4.5 MTX score @ 12wk200 mg
NCT02886728 · Phase 3 · monotherapy
5.8 vs 6 MTX score @ 24wk200 mg
NCT02886728 · Phase 3 · monotherapy
5.4 vs 6.2 MTX score @ 36wk200 mg
NCT02886728 · Phase 3 · monotherapy
6.1 vs 6.5 MTX score @ 52wk200 mg
NCT02886728 · Phase 3 · monotherapy
3.9 vs 2.3 placebo score @ 4wk200 mg
NCT02889796 · Phase 3
5.4 vs 4.1 placebo score @ 12wk200 mg
NCT02889796 · Phase 3
6.1 vs 5.6 placebo score @ 24wk200 mg
NCT02889796 · Phase 3
6.2 vs 6.9 placebo score @ 36wk200 mg
NCT02889796 · Phase 3
6.7 vs 7.2 placebo score @ 52wk200 mg
NCT02889796 · Phase 3
3 vs 1.2 placebo score @ 4wk100 mg
NCT02873936 · Phase 3
4.6 vs 3.7 placebo score @ 12wk100 mg
NCT02873936 · Phase 3
4.6 vs 4.3 placebo score @ 24wk100 mg
NCT02873936 · Phase 3
3.4 vs 2.3 placebo score @ 4wk100 mg
NCT02889796 · Phase 3
5.4 vs 4.1 placebo score @ 12wk100 mg
NCT02889796 · Phase 3
5.7 vs 5.6 placebo score @ 24wk100 mg
NCT02889796 · Phase 3
6.6 vs 6.9 placebo score @ 36wk100 mg
NCT02889796 · Phase 3
6.9 vs 7.2 placebo score @ 52wk100 mg
NCT02889796 · Phase 3
4.1 vs 1.9 MTX score @ 4wk200 mg
NCT02886728 · Phase 3 · combination
5.3 vs 4.5 MTX score @ 12wk200 mg
NCT02886728 · Phase 3 · combination
5.4 vs 6 MTX score @ 24wk200 mg
NCT02886728 · Phase 3 · combination
6.5 vs 6.2 MTX score @ 36wk200 mg
NCT02886728 · Phase 3 · combination
6.2 vs 6.5 MTX score @ 52wk200 mg
NCT02886728 · Phase 3 · combination
3.6 vs 1.9 MTX score @ 4wk100 mg
NCT02886728 · Phase 3 · combination
5.7 vs 4.5 MTX score @ 12wk100 mg
NCT02886728 · Phase 3 · combination
6.6 vs 6 MTX score @ 24wk100 mg
NCT02886728 · Phase 3 · combination
7.3 vs 6.2 MTX score @ 36wk100 mg
NCT02886728 · Phase 3 · combination
6.8 vs 6.5 MTX score @ 52wk100 mg
NCT02886728 · Phase 3 · combination
EQ-5D-VAS 59 vs 52 placebo score @ 4wk200 mg
absolute value · score
NCT02873936 · Phase 3
show 30 more results
66 vs 58 placebo score @ 12wk200 mg
NCT02873936 · Phase 3
70 vs 62 placebo score @ 24wk200 mg
NCT02873936 · Phase 3
62 vs 56 MTX score @ 4wk200 mg
NCT02886728 · Phase 3 · monotherapy
66 vs 64 MTX score @ 12wk200 mg
NCT02886728 · Phase 3 · monotherapy
68 vs 69 MTX score @ 24wk200 mg
NCT02886728 · Phase 3 · monotherapy
69 vs 68 MTX score @ 36wk200 mg
NCT02886728 · Phase 3 · monotherapy
71 vs 71 MTX score @ 52wk200 mg
NCT02886728 · Phase 3 · monotherapy
59 vs 56 placebo score @ 4wk200 mg
NCT02889796 · Phase 3
66 vs 59 placebo score @ 12wk200 mg
NCT02889796 · Phase 3
67 vs 64 placebo score @ 24wk200 mg
NCT02889796 · Phase 3
69 vs 73 placebo score @ 36wk200 mg
NCT02889796 · Phase 3
72 vs 73 placebo score @ 52wk200 mg
NCT02889796 · Phase 3
60 vs 52 placebo score @ 4wk100 mg
NCT02873936 · Phase 3
65 vs 58 placebo score @ 12wk100 mg
NCT02873936 · Phase 3
69 vs 62 placebo score @ 24wk100 mg
NCT02873936 · Phase 3
59 vs 56 placebo score @ 4wk100 mg
NCT02889796 · Phase 3
66 vs 59 placebo score @ 12wk100 mg
NCT02889796 · Phase 3
69 vs 64 placebo score @ 24wk100 mg
NCT02889796 · Phase 3
72 vs 73 placebo score @ 36wk100 mg
NCT02889796 · Phase 3
73 vs 73 placebo score @ 52wk100 mg
NCT02889796 · Phase 3
65 vs 56 MTX score @ 4wk200 mg
NCT02886728 · Phase 3 · combination
69 vs 64 MTX score @ 12wk200 mg
NCT02886728 · Phase 3 · combination
73 vs 69 MTX score @ 24wk200 mg
NCT02886728 · Phase 3 · combination
73 vs 68 MTX score @ 36wk200 mg
NCT02886728 · Phase 3 · combination
75 vs 71 MTX score @ 52wk200 mg
NCT02886728 · Phase 3 · combination
61 vs 56 MTX score @ 4wk100 mg
NCT02886728 · Phase 3 · combination
67 vs 64 MTX score @ 12wk100 mg
NCT02886728 · Phase 3 · combination
72 vs 69 MTX score @ 24wk100 mg
NCT02886728 · Phase 3 · combination
71 vs 68 MTX score @ 36wk100 mg
NCT02886728 · Phase 3 · combination
72 vs 71 MTX score @ 52wk100 mg
NCT02886728 · Phase 3 · combination
EQ-5D VAS 10 vs 6 placebo score @ 4wk200 mg
absolute change · score
NCT02873936 · Phase 3
show 30 more results
17 vs 12 placebo score @ 12wk200 mg
NCT02873936 · Phase 3
22 vs 17 placebo score @ 24wk200 mg
NCT02873936 · Phase 3
11 vs 7 MTX score @ 4wk200 mg
NCT02886728 · Phase 3 · monotherapy
15 vs 14 MTX score @ 12wk200 mg
NCT02886728 · Phase 3 · monotherapy
17 vs 19 MTX score @ 24wk200 mg
NCT02886728 · Phase 3 · monotherapy
18 vs 19 MTX score @ 36wk200 mg
NCT02886728 · Phase 3 · monotherapy
20 vs 22 MTX score @ 52wk200 mg
NCT02886728 · Phase 3 · monotherapy
11 vs 10 placebo score @ 4wk200 mg
NCT02889796 · Phase 3
18 vs 13 placebo score @ 12wk200 mg
NCT02889796 · Phase 3
19 vs 18 placebo score @ 24wk200 mg
NCT02889796 · Phase 3
21 vs 28 placebo score @ 36wk200 mg
NCT02889796 · Phase 3
25 vs 29 placebo score @ 52wk200 mg
NCT02889796 · Phase 3
14 vs 6 placebo score @ 4wk100 mg
NCT02873936 · Phase 3
19 vs 12 placebo score @ 12wk100 mg
NCT02873936 · Phase 3
25 vs 17 placebo score @ 24wk100 mg
NCT02873936 · Phase 3
10 vs 10 placebo score @ 4wk100 mg
NCT02889796 · Phase 3
17 vs 13 placebo score @ 12wk100 mg
NCT02889796 · Phase 3
21 vs 18 placebo score @ 24wk100 mg
NCT02889796 · Phase 3
23 vs 28 placebo score @ 36wk100 mg
NCT02889796 · Phase 3
24 vs 29 placebo score @ 52wk100 mg
NCT02889796 · Phase 3
16 vs 7 MTX score @ 4wk200 mg
NCT02886728 · Phase 3 · combination
19 vs 14 MTX score @ 12wk200 mg
NCT02886728 · Phase 3 · combination
24 vs 19 MTX score @ 24wk200 mg
NCT02886728 · Phase 3 · combination
23 vs 19 MTX score @ 36wk200 mg
NCT02886728 · Phase 3 · combination
26 vs 22 MTX score @ 52wk200 mg
NCT02886728 · Phase 3 · combination
10 vs 7 MTX score @ 4wk100 mg
NCT02886728 · Phase 3 · combination
17 vs 14 MTX score @ 12wk100 mg
NCT02886728 · Phase 3 · combination
21 vs 19 MTX score @ 24wk100 mg
NCT02886728 · Phase 3 · combination
21 vs 19 MTX score @ 36wk100 mg
NCT02886728 · Phase 3 · combination
22 vs 22 MTX score @ 52wk100 mg
NCT02886728 · Phase 3 · combination
WPAI Work Time Missed -4.3% (n=35) vs 4% (n=48) placebo @ 4wk200 mg
absolute change · percentage points
NCT02873936 · Phase 3
show 30 more results
-3.6% (n=35) vs 3.8% (n=48) placebo @ 12wk200 mg
NCT02873936 · Phase 3
-4.6% (n=35) vs 3.7% (n=48) placebo @ 24wk200 mg
NCT02873936 · Phase 3
-4% (n=210) vs -1.3% (n=416) MTX @ 4wk200 mg
NCT02886728 · Phase 3 · monotherapy
-2.3% (n=210) vs -5.2% (n=416) MTX @ 12wk200 mg
NCT02886728 · Phase 3 · monotherapy
-3.1% (n=210) vs -10.6% (n=416) MTX @ 24wk200 mg
NCT02886728 · Phase 3 · monotherapy
-4.1% (n=210) vs -7.9% (n=416) MTX @ 36wk200 mg
NCT02886728 · Phase 3 · monotherapy
-2.8% (n=210) vs -6.7% (n=416) MTX @ 52wk200 mg
NCT02886728 · Phase 3 · monotherapy
-1.4% (n=195) vs -5.7% (n=162) placebo @ 4wk200 mg
NCT02889796 · Phase 3
-4.3% (n=195) vs -5.9% (n=162) placebo @ 12wk200 mg
NCT02889796 · Phase 3
-6.1% (n=195) vs -1.5% (n=162) placebo @ 24wk200 mg
NCT02889796 · Phase 3
-4.4% (n=195) vs -6.2% (n=76) placebo @ 36wk200 mg
NCT02889796 · Phase 3
-6.8% (n=195) vs -7.4% (n=76) placebo @ 52wk200 mg
NCT02889796 · Phase 3
-3.4% (n=54) vs 4% (n=48) placebo @ 4wk100 mg
NCT02873936 · Phase 3
-7% (n=54) vs 3.8% (n=48) placebo @ 12wk100 mg
NCT02873936 · Phase 3
-3.1% (n=54) vs 3.7% (n=48) placebo @ 24wk100 mg
NCT02873936 · Phase 3
-2.1% (n=193) vs -5.7% (n=162) placebo @ 4wk100 mg
NCT02889796 · Phase 3
-3.8% (n=193) vs -5.9% (n=162) placebo @ 12wk100 mg
NCT02889796 · Phase 3
-3.8% (n=193) vs -1.5% (n=162) placebo @ 24wk100 mg
NCT02889796 · Phase 3
-1.5% (n=193) vs -6.2% (n=76) placebo @ 36wk100 mg
NCT02889796 · Phase 3
-1.7% (n=193) vs -7.4% (n=76) placebo @ 52wk100 mg
NCT02889796 · Phase 3
-1.5% (n=416) vs -1.3% (n=416) MTX @ 4wk200 mg
NCT02886728 · Phase 3 · combination
-4.9% (n=416) vs -5.2% (n=416) MTX @ 12wk200 mg
NCT02886728 · Phase 3 · combination
-4.8% (n=416) vs -10.6% (n=416) MTX @ 24wk200 mg
NCT02886728 · Phase 3 · combination
-6.7% (n=416) vs -7.9% (n=416) MTX @ 36wk200 mg
NCT02886728 · Phase 3 · combination
-4.8% (n=416) vs -6.7% (n=416) MTX @ 52wk200 mg
NCT02886728 · Phase 3 · combination
-3.3% (n=207) vs -1.3% (n=416) MTX @ 4wk100 mg
NCT02886728 · Phase 3 · combination
-11% (n=207) vs -5.2% (n=416) MTX @ 12wk100 mg
NCT02886728 · Phase 3 · combination
-15.5% (n=207) vs -10.6% (n=416) MTX @ 24wk100 mg
NCT02886728 · Phase 3 · combination
-16.4% (n=207) vs -7.9% (n=416) MTX @ 36wk100 mg
NCT02886728 · Phase 3 · combination
-15.7% (n=207) vs -6.7% (n=416) MTX @ 52wk100 mg
NCT02886728 · Phase 3 · combination

+ 246 further endpoints in the CSV export.

upadacitinib

CDAI Low Disease Activity 40.3% (n=221) vs 19% (n=221) placebo @ 12wk15 mg
responder rate · % of participants
NCT02675426 · Phase 3
show 23 more results
35.5% (n=169) vs 11.2% (n=169) placebo @ 12wk15 mg
NCT02955212 · Phase 3 · registry result, not featured evidence
42% (n=219) vs 19% (n=221) placebo @ 12wk30 mg
NCT02675426 · Phase 3
9.8% (n=41) vs 10.5% (n=19) placebo @ 2wk60 mg
NCT03682705 · Phase 2 · registry result, not featured evidence
12.2% (n=41) vs 10.5% (n=19) placebo @ 4wk60 mg
NCT03682705 · Phase 2 · registry result, not featured evidence
17.1% (n=41) vs 5.3% (n=19) placebo @ 8wk60 mg
NCT03682705 · Phase 2 · registry result, not featured evidence
34.1% (n=41) vs 26.3% (n=19) placebo @ 12wk60 mg
NCT03682705 · Phase 2 · registry result, not featured evidence
36.7% (n=49) vs 21.3% (n=47) placebo @ 12wk24 mg QD
NCT02066389 · Phase 2 · registry result, not featured evidence
0% (n=39) vs 10.5% (n=19) placebo @ 2wk20 mg
NCT03682705 · Phase 2 · registry result, not featured evidence
7.7% (n=39) vs 10.5% (n=19) placebo @ 4wk20 mg
NCT03682705 · Phase 2 · registry result, not featured evidence
20.5% (n=39) vs 5.3% (n=19) placebo @ 8wk20 mg
NCT03682705 · Phase 2 · registry result, not featured evidence
17.9% (n=39) vs 26.3% (n=19) placebo @ 12wk20 mg
NCT03682705 · Phase 2 · registry result, not featured evidence
49% (n=49) vs 21.3% (n=47) placebo @ 12wk18 mg BID
NCT02066389 · Phase 2 · registry result, not featured evidence
16.1% (n=62) vs 10.5% (n=19) placebo @ 2wk15 mg/60 mg
NCT03682705 · Phase 2 · registry result, not featured evidence · combination
29% (n=62) vs 10.5% (n=19) placebo @ 4wk15 mg/60 mg
NCT03682705 · Phase 2 · registry result, not featured evidence · combination
46.8% (n=62) vs 5.3% (n=19) placebo @ 8wk15 mg/60 mg
NCT03682705 · Phase 2 · registry result, not featured evidence · combination
37.1% (n=62) vs 26.3% (n=19) placebo @ 12wk15 mg/60 mg
NCT03682705 · Phase 2 · registry result, not featured evidence · combination
40% (n=50) vs 21.3% (n=47) placebo @ 12wk12 mg BID
NCT02066389 · Phase 2 · registry result, not featured evidence
40.8% (n=49) vs 21.3% (n=47) placebo @ 12wk6 mg BID
NCT02066389 · Phase 2 · registry result, not featured evidence
2.4% (n=41) vs 10.5% (n=19) placebo @ 2wk5 mg
NCT03682705 · Phase 2 · registry result, not featured evidence
12.2% (n=41) vs 10.5% (n=19) placebo @ 4wk5 mg
NCT03682705 · Phase 2 · registry result, not featured evidence
24.4% (n=41) vs 5.3% (n=19) placebo @ 8wk5 mg
NCT03682705 · Phase 2 · registry result, not featured evidence
17.1% (n=41) vs 26.3% (n=19) placebo @ 12wk5 mg
NCT03682705 · Phase 2 · registry result, not featured evidence
40.8% (n=49) vs 21.3% (n=47) placebo @ 12wk3 mg BID
NCT02066389 · Phase 2 · registry result, not featured evidence
Morning Stiffness Duration -85.28 vs -34.27 placebo minutes @ 12wk15 mg
absolute change · minutes
NCT02675426 · Phase 3
show 3 more results
-94.56 vs -53.03 Methotrexate minutes @ 14wk15 mg
NCT02706951 · Phase 3
-85.13 vs -34.27 placebo minutes @ 12wk30 mg
NCT02675426 · Phase 3
-102.34 vs -53.03 Methotrexate minutes @ 14wk30 mg
NCT02706951 · Phase 3
mTSS no Progression 87.5% (n=279) vs 77.7% (n=264) Methotrexate @ 24wk15 mg
responder rate · % of participants
NCT02706873 · Phase 3
show 4 more results
80.8% (n=26) vs 46.2% (n=26) Methotrexate @ 24wk15 mg
NCT02706873 · Phase 3
89.3% (n=270) vs 77.7% (n=264) Methotrexate @ 24wk30 mg
NCT02706873 · Phase 3
79.2% (n=24) vs 46.2% (n=26) Methotrexate @ 24wk30 mg
NCT02706873 · Phase 3
82.4% (n=51) vs 46.2% (n=26) Methotrexate @ 24wk7.5 mg
NCT02706873 · Phase 3
RA Work Instability Scale -2.74 vs -0.69 placebo score @ 12wk15 mg
absolute change · score
NCT02720523 · Phase 2/3 · registry result, not featured evidence
show 2 more results
-2.24 vs -0.69 placebo score @ 12wk30 mg
NCT02720523 · Phase 2/3 · registry result, not featured evidence
-3.22 vs -0.69 placebo score @ 12wk7.5 mg
NCT02720523 · Phase 2/3 · registry result, not featured evidence
Morning Stiffness Severity -2.84 vs -1.02 placebo score @ 12wk15 mg
absolute change · score
NCT02720523 · Phase 2/3 · registry result, not featured evidence
show 18 more results
-2.98 vs -1.02 placebo score @ 12wk30 mg
NCT02720523 · Phase 2/3 · registry result, not featured evidence
-2.83 vs -1.02 placebo score @ 12wk7.5 mg
NCT02720523 · Phase 2/3 · registry result, not featured evidence
-0.91 vs -1.76 placebo score @ 2wk60 mg
NCT03682705 · Phase 2 · registry result, not featured evidence
-0.82 vs -1.76 placebo score @ 4wk60 mg
NCT03682705 · Phase 2 · registry result, not featured evidence
-1.3 vs -1.67 placebo score @ 8wk60 mg
NCT03682705 · Phase 2 · registry result, not featured evidence
-1.27 vs -1.61 placebo score @ 12wk60 mg
NCT03682705 · Phase 2 · registry result, not featured evidence
-0.68 vs -1.76 placebo score @ 2wk20 mg
NCT03682705 · Phase 2 · registry result, not featured evidence
-0.83 vs -1.76 placebo score @ 4wk20 mg
NCT03682705 · Phase 2 · registry result, not featured evidence
-0.97 vs -1.67 placebo score @ 8wk20 mg
NCT03682705 · Phase 2 · registry result, not featured evidence
-1.3 vs -1.61 placebo score @ 12wk20 mg
NCT03682705 · Phase 2 · registry result, not featured evidence
-2.02 vs -1.76 placebo score @ 2wk15 mg/60 mg
NCT03682705 · Phase 2 · registry result, not featured evidence · combination
-2.71 vs -1.76 placebo score @ 4wk15 mg/60 mg
NCT03682705 · Phase 2 · registry result, not featured evidence · combination
-3.07 vs -1.67 placebo score @ 8wk15 mg/60 mg
NCT03682705 · Phase 2 · registry result, not featured evidence · combination
-3.23 vs -1.61 placebo score @ 12wk15 mg/60 mg
NCT03682705 · Phase 2 · registry result, not featured evidence · combination
-0.59 vs -1.76 placebo score @ 2wk5 mg
NCT03682705 · Phase 2 · registry result, not featured evidence
-1.08 vs -1.76 placebo score @ 4wk5 mg
NCT03682705 · Phase 2 · registry result, not featured evidence
-1.5 vs -1.67 placebo score @ 8wk5 mg
NCT03682705 · Phase 2 · registry result, not featured evidence
-1.66 vs -1.61 placebo score @ 12wk5 mg
NCT03682705 · Phase 2 · registry result, not featured evidence
DAS28-CRP LDAS 22% (n=41) vs 21.1% (n=19) placebo @ 12wk60 mg
responder rate · % of participants
NCT03682705 · Phase 2 · registry result, not featured evidence
show 3 more results
10.3% (n=39) vs 21.1% (n=19) placebo @ 12wk20 mg
NCT03682705 · Phase 2 · registry result, not featured evidence
41.9% (n=62) vs 21.1% (n=19) placebo @ 12wk15 mg/60 mg
NCT03682705 · Phase 2 · registry result, not featured evidence · combination
14.6% (n=41) vs 21.1% (n=19) placebo @ 12wk5 mg
NCT03682705 · Phase 2 · registry result, not featured evidence
CDAI Clinical Remission 0% (n=41) vs 0% (n=19) placebo @ 2wk60 mg
responder rate · % of participants
NCT03682705 · Phase 2 · registry result, not featured evidence
show 20 more results
2.4% (n=41) vs 0% (n=19) placebo @ 4wk60 mg
NCT03682705 · Phase 2 · registry result, not featured evidence
7.3% (n=41) vs 0% (n=19) placebo @ 8wk60 mg
NCT03682705 · Phase 2 · registry result, not featured evidence
7.3% (n=41) vs 5.3% (n=19) placebo @ 12wk60 mg
NCT03682705 · Phase 2 · registry result, not featured evidence
6.1% (n=49) vs 4.3% (n=47) placebo @ 12wk24 mg QD
NCT02066389 · Phase 2 · registry result, not featured evidence
0% (n=39) vs 0% (n=19) placebo @ 2wk20 mg
NCT03682705 · Phase 2 · registry result, not featured evidence
2.6% (n=39) vs 0% (n=19) placebo @ 4wk20 mg
NCT03682705 · Phase 2 · registry result, not featured evidence
2.6% (n=39) vs 0% (n=19) placebo @ 8wk20 mg
NCT03682705 · Phase 2 · registry result, not featured evidence
5.1% (n=39) vs 5.3% (n=19) placebo @ 12wk20 mg
NCT03682705 · Phase 2 · registry result, not featured evidence
14.3% (n=49) vs 4.3% (n=47) placebo @ 12wk18 mg BID
NCT02066389 · Phase 2 · registry result, not featured evidence
3.2% (n=62) vs 0% (n=19) placebo @ 2wk15 mg/60 mg
NCT03682705 · Phase 2 · registry result, not featured evidence · combination
6.5% (n=62) vs 0% (n=19) placebo @ 4wk15 mg/60 mg
NCT03682705 · Phase 2 · registry result, not featured evidence · combination
12.9% (n=62) vs 0% (n=19) placebo @ 8wk15 mg/60 mg
NCT03682705 · Phase 2 · registry result, not featured evidence · combination
14.5% (n=62) vs 5.3% (n=19) placebo @ 12wk15 mg/60 mg
NCT03682705 · Phase 2 · registry result, not featured evidence · combination
6% (n=50) vs 4.3% (n=47) placebo @ 12wk12 mg BID
NCT02066389 · Phase 2 · registry result, not featured evidence
14.3% (n=49) vs 4.3% (n=47) placebo @ 12wk6 mg BID
NCT02066389 · Phase 2 · registry result, not featured evidence
0% (n=41) vs 0% (n=19) placebo @ 2wk5 mg
NCT03682705 · Phase 2 · registry result, not featured evidence
0% (n=41) vs 0% (n=19) placebo @ 4wk5 mg
NCT03682705 · Phase 2 · registry result, not featured evidence
2.4% (n=41) vs 0% (n=19) placebo @ 8wk5 mg
NCT03682705 · Phase 2 · registry result, not featured evidence
0% (n=41) vs 5.3% (n=19) placebo @ 12wk5 mg
NCT03682705 · Phase 2 · registry result, not featured evidence
12.2% (n=49) vs 4.3% (n=47) placebo @ 12wk3 mg BID
NCT02066389 · Phase 2 · registry result, not featured evidence
DAS28-ESR -0.52 vs -0.46 placebo score @ 2wk60 mg
absolute change · score
NCT03682705 · Phase 2 · registry result, not featured evidence
show 15 more results
-0.79 vs -0.86 placebo score @ 4wk60 mg
NCT03682705 · Phase 2 · registry result, not featured evidence
-1.07 vs -0.8 placebo score @ 8wk60 mg
NCT03682705 · Phase 2 · registry result, not featured evidence
-1.41 vs -1.18 placebo score @ 12wk60 mg
NCT03682705 · Phase 2 · registry result, not featured evidence
-0.46 vs -0.46 placebo score @ 2wk20 mg
NCT03682705 · Phase 2 · registry result, not featured evidence
-0.59 vs -0.86 placebo score @ 4wk20 mg
NCT03682705 · Phase 2 · registry result, not featured evidence
-1.15 vs -0.8 placebo score @ 8wk20 mg
NCT03682705 · Phase 2 · registry result, not featured evidence
-1.24 vs -1.18 placebo score @ 12wk20 mg
NCT03682705 · Phase 2 · registry result, not featured evidence
-1.48 vs -0.46 placebo score @ 2wk15 mg/60 mg
NCT03682705 · Phase 2 · registry result, not featured evidence · combination
-1.93 vs -0.86 placebo score @ 4wk15 mg/60 mg
NCT03682705 · Phase 2 · registry result, not featured evidence · combination
-2.41 vs -0.8 placebo score @ 8wk15 mg/60 mg
NCT03682705 · Phase 2 · registry result, not featured evidence · combination
-2.53 vs -1.18 placebo score @ 12wk15 mg/60 mg
NCT03682705 · Phase 2 · registry result, not featured evidence · combination
-0.57 vs -0.46 placebo score @ 2wk5 mg
NCT03682705 · Phase 2 · registry result, not featured evidence
-0.92 vs -0.86 placebo score @ 4wk5 mg
NCT03682705 · Phase 2 · registry result, not featured evidence
-1.2 vs -0.8 placebo score @ 8wk5 mg
NCT03682705 · Phase 2 · registry result, not featured evidence
-1.44 vs -1.18 placebo score @ 12wk5 mg
NCT03682705 · Phase 2 · registry result, not featured evidence
DAS Low Disease Activity 45.5% (n=55) vs 25.5% (n=55) placebo @ 12wk18 mg BID
event count · % of participants
NCT01960855 · Phase 2 · registry result, not featured evidence · converted to % from 25 Participants as posted
show 3 more results
52.7% (n=55) vs 25.5% (n=55) placebo @ 12wk*12 mg BID
NCT01960855 · Phase 2 · registry result, not featured evidence · converted to % from 29 Participants as posted
37.7% (n=53) vs 25.5% (n=55) placebo @ 12wk*6 mg BID
NCT01960855 · Phase 2 · registry result, not featured evidence · converted to % from 20 Participants as posted
33.3% (n=54) vs 25.5% (n=55) placebo @ 12wk*3 mg BID
NCT01960855 · Phase 2 · registry result, not featured evidence · converted to % from 18 Participants as posted
DAS Remission 30.9% (n=55) vs 12.7% (n=55) placebo @ 12wk18 mg BID
responder rate · % of participants
NCT01960855 · Phase 2 · registry result, not featured evidence · converted to % from 17 Participants as posted
show 3 more results
32.7% (n=55) vs 12.7% (n=55) placebo @ 12wk*12 mg BID
NCT01960855 · Phase 2 · registry result, not featured evidence · converted to % from 18 Participants as posted
26.4% (n=53) vs 12.7% (n=55) placebo @ 12wk*6 mg BID
NCT01960855 · Phase 2 · registry result, not featured evidence · converted to % from 14 Participants as posted
24.1% (n=54) vs 12.7% (n=55) placebo @ 12wk*3 mg BID
NCT01960855 · Phase 2 · registry result, not featured evidence · converted to % from 13 Participants as posted

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: filgotinib's landscape · upadacitinib's landscape